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General introduction 
Prostate cancer is nowadays the most common non-cutaneous cancer in men 
in the Western world.  Since the introduction of Prostate Specific Antigen 
(PSA) testing in the last decade, prostate cancer incidence increased 
dramatically. In addition, the population is aging, and prostate cancer 
incidence increases with higher age. The dilemma of prostate cancer is that 
more men die with prostate cancer than from prostate cancer, as reflected by 
the observation that in 70% of men who are 80 years or older prostate cancer 
is diagnosed histologically on autopsy. As a consequence of this high 
incidence on autopsy, it may be anticipated that a large proportion of old men 
are diagnosed with prostate cancer when undergoing prostate biopsy and a 
great proportion of prostate cancers detected in screening programs may be 
over-diagnosed. It is as yet unclear whether PSA based screening reduces 
prostate cancer mortality. Due to screening with PSA most cancers are 
diagnosed in an early stage and therefore possibly in a curable stage. As a 
result, cancer is removed in an early stage, before the tumor is able to 
metastasize. It is conceivable that population-based early prostate cancer 
screening will reduce prostate cancer mortality. In order to investigate this 
further, randomized clinical trials have been introduced. In the USA the 
Prostate Lung Colorectal and Ovary cancer (PLCO) study investigates if 
prostate cancer screening is justified. In Europe the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) is conducted in 8 European 
countries to study whether prostate cancer screening can reduce prostate 
cancer specific mortality at affordable costs and quality of life. The European 
screening centers differ with regard to the screening procedure but they share 
PSA testing and most other features (Table 1). At the Rotterdam section of the 
ERSPC the screening protocol comprises serum PSA testing followed – in case 
of an elevated serum PSA level- by six lateralized needle biopsies, three from 
each side of the prostate (systematic sextant biopsy) in men aged between 55 
and 75 years. Every four years the same cohort of men is screenend. Men are 
excluded from screening in the 2nd round if a previous diagnosis of prostate 
cancer is made and those with interval carcinoma (i.e. cancers detected after 
the 1st round, but during the 4-year screening interval period. Unfortunately, 
the final outcome of the ERSPC will not be here until the end of 2008 or later. 
This thesis is restricted to an analysis of the data from first and second 
screening rounds at the Rotterdam section of the ERSPC. 
Awaiting the final outcome of the ERSPC, the investigations collected 
in this thesis are aimed to provide insight in 1) intermediate endpoints, 
concerning stage and grade of prostate cancer in subsequent screening rounds 
and the forthcoming therapy choices, 2) the efficiency of the screening 
protocol employed at the Rotterdam section of the ERSPC and 3) the natural 
biology of prostate cancer and its possible premalignant lesions.  
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Table 1 
country number of men 
randomized 
age (years) screening 
interval 
(years) 
PSA cut-off 
(ng/ml) for 
sextant biopsy 
Netherlands 42376 55-75 4  ≥3.01 
Finland 80458 55-65 4 ≥4.0 or 
abnormal DRE 
at PSA ≥3.0 
Sweden 32298 50-66 2 ≥3.0  
Belgium 9284 55-74 7 ≥4.0 or 
abnormal DRE 
or TRUS 
France Randomization 
ongoing 
55-69 2 ≥3.0 
Spain 4278 45-70 4 ≥2.92 
Italy 14577 55-70 4 ≥4.0 or 
abnormal DRE 
and/or TRUS 
≥2.5 
Switzerland Randomization 
ongoing 
55-70 4 ≥3.0 
PSA prostatic specific antigen, DRE digital rectal examination, TRUS transrectal 
ultrosonography 
1Since May 1997, before that PSA ≥4.0 ng/ml and abnormal DRE and/or TRUS used to be 
indicators for sextant biopsy. 
2Since May 1998, it used to be ≥4.0 ng/ml 
 
Part 1 Introduction to prostate cancer, pathology and clinical features 
Chapter 1 provides a general background for the understanding of prostate 
cancer as a disease, including a description of the anatomy of the prostate, 
prostate cancer staging and grading, and current methods for detection of 
prostate cancer. In addition, an overview of the worldwide prostate cancer 
incidence, the effect of PSA testing on prostate cancer incidence and prostate 
cancer screening is given. This chapter also reviews the results of studies that 
have been published so far on prostate cancer screening. 
 
Part 2 Importance of lesions with potentially increased risk for subsequent 
detection of prostate cancer 
Premalignant lesions are considered as precursor lesions for cancer, as it is 
thought that these lesions would in time progress to prostate cancer. In 
literature high-grade prostatic intra-epithelial neoplasia (PIN) is generally 
accepted as the precursor lesion of prostate cancer, both on the basis of 
morphological resemblance of the cells composing PIN and the similarity of 
genetic alterations in PIN and prostate cancers. Recently attention was drawn 
to atrophy as another potential premalignant prostate lesion. It was thought 
that atrophy could be a precursor lesion because of the adjacent location near 
prostate cancer and the resemblance of morphology of some forms of atrophy 
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to that of prostate cancer. In addition, some studies report a similarity of 
molecular changes in atrophy and prostate cancer.  
The biopsy diagnosis “lesion suspicious for prostate cancer (LSPC)” is 
made if the pathologist is not able to deliver with certainty a definite 
diagnosis of prostate cancer, because the lesion lacks some of the criteria 
necessary to make the diagnosis.  In case of a diagnosis of PIN or LSPC made 
on the biopsy, the participant in the screening program will be asked to 
undergo a repeat biopsy. Repeat sextant biopsies are performed in these cases 
in order to increase the chance of detection, as these lesions are considered to 
be associated with a concurrent prostate cancer. It is important to have 
quantitative data on the frequency of these lesions in a screened population. 
They reflect the general population and directly impact on the costs related to 
screening and the accompanying increased stress, associated with repeat 
biopsy, which possibly lowers quality of life.  In addition, we wished to 
investigate if the frequency and diagnostic relevance of PIN and LSCP would 
change during the subsequent screening round, four years after the first 
round. This part of the thesis reports the incidence of these lesions diagnosed 
in a screening population and the related incidence of prostate cancer. In 
addition, the possible relationship between atrophy and subsequent prostate 
cancer detection was investigated. 
Chapter 2 outlines the incidence of PIN and LSPC in men screened for 
prostate cancer during the first (prevalence) and second screening round. The 
incidence of prostate cancer after repeat biopsies for these precursor lesions 
was compared with the incidence of prostate cancer in men biopsied one year 
after a benign biopsy outcome.   
Chapter 3 deals with the recently proposed premalignant lesion: prostatic 
atrophy. We distinguished three variants of atrophy and we investigated the 
incidence and extent of each variant of atrophy and the frequency of 
subsequent prostate cancer during a follow-up period of 8 years. 
 
Part 3 Intermediate endpoints to determine the efficacy of the screening 
protocol 
In this part of the thesis the efficacy of the screening protocol used in the 
Rotterdam section of the ERSPC is monitored. This was done by investigation 
of the incidence of potentially advanced and focal cancers in the 2nd screening 
round. If screening during the 1st round were effective, we would expect that 
after a 4-year screening interval the cancer detection rate would decrease. We 
also expected a decrease in potentially advanced cancers and an increase of 
focal cancers. If we did not see a change towards the incidence of favorable 
cancers after a 4-year screening interval, tumors would have enough time to 
re-grow to the same level as they were diagnosed in the prevalence screening 
round and the screening interval might be considered as too long. This might 
also be reflected in the tumor volume in subsequent screening rounds. 
Another aspect of testing the screening protocol would be a comparison 
between the incidence, stage and grade of cancers of the screening and control 
arm. In the control arm, men might for instance, undergo opportunistic 
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screening (undergoing a PSA test upon request) or might be diagnosed 
incidentally with a prostate cancer on trans-urethral resection of the prostate 
(TURP) or cystoprostatectomy. Both the opportunistic screening and 
incidental finding might lead to a proportional increase of favorable tumors in 
the control arm and thus lower the prostate cancer specific mortality. In 
addition, a comparison of incidence, stage and grade between screening and 
control arm was made. 
Chapter 4 compares the incidence of potentially advanced tumors on sextant 
biopsies in the 1st and 2nd screening round. Potentially advanced cancers were 
defined as high-grade (Gleason score 8-10) prostate cancers, or cancers largely 
composed of poorly differentiated tumor (Gleason pattern 4). These cancers 
carry a poor prognosis. Stage, grade and follow-up of these potentially 
advanced cancers are reported.  
Chapter 5 deals with the incidence of focal cancer on sextant biopsy in the 1st 
and 2nd screening round. A focal cancer is a minimal focus of well-
differentiated (Gleason score 3+3) cancer in one biopsy core. These cancers 
carry a favorable prognosis and might be an indicator of potential over-
diagnosis. The follow-up of men treated with radical prostatectomy and 
watchful waiting was reported. For men managed with watchful waiting PSA 
doubling times were calculated.  
Chapter 6 describes the differences between 1st and 2nd screening round 
findings, concerning therapy choice and radical prostatectomy. The follow-up 
of men treated with radical prostatectomy is reported together with 
prognostic factors for biochemical recurrence in men treated with radical 
prostatectomy. 
In Chapter 7 the clinical outcome of all men diagnosed with prostate cancer in 
the screening arm are compared to men diagnosed in the control arm. Follow-
up of men who underwent radical prostatectomy is given. 
 
Part 4 Natural history of screen detected prostate cancers  
Prostate cancer is a heterogeneous and often multi-focal cancer, which is 
characterized by different Gleason patterns in one tumor. Two opposing 
hypotheses may explain the presence of both high-grade and low-grade 
components in prostatic cancer growth. 1) During its development a prostatic 
cancer starts to grow and to dedifferentiate from a well differentiated (low 
Gleason score) to a poorly differentiated (high Gleason score) tumor, or 2) the 
combination of low and high grade Gleason scores evolves from pluri-potent 
stem cells that shed throughout the prostate and grow in different sites of the 
prostate to form a heterogeneous cancer, which eventually collides to a big 
tumor with low-and high-grade components. Both mechanisms might also 
occur at the same time.  
Chapter 8 This chapter examines the relation between age and Gleason score 
of cancers detected in the different screening rounds and the control arm. To 
support or to reject the hypothesis of dedifferentiation, the MISCAN model 
was used, which is a computer model that simulates screening. Two MISCAN 
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models were fitted (testing 1 and 2) to investigate which model would fit best 
to the screening situation.   
Chapter 9 investigates whether there were significant genetic differences in 
well differentiated (Gleason score 6) and moderately differentiated (Gleason 
score 7) screen detected prostate cancers. As Gleason scores 6 and 7 are 
composed of Gleason pattern 3+3 and 3+4, it was investigated whether the 
Gleason patterns 3 from either Gleason score 6 or 7 prostate cancer, differed 
from each other and whether there were significant differences between a 
Gleason 3 and 4 pattern of a Gleason score 7 tumor.   
Chapter 10 investigates the level of apoptosis measured by 
immunohistochemistry. Several studies have shown that prostate cancer 
could be prevented by drugs that induce apoptosis. Several studies reported a 
decreased apoptosis rate in advanced prostate cancer. However, no reports 
have been documented on early prostate cancer as far as we know. In this 
chapter the apoptosis activity is measured in screen detected prostate cancer. 
For this purpose a tissue micro-array (TMA) was used. A TMA consists of 
multiple small cores of tissue located on one slide. The TMA presented here 
contained screen detected prostate cancer and benign tissue. The screen-
detected cases were composed of well differentiated and poorly differentiated 
(different Gleason scores) cancer and small and larger tumors (tumor 
volume).  Tumor volume and differentiation were investigated, because it 
was thought that bigger and poorly differentiated tumors would have a 
different apoptosis level, compared to smaller and well differentiated tumors. 
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Figure 1 ERSPC Consort Diagram 
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Interval  
carcinomas 
 
 
 
42,376 men randomized 
age 55 – 74 
December 1993 – January 1999 
Control 
N = 21,166 (49.9%) 
Screening 
N = 21,210 (50.1%) 
Protocol: PSA >= 4.0 ng/ml  
and/or a suspicious DRE and/or a suspicious TRUS 
Protocol: 
PSA >= 3.0 ng/ml as a sole biopsy indication 
 
10,754 men screened  
1,850 biopsies performed 
541 cancers detected 
Protocol:  
PSA >= 3.0 ng/ml as a sole biopsy indication 
10,456 men screened 
2,266 biopsies performed 
473 cancers detected 
1,218 men screened 
510 biopsies performed 
63 cancers detected 
Interval carcinomas:  
prostate cancers detected in between fully completed screening rounds 
Most recent link with the Cancer Registry is from January 1st, 2003. 
Follow up data are pending. 
Early recall (1year) 
Protocol: a biopsy indication in the prevalence screen with a negative 
biopsy 
Follow up available 
Screened from December 1993 – March 2004 
12,520 men screened 
2,904 biopsies performed 
550 cancers detected 
94 cancers detected 
Non-compliant group: 
Men who were randomized but never actually screened 
1,240 men non-compliant 
number of biopsies unknown 
24 cancers detected 
Until July 2003, 622 cancers 
detected 
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Part 1 
Chapter 1 
Introduction to prostate cancer, pathology and clinical features 
 
Renske Postma   
Fritz H. Schröder  
Theodorus H. van der Kwast 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on  
R. Postma, F.H. Schröder  
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Introduction 
Over the last decade, considerable debate has occurred about whether 
screening for prostate cancer should be performed in asymptomatic men. PSA 
testing is mainly responsible for the changing statistics in prostate cancer. 
Presently, two large randomized clinical trials for prostate cancer are ongoing, 
one in Europe (European Randomized Study of Screening for Prostate Cancer, 
ERSPC) and one in the USA (Prostate Lung Colorectal and Ovary cancer, 
PLCO). The trials differ considerably in design. The answer with adequate 
evidence whether screening reduces mortality from these randomized clinical 
trials will not be available before 2008 or later. Until this time the debate about 
PSA based screening will go on. The goal of the ERSPC is to evaluate whether 
population based screening reduces mortality from prostate cancer at an 
acceptable price in terms of quality of life and costs. Within the ERSPC, 
approximately 193,000 men in eight European countries were recruited and 
randomized 1.  
For justifying population based screening for disease, Wilson and Jungner 
developed ten criteria (Table 1). The Wilson and Jungner 2 table is the 
backbone of this review.  
 
Table 1 Ten criteria to justify population based screening for a disease 
(Wilson and Jungner) 
 
1 The condition sought should be an important health problem 
2  There should be an accepted treatment for patients with 
recognizable disease 
3 Facilities for diagnosis and treatment should be available 
4 There should be a recognizable latent or early symptomatic 
stage  
5 There should be a suitable test or examination  
6 The test should be acceptable for the population 
7 The natural history of the condition, including development 
from latent to declared disease, should be adequately 
understood 
8 There should be an agreed policy on whom to treat as 
patients 
9 The cost of case-finding (including diagnosis and treatment 
of patients diagnosed) should be economically balanced in 
relation to possible expenditure on medical care as a whole 
10 Case-finding should be a continuing process and not a “once 
and for all” project 
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Anatomy, Morphology and function of the prostate  
The normal prostate is a glandular organ with the size of a chestnut and 
surrounds the urethra as it exits the bladder, below the bladder neck (Figure 
1). The prostate can be subdivided in several biologically distinct regions, a 
transition, central and peripheral zone (Figure 2). In the transition and central 
zone the most prominent lesion that occurs is hyperplasia, also referred to as 
benign prostatic hyperplasia. The incidence of these lesions increases with 
age, reaching 90% by the eighth decade. It results in enlargement of the 
prostate and in some cases can cause urinary obstruction. The peripheral zone 
is the site of origin of 70-80% of the carcinomas 3.  
 
Figure 1 
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Figure 2 Zones of the prostate (Baylor college of medicine) 
 
 
 
The prostate consists of groups of exocrine glands, which produce substances 
that are added to the spermatozoa. One major component is prostate specific 
antigen (PSA), a member of the kalikrein family, which are proteins with a 
proteolytic function. PSA influences the viscosity of the ejaculate. The 
histology of the normal prostate is depicted in figure 3. A double epithelial 
layer lines the exocrine glands of the prostate. The inner or luminal secretory 
epithelial cells have a cuboidal shape. They produce an array of proteins 
(including PSA) that are released in the ejaculate. The outer layer is a 
continuous layer consisting of mostly flattened basal epithelial cells. The 
glands are surrounded by a dense stroma, rich in smooth muscle fibers, 
whose function is to squeeze out the prostate secretion 3. 
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Figure 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prostate cancer  
Epidemiology of prostate cancer- an important health care problem 
Prostate cancer is the now the most common non-cutaneus cancer in the 
western world. It occurs mainly in men who are older than 50 years; prostate 
cancer incidence is highest in men of 75 years and older 4. It is estimated that 
prostate cancer will be diagnosed in 232,090 (life time risk 1 in 6 men) men in 
the USA in 2005 and that 1 out of 8 men will die from the disease 5. The 
importance of prostate cancer as a health care problem worldwide is further 
illustrated in Table 2. Prostate cancer incidence varies widely between 
countries and ethnic populations. These variations can be attributed for a 
large part to the frequencies of PSA testing. When standardized for age in the 
world population, the incidences of different world parts can be compared.  
 
Table 2 Incidence and mortality from prostate cancer worldwide 
 
part of the 
World/Country incidence 
ASR 
(World) SIR (%) 
mortality 
incidence SMR (%) 
United States of 
America 140.8 104.3 472 26.2 227 
Canada 121.1 83.9 388 26.1 216 
China 1.5 1.7 8 0.9 13 
Northern 
Europe 80.1 45.4 218 36.3 254 
Western Europe 94.5 54.9 260 34.3 245 
South Africa 18.4 42.8 194 11.1 333 
World 17.8 21.2 100 6.7 100 
 
(Mortality) Incidence is noted as rate of prostate cancers or prostate cancer deaths per 
100,000 person years of observation  
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ASR Age standardized rate, the prostate cancer incidence per 100,000 person years that a 
population would have if it had a standard age structure. The world population was taken as 
a standard. 
SIR/SMR standardized incidence/mortality ratio, observed number of prostate cancer 
cases/prostate cancer deaths by the expected number, using the age specific 
incidence/mortality of the world as standard. i.e. a 100% SIR means the observed incidence is 
equal the expected incidence, standardized by age. 
 
The prostate cancer incidence is highest among countries where regular PSA 
testing is recommended (i.e. USA and Canada). According to the 
standardized incidence ratio the incidence in the USA and Canada is almost 5 
and 4 times higher compared to the world standardized incidence ratio, 
respectively. They are followed by western en Northern Europe. In Europe, 
the prostate cancer incidence decreases when heading towards the 
Mediterranean Sea. The lowest incidence is in China and India (data not 
shown). Black men are at increased risk for prostate cancer as compared to 
white men. The risk of dying from prostate cancer is higher in Europe 
compared to Northern America. Worldwide the chance of dying from 
prostate cancer however, is small 6. 
 
Tools for clinical detection of prostate cancer 
Digital rectal examination (DRE) 
Before the PSA era, in 1990, a digital rectal examination (DRE) was the 
traditional method for detection of prostate cancer, when the posterior surface 
of the prostate is palpated digitally. The result of a DRE is considered 
suspicious for prostate cancer when an induration, or a discrete hard nodule 
of the prostate is found 7. The DRE remains the simplest and least invasive 
method of assessing patients for prostate cancer. The inter-observer and 
reproducibility varies among urologists, urologists in training and general 
practitioners and therefore the prostate cancer incidence would differ when 
DRE was used as the only screening tool 8,9. The positive predictive value of 
DRE is low, especially in the low PSA range. In the ERSPC the positive 
predictive value of DRE in the PSA range 0-2.9 ng/ml was 4-11% 10. The 
limited use of DRE is also illustrated by the concordance between clinical and 
pathological staged prostate cancers. Of 172 patients in the ERPSC who 
underwent radical prostatectomy, 50 (29%) had impalpable disease on DRE 11.  
 
Transrectal ultrasonography (TRUS) 
Adenocarcinoma of the prostate can be visualized as a hypoechogenic area at 
TRUS 12. The value of TRUS is limited in detecting prostate cancer. In a study 
where TRUS was evaluated for its’ potential benefit, a lesion was detected in 
37% of the prostate cancer cases 13. Even if TRUS is combined with DRE, the 
value is limited . TRUS is, however, useful in calculating the size of the 
prostate. This would allow the calculation of PSA density (PSA/prostate 
volume). In prostates with a limited prostate volume brachytherapy might be 
considered and therefore TRUS is useful 14.  
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Prostatic specific antigen (PSA) 
The test, that among other things changed the prostate cancer incidence 
worldwide and in addition is used in the follow-up after therapy for prostate 
cancer, is the determination of serum concentration of prostate specific 
antigen (PSA). PSA is synthesized in the luminal cells of the prostate. The 
exact mechanism of PSA leakage is as yet unclear, generally it is assumed that 
PSA leaks through the walls of imperfectly built cancerous glands, and 
eventually enters the bloodstream by way of diffusing through the capillary 
membranes 7. An elevation of serum PSA may be caused by prostate cancer, 
however, also prostatitis, benign prostatic hyperplasia (BPH) and other 
conditions (i.e. ejaculation, prostate biopsy and surgery) have been shown to 
increase serum PSA . Therefore, PSA, although predominantly prostate 
specific, is not cancer specific. PSA is not only produced by the prostate. It is 
reported that female breast tumors, ovarian tumors and even benign breast 
tissue are able to produce PSA .  
 
Tumor classification Tumor stage and grade 
The extent of prostate cancer is reported according to TNM classification 15 
(Table 3). Initially, prostate cancers are staged clinically, by means of DRE and 
TRUS. After radical prostatectomy, with concomitant lymph node 
dissesection a pathological T and N stage can be given. In the TNM stage, T1 
is sub classified in T1a, T1b and T1c. Clinical stage T1a and T1b is not 
possible, because T1a and T1b are diagnosed incidentally at TURP. On the 
contrary, pathological stage T1c is not possible, because it is diagnosed when 
no abnormalities on DRE and TRUS are present, but prostate cancer was 
diagnosed on biopsy.  
Clinical staging of prostate cancer is difficult as described above, due 
to the low predictive value of DRE and TRUS. Once the prostate is eligible for 
pathologic staging, 25-50% of the cancers were initially under staged, 
meaning the final stage is higher compared to the initial stage 16. The grading 
of prostate cancer used in the ERSPC is the Gleason score system 17, which is 
based on architectural features. Generally more than one growth pattern is 
present in the tumor. The Gleason score system combines the two most 
prominent patterns. However, when a growth pattern occupies less than 5% 
of the tumor, it will not be noted in the Gleason score. Growth patterns are 
divided in five categories (figure 4 and 5). Therefore Gleason score ranges 
from 2-10. With Gleason score 2 as the most well differentiated tumor and 
Gleason score 10 as the least differentiated tumor. Generally Gleason score 2-6 
is considered as a well-differentiated tumor. Gleason score 7 is intermediate 
and Gleason score 8-10 is considered as poorly differentiated . Internationally 
it is agreed that a needle biopsy is not graded under Gleason score 6 18. 
Gleason score is an important predictor for prostate cancer specific survival 19.  
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Table 3 TNM classification (UICC 2002) 15 
  
Tumor category 
T 
 
Tx No information on primary tumor possible 
T0 No indication for a primary tumor 
T1 No clinical evidence of tumor (non palpable, not visible on 
TRUS) 
T1a Tumor diagnosed incidentally at trans-urethral resection in 
≤5% of TURP tissue 
T1b Tumor diagnosed incidentally at trans-urethral resection in 
>5% of TURP tissue 
T1c Tumor diagnosed on needle biopsy  
T2 Tumor is confined to the prostate 
T2a Tumor in one side of the prostate with the maximum side of 
half a lobe 
T2b Tumor in one side of the prostate, larger than half a lobe, not 
in both lobes 
T2c Tumor in both sides of the prostate 
T3 Tumor with extra-prostatic extension 
T3a Tumor extends into the periprostatic tissue one- or both sides 
T3b Seminal vesicle invasion in one- ore both sides 
T4 Tumor is fixated into nearby organs, other than seminal 
vesicle: bladder neck, levator musculature, external sphincter 
or pelvic wall invasion 
Node category 
N 
Invasion of regional lymph nodes 
Nx No information on lymph nodes possible 
N0 No regional lymph node metastases 
N1 Metastases in to regional lymph nodes 
Metastasis 
category M 
 
Mx No information on distant metastasis possible 
M0 No distant metastases 
M1 Distant metastasis 
M1a Metastases to non-regional lymph nodes 
M1b Bone metastases 
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Figure 4 a Gleason pattern, b Gleason pattern 2, c Gleason pattern 3, d Gleason 
pattern 4, e Gleason pattern 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The modified Gleason score does take into account the Gleason pattern 
occupying less than 5% of the tumor, which is normally not included despite 
their probable prognostic significance. A modified Gleason score comprising 
the conventional Gleason sore and tertiary patterns of higher grade has been 
proposed, because it appears superior to the conventional Gleason score in 
identifying patients at increased risk of disease progression 20. Gleason score 
can artificially be higher in patients who received hormonal therapy, because 
it changes the morphology, resembling high Gleason scores 21. Overall the 
consensus view is that one should not report histologic grade after hormonal 
therapy .  
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Figure 5 Schematic overview of Gleason pattern 
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Prostate biopsy 
The definite diagnosis after PSA elevation can only be made by needle biopsy 
of the prostate. Systemic sextant biopsy used to be the most commonly used 
biopsy strategy. This systematic sextant biopsy procedure has now become 
controversial, because it has been reported that 20-30% of cancers are missed 
by this procedure 22. Vashi et al.  recommended to increase the number of 
biopsy cores as prostate volume increases and prostate cancer volume 
decreases, i.e. for a prostate of 40 ml or greater at least 12 cores are needed to 
detect a tumor of 1 ml. The final decision on the appropriate extent of biopsy 
procedures will depend on a better understanding of the balance between 
overdiagnosis and the prevention of prostate cancer deaths. 
The prostate biopsy can bring about complications. Within the ERSPC 
after performing over 5000 sextant biopsies, hematuria and hematospermia 
still present after 3 days occurred in 23% and 50% of men, respectively. More 
severe side effect such as fever (3,5%) and urinary retention (0.4%), wherefore 
hospitalization was needed (0.5%) were far less frequent 23.  
 
Histology of prostate cancer and lesions which potentially increase the risk 
for subsequent detection of prostate cancer 
Prostate cancer histology 
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The diagnosis of prostate cancer is preferably made on needle biopsy, this 
provides more specific information about grade and extent of tumor in 
comparison to fine-needle aspiration. Morphologically prostate cancer is 
difficult to diagnose, because only a few histological findings are specific for 
prostate cancer 24; 1) architectural changes, 2) the absence of  basal membrane 
cells and 3) nuclear abnormalities. Other less important criteria include 
mitosis, hyperchromasia, and the presence of amorphous substance in the 
lumina . Microscopically, prostatic adenocarcinomas can exhibit a wide 
spectrum of appearances ranging from anaplastic tumors to highly 
differentiated neoplasms. The well-differentiated lesions are composed of 
small glands that infiltrate the adjacent stroma. Glands are not separated by 
stroma, but lay back to back.  The basal cell layer, seen in benign glands is 
absent. The neoplastic glands are lined by a single layer of cuboidal cells with 
prominent nucleoli. Prostate cancer is multi-focal in 75-85% of the radical 
prostatectomy specimens . When doubting the diagnosis of prostate cancer on 
histology, immunohistochemistry may help to make a definite diagnosis. An 
antibody against high molecular weight cytokeratin (i.e. 34βE12) is a 
frequently used basal cell marker. Absence of this basal cell marker in a lesion 
histologically suspicious for cancer supports a diagnosis of prostate cancer. 
However, absence of basal cells demonstrable by basal cell 
immunohistochemistry is not always conclusive for prostate cancer. Some 
benign prostatic lesions may have inconspicuous or even lack basal cell lining 
focally . The recently described marker P504S, or α-methylacyl CoA racemase 
(AMACR), has great promise in this regard. Positive staining AMACR can be 
used to support a diagnosis of cancer on prostate needle core biopsies when 
the focus in question is <1 mm in maximum dimension .  
Prostate cancer spreads initially in the prostate itself (i.e. ducts and 
acini, fibromuscular stroma and blood vessels) before invading the seminal 
vesicles and apex of the prostate and bladder. Metastatic spread occurs 
mainly to the skeleton and lymph nodes. Bone metastases are usually 
multiple and are osteoblastic 3. 
 
Lesions which potentially increase the risk for subsequent detection of prostate cancer 
High-grade prostatic intra-epithelial neoplasia (PIN) can be found adjacent to 
invasive carcinoma in 80% of the cases . Based on this finding and because 
PIN has similar cytogenetic aberrations  PIN was found as a precursor lesion 
for prostate cancer.  
Recently, atrophy has been considered as lesions predictive for associated 
prostate cancer. This is because some forms of atrophy mimic prostate cancer 
morphology and genetic abnormality. In addition, atrophy is a proliferative 
lesion associated with inflammation. Inflammation has been linked to cancer 
progression in other organs. Therefore it is thought that atrophy is a pre-
cancerous condition .  
Lesions that are suspicious for prostate cancer (LSPC), but not diagnostic for 
cancer, are no precursor lesions for prostate cancer. They are sometimes 
referred to as atypical small acinar proliferations (ASAP), however, they lack 
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histologic criteria to make a definitive diagnosis of prostate cancer. Despite 
not being a precursor lesion, the chance of concurrent prostate cancer is high 
and therefore repeat biopsy is required.  
 
Treatment of prostate cancer 
Due to PSA testing, an increasing proportion of men are detected with early-
stage prostate cancer, allowing curative treatment in these men. Roughly, 
there are four treatment options for early stage prostate cancer available; 
surgery, radiotherapy, hormone therapy, and observation, also known as 
watchful waiting, or active surveillance. The advantages of radiotherapy and 
radical prostatectomy are obvious; the intention of treatment is usually 
curative. However side effects of both curative treatments are significant. 
Aside from sexual dysfunction, which are obvious in both treatments, pre- vs. 
post-therapy effect sizes in radical prostatectomy and radiotherapy were large 
and medium for urinary function inconveniences, small and large effect on 
bowel function, in localized prostate cancer patients, respectively. Changes 
were significantly different pre-vs. post-treatment for urinary function in 
radical prostatectomy and bowel function in radiotherapy 25. Despite 
differences of side effects, no association between primary therapy and health 
related quality of life could be found . Within the ERSPC patients treated with 
radiotherapy reported decreased quality of life compared to patients treated 
with radical prostatectomy, however patients treated with radiotherapy were 
older . Patients in the ERSPC with screen-detected and clinically diagnosed 
prostate cancer reported similar health-related quality-of-life after treatment 
with radical prostatectomy or radiotherapy. Contrary to this, Steineck et al.  
published on the different effects in patients treated with radical 
prostatectomy or watchful waiting, these authors found that erectile 
dysfunction (80 vs. 45%) and urinary leakage (49 vs. 21%) were more common 
after radical prostatectomy as compared to watchful waiting. Apparently, the 
knowledge of being diagnosed with prostate cancer also influences sexual 
function even when no treatment is given (watchful waiting). The optimal 
curative therapy, considering disease recurrence, prostate cancer specific 
survival and side effects is as yet unclear. There have been very few 
randomized clinical trials for treating prostate cancer. These trials come along 
with difficulties and long follow-up is needed. Retrospective analysis of 
surgery, external beam radiotherapy and brachytherapy showed similar 
results for early stage prostate cancer . A randomized clinical trial comparing 
radical prostatectomy and watchful waiting showed a significantly decreased 
prostate cancer specific survival in men managed by watchful waiting 
(discussed below)  
 
Radical prostatectomy 
Radical prostatectomy allows a full Radical prostatectomy allows a full 
pathologic assessment of the tumor. Extra capsular extension, seminal vesicle 
invasion, extension to surrounding structures and presence of positive 
surgical margins can be assessed. Apart from Gleason score, which is mostly 
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upgraded in the pathologic assessment of prostate cancer, upstaging is not 
uncommon 33-35. Both can be explained due through sampling bias. After 
prostatectomy PSA is undetectable, any rise in PSA is suspicious for disease 
recurrence (biochemical recurrence). This contrasts the follow-up after 
radiotherapy where a PSA rise not always indicates disease recurrence. 
Despite these advantages, radical prostatectomy is a major surgical procedure 
and requires the patient to be able to tolerate the procedure without 
substantial risk.  In addition, quite some side-effects can occur; urinary 
leakage, and impotence. Because radical prostatectomy requires an 
anastomosis between the bladder and the urethra distal to the prostate, 
urinary incontinence can develop. Diminished or absent potency can occur 
after surgery because neurovascular bundles are manipulated.  The 
proportion of patients that regained urinary continance was 92%.  Depending 
on whether unilateral or bilateral nerve sparing surgery was offered. 
Impotence ranged from 32 to 53%, respectively{Catalona, 1999 #385}.  
Robotic-assissted laparoscopic prostatectomy has been introduced as a less 
invasive surgical approach.  In the hands of experienced surgeons, hospital 
stay, operation time, postoperative pain and intra-operative bleeding are 
more advancious compared to convential radical prostatectomy. The 
oncologic outcome in centres that have more familiarity in laparoscopic 
approaches, surgical margin status is comparable to centres were a high 
volume of conventional prostatectomy is performed. Wheter urinary 
incontinance and erectile dysfunction is improved as compared to 
conventional radical prostatectomy is as yet inconclusive {Smith, 2005 #386}.  
 
Radiotherapy 
The advantage of radiotherapy is that it involves no risk of anesthesia 
therefore is suitable in men with extensive co-morbidities. After radiotherapy, 
the prostate is in place and continues to produce PSA, with the possibilities 
for benign PSA increases as described above 29. A PSA rise after radiotherapy 
therefore not indicates prostate cancer recurrence. Brachytherapy involves 
placements of radioactive sources in the prostate. It is more localized 
compared with radiotherapy resulting in a reduction of  the radiation dose to 
surrounding structures 30. 
 
Watchful waiting 
Watchful waiting, which indicates active surveillance of a man with prostate 
cancer by means of PSA testing, might be appropriate for men with low life 
expectancy and low grade disease 19,31. In recent years, as more early stage 
cancers are diagnosed in younger men, discussion about watchful waiting in 
young men as initial treatment came up with the possibility to deferred 
treatment. A randomized clinical trial considering radical prostatectomy 
versus watchful waiting in clinically localized prostate cancer favored radical 
prostatectomy with an adjusted hazard rate of 0.45 for death from prostate 
cancer. However, no significant difference was found in overall mortality. In 
this study, a limited proportion of patients with poorly differentiated Gleason 
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scores (i.e. Gleason pattern 4  (25%) and 5 (5%)) were included in both arms 
and therefore these men were at increased risk of dying from prostate cancer 
without curative treatment . Two studies mentioned in the natural history 
section reported good follow-up results in well-differentiated tumors of 
patients managed with watchful waiting (discussed below) 19,31. 
 
Adjuvant therapies/ other therapies 
One of the advantages of radical prostatectomy is that adjuvant radiotherapy 
can be given. Salvage radiotherapy after biochemical recurrence for radical 
prostatectomy has a 4-year progression-free survival of 45% in high risk 
patients 32. A recent clinical trial randomizing patients with a pT3 stage 
prostate cancer in adjuvant radiotherapy and surveillance, showed a 
significantly lower PSA progression free survival rate in the surveillance 
group. However after a 10-year follow-up, no differences were seen in 
presence of metastasis and overall survival . Whether adjuvant radiotherapy 
for positive surgical margins is beneficial, is now being investigated in a 
randomized clinical trial. Salvage radical prostatectomy might also be 
performed after local recurrence after radiotherapy. Long-term results show a 
5-year progression-free survival of 55% (95% confidence interval, 46-64%) 33.  
 Cryosurgery is a relatively new treatment for prostate cancer, it is a 
technique that involves using freezing by inserting probes into the prostate in 
order to destroy the prostate cancer cells. Cryosurgery is suitable for patients 
who are unwilling to undergo radical prostatectomy and radiotherapy, even 
in high risk patients 34. In a longer follow-up of 590 patients with localized or 
locally advanced prostate cancer 7-year biochemical disease-free survival was 
between 61-68% for low-, medium- and high-risk patients, respectively 35.  
High-intensity focused ultrasound (HIFU) can kill tissue through 
coagulative necrosis. HIFU can be used for localized prostate cancer or for 
recurrent prostate cancer or as adjuvant treatment. The 5-year disease free 
survival rate was 65% in one study 36 the overall population. The main side 
effects are incontinence and bladder neck stenosis. The treatment repeatability 
remains an unique advantage of this option 37.  
 
Treatment of metastasized prostate cancer 
Metastasized prostate cancer can be treated with hormones (endocrine 
therapy), because most prostate cancers depend on androgens for their 
growth. Metastatic prostate cancer shows a rapid response to surgical or 
medical castration, with improvement in bone pain, regression of soft-tissue 
metastases, and a decline in serum prostate-specific antigen (PSA) levels. 
Nevertheless, in virtually all patients the tumor ultimately becomes androgen-
independent , because most tumors will eventually acquire  mechanisms for 
independent growth 38,39. This happens after castration at a median of 18 to 24 
months. Chemotherapy studies have been carried out in these hormone 
refractory prostate cancers. Two trials reported the benefit of docetaxel given 
every 21 days. It significantly elongated survival with two months. Currently, 
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docetaxel should be advised in androgen-independent prostate cancer for the 
time being 40,41.  
 
Natural history 
The natural history of prostate cancer is for a great deal uncertain, because 
men are much more likely to die with, rather than of, prostate cancer 42. From 
autopsy studies it is known that prostate cancer can be found in 55% of men 
in their 5th and 64% in their 7th decade, respectively 43. Furthermore 
incidental prostate cancer diagnosed in trans urethral resection of the prostate 
(TURP) or at cystoprostatectomy is found in 10 and 46%, respectively 44,45. 
This illustrates the substantial proportion of prostate cancers that are not 
likely to kill. 
 Clinical symptoms of prostate cancer are rare. When a prostate cancer 
is extensive it will give complaints mimicking BPH. These include weak urine 
stream, dribbling at the end of urination, hesitation before urine flow starts, a 
sense that the bladder has not emptied completely .  
Albertsen et al. 31 describe the natural history of prostate cancer. They 
followed patients with localized prostate cancer (n=767) for 20 years who 
were not treated curatively. They found a mean prostate cancer specific 
mortality of 7%, 14%, 27%, 45% and 66% in the age category 55-74 years with 
Gleason score 2-4, 5, 6, 7 and 8-10, respectively. In this study prostate cancer 
was diagnosed between 1971 and 1984, by clinical means. In this era, PSA was 
not yet in use and accurate staging was lacking in many patients, therefore 
patients with occult metastasis might have been included in the analysis. Also 
endocrine therapy was given in different protocols (immediate or delayed) 
and not in every patient . Anyway, the data are likely to overestimate risks 
with respect to screen-detected cancers. Reliable information on the natural 
history on screen detected prostate cancer is not yet available. Johansson et 
al.19 recently studied 223 patients with organ-confined prostate cancer who 
were not initially treated. Orchidectomy or exogenous estrogens were offered 
if progression to symptomatic disease occurred. The authors found that after 
a median follow-up time of 21 years, in total 91% of the patients died, but 
prostate cancer was the cause of death only in 16% of the entire cohort, 40% 
had progression of disease of whom almost half developed distant metastasis. 
The most significant predictor for mortality was a poorly differentiated tumor 
(prostate cancer specific survival of less than 30% after a 5 year follow-up). 
When however diagnosed with an organ confined well-differentiated tumor 
the cause specific survival after a 20-year follow-up was 72%, without initial 
treatment. Even with this relatively good cause specific survival in men with 
favorable and known tumor characteristics managed by watchful waiting, it 
remains difficult to predict tumor progression in the individual patient. 
Gleason scores in biopsies are frequently under graded as is clinical staging 
when compared to the Gleason score and pT-stage in radical prostatectomy 
specimens . Still, Gleason grading in biopsies as well as in radical 
prostatectomy specimens have been shown to be predictive for disease 
specific survival after radical prostatectomy 46. 
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Controversy of screening 
Although the benefit of prostate cancer screening has not yet been established 
in randomized clinical trials, the American Cancer Society Recommends 
yearly PSA testing and digital rectal examination, beginning at age 50 in every 
healthy man 47. The NCCN (National Comprehensive Cancer Network) even 
recommends PSA testing in men beginning at age 40 with a PSA cut-off level 
for further screening of 0.6 ng/ml, and when the biopsy result is negative in 
the PSA range between 2.6-4.0 ng/ml re-screening should be done within 6-12 
months . Even without screening men more often die with prostate cancer 
than from prostate cancer. Screening will increase the risk of over-diagnosing 
prostate cancer, which was calculated as high as 48% within a screening 
population with a 4-year screening interval 48. McGregor et al. 49 calculated 
only one in 8 screen-detected cancers is likely to kill its carrier if left 
untreated. Over diagnosis results in over-treatment. In addition, the serious 
adverse effects of radical prostatectomy and radiotherapy must be taken into 
account if reduced mortality is seen in a screened population 48.  
 
Primary prevention 
Apart from regional differences, which partly depend on hereditary factors 
(in the USA African-Americans are at increased risk for prostate cancer), there 
are also external risk factors that influence the transformation to prostate 
cancer. For example, if a Chinese man living in China moves to the USA, the 
risk of developing prostate cancer increases with 50% compared to if he 
continued living in China 50,51.  
The prostate cancer risk is two to three-folds higher in men who 
reported a history of prostate cancer in first-degree relatives. In monozygotic 
twins there is a higher concordance in prostate cancer incidence compared to 
dizygotic twins, suggesting a genetic influence of 42% 52. It is estimated that 5-
10% of all prostate cancer cases may have a hereditary basis 53.  
Diet is one of the external risk factors, associated with prostate cancer. 
A diet rich in lycopene (tomatoes), vitamin D and E, high consumption of fish 
and soybean products was associated with a decreased prostate cancer risk. A 
high consumption of diary products, meat and fat, however were associated 
with an increased prostate cancer risk 54. Despite the promising 
epidemiological association between prostate cancer and vegetables and fruit, 
a recently reported prospective study could not find a significant association 
between the intake and a decreased prostate cancer incidence 55. Further 
prospective studies are needed to establish significant associations between 
diet and prostate cancer incidence. Alcohol intake has neither a positive nor 
negative effect on prostate cancer development56. Epidemiological evidence 
exists that there is a link between infections (i.e. sexual transmitted disease) 
and inflammation (prostatitis) and prostate cancer . Some authors might 
suggest that post-inflammatory atrophy would be a pre-cancerous condition . 
In addition to this hypothesis non-steroidal anti-inflammatory drugs 
(NSAIDs) are protective for prostate cancer . A large trial was set up (ViP) 
with rofecoxib (a COX-2 inhibitor (NSAID family)) to prevent prostate cancer 
30
 30
57. However, rofecoxib was withdrawn of the market because of 
cardiovascular side effects 58.   
Hormonal factors (androgens) appear to play a role in the development 
of prostate cancer, the disease does not occur in eunuchs castrated before 
puberty, and the incidence is low in patients with hyperestrogenism (i.e. liver 
cirrhosis) 59. Because hormones were associated with prostate cancer 
development, the prostate cancer prevention trial was conducted . In the 
prostate cancer prevention trial, participants were randomized into a study 
and placebo group to study the effect of finasteride (inhibitor of the 
conversion of testosterone to dihydrotestosterone, the primary androgen in 
the prostate) on the prostate cancer incidence. There was a 24.8 % prostate 
cancer reduction over a seven-year period in the study group compared to the 
placebo group. It remains however unknown whether this finding will 
translate into a decrease of prostate cancer mortality or if finasteride only 
causes a delay in prostate cancer diagnosis. Higher Gleason scores compared 
to men within the placebo group accompanied the substantial reduction in 
prostate cancer incidence in men with positive biopsies in the study group. 
Finasteride also adversely influences sexual function and this needs to be 
weighed if finasteride is considered to be given to men as a protective agent. 
 
Secondary prevention: rationale for screening and results of studies 
Worldwide epidemiological surveys demonstrate decreased prostate cancer 
mortality since 1993 in several countries (Table 4). This phenomenon can be 
seen in areas of the world where screening is prevalent and not prevalent . 
However, this decrease in mortality rates is more impressive in countries 
where screening is more common, as in the USA and Canada. The fall in 
prostate cancer mortality in the USA was mostly attributable to the reduction 
in the number of men who were initially diagnosed with distant metastases 
and eventually died rapidly. Nonetheless, temporal and geographical 
differences provide inconclusive evidence suggesting the potential benefits of 
PSA screening. Coldman et al. studied the incidence and mortality in Canada 
and confined that the incidence of prostate cancer increases with more PSA 
use. Strikingly, regions with the smallest increases in incidence had the largest 
declines in mortality. This suggests that mortality reduction may be (in part) 
due to factors other than PSA screening. Notably decreases in mortality were 
only in part related to prostate cancer. 
 
Table 4 Relative survivals in percentages during three time periods by cancer site 
Site 1974-1976 (%) 1983-1985 (%) 1992-1999 (%) 
prostate 67 75 98 
colon and rectum 50 57 62 
lung and 
bronchus 
12 14 15 
pancreas 3 3 4 
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To date, final outcome of one randomized screening trial has become 
available. The authors claim a 62% reduction in disease specific mortality . 
However, an earlier report of this study was heavily criticized, because of 
methodological flaws. This large reduction in mortality resulted from a 
“screening received” analysis, disregarding randomization. The intention to 
screen” analysis resulted in a 16% increased risk of death in the screen arm 
(RR=1.16). The participation in the screen arm was only 23%. In addition, the 
time from randomization to screening was 3 years in the screening arm and 
therefore the time to observe mortality was 3 years shorter compared to the 
control group, because men diagnosed with prostate cancer before the 
screening date were excluded .  
The Tyrol mass-screening study wherein PSA testing was freely 
available in the federal state of Tyrol showed promising results when prostate 
cancer mortality was compared to other parts of Austria where PSA testing 
was not freely available and to expected death rates in Tyrol. However, this 
was not a randomized controlled trial 60. Several case-control studies were 
conducted in the USA with DRE and PSA screening that also support the 
benefit of screening, showing an inverse association between the screening 
test and the prostate cancer mortality (odds ratio 0.7). Nevertheless, the 95% 
confidence interval was 0.5-1.1 and the DRE screening effect could not be 
separated from the PSA screening effect .  
Within the ERSPC results will not be available until 2008. However, 
there is confirmatory evidence that screening introduces more favorable 
prostate cancer characteristics. Within the Finnish section of the ERSPC, the 
proportion of clinically organ confined prostate cancer in the screening arm 
was 82% compared to 65% in the control arm 61. In the Rotterdam section of 
the ERSPC, radical prostatectomy specimens of patients not in a screened 
population were compared with patients from a screened cohort. Metastasis 
was not seen in the screened cohort, whereas 18% of the control population 
had metastases. Gleason score and pathological stage was also significantly 
lower in the screened cohort as compared to the not screened cohort. This 
report presents clear evidence for favorable disease stages in prostate cancer 
in the screening arm 62. 
Screening may miss its original goal and cause more harm than 
benefits. Screening introduces lead-time: this means that through screening, 
prostate cancer is diagnosed earlier than based on clinical incidence. The 
calculated lead-time for prostate cancer ranges between 4.5 and 12 years. 
Lead-time depends on age and aggressiveness of the cancer. Younger men 
and indolent prostate cancers have longer lead times, compared to older men 
with high grade disease .As yet the optimal screening interval in trials is 
unknown, notwithstanding, yearly PSA testing is recommended in the USA 
as mentioned above 47. Thornblom et al. who screened with PSA >10.0 ng/ml 
and/or abnormal DRE and TRUS, found no over diagnosis at all after 12 
years of follow-up, when screening was only performed once. All centers in 
the ERSPC, except Sweden and Belgium have a screening interval of 4 years. 
The lead time at the ERSPC section in Rotterdam was estimated at a median 
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of 10.7 years, which would imply that a screening interval of 4 years is 
sufficient .  
Despite discouragement of PSA testing in Europe due to the lack of 
beneficial convincing evidence, PSA testing has become very common. The 
French urological association recommended recently PSA screening 63. In a 
population where the National Health Service does not approve screening, 
PSA testing was calculated as high as 36% in men in the UK between 1994-
1999. Miller et al. recently reviewed over 50,000 patients from the American 
College of Surgeons National Cancer Data Base (NCDB) and found that 69% 
of cases were diagnosed without symptoms and the majority of these men 
(78%) presenting with prostate cancer in the absence of symptoms was 59 
years or younger. In men 80 years and older, 46% were diagnosed 
asymptomatically, which probably indicates detection trough screening. This 
“contamination” may also occur in the control arms of randomized clinical 
trials and might blur their outcome.  
Recently for the Dutch part of the ERSPC, Otto et al. showed that the 
contamination rate in the control arm, which was measured in a 3-year 
follow-up amounted to 20.2% of men in the control-arm who had their PSA 
tested. Only 7-8% of men with PSA ≥3.0 ng/ml underwent prostate biopsy. 
This translates into a contamination rate in the control arm of the ERSPC of 
3% per year which may be considered as low and is taken into account by the 
sample size calculation 64.   
 
Screening with PSA 
Despite the lack of specificity, PSA has been found suitable as a screening 
tool. The most favored cut-off to use PSA as a screening tool, is the PSA range 
<4.0 ng/ml. Catalona et al. 65 initially used this cut-off as an indicator for 
biopsy and biopsies were also performed if patients had a digital rectal 
examination (DRE) suspicious for cancer. In the ERSPC a cut-off of PSA 4.0 
ng/ml was initially used as an indication for sextant biopsy as well as 
abnormal DRE and TRUS in the PSA ranges 1.0-3.9 ng/ml. However, it 
turned out that the relative sensitivity and positive predictive value (PPV) of 
DRE and TRUS was only 37% and 9.7% in the PSA range <4.0 ng/ml, based 
on the “a priori prevalence assessment” 66 (Table 5 shows the sensitivity and 
specificity of the DRE test alone of men who underwent sextant biopsy in two 
PSA ranges).  
 
Table 5 Sensitivity, specificity, positive predictive value (PPV) and negative 
predicting value (NPV) of the digital rectal examination (DRE) in two PSA 
ranges in the 1st screening round of the ERSPC. Every percentage is relative 
since in this table only men who underwent sextant biopsy (n=4117) were 
included. 
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PSA 
range 
ng/ml 
relative 
sensitivity 
% 
relative 
specificity 
% 
PPV % NPV % 
PSA<3.0 62 42 0.9 55 
PSA<4.0 50 54 16 86 
 
In addition to these unfavorable test characteristics it was shown that the 
proportion of cases with favorable prognostic factors increases with lower 
PSA values 10,66. At the same time evidence accumulated that in the PSA range 
2.0-4.0 ng/ml up to 65% of the cancers were missed by DRE and TRUS. With 
the (unproven) assumption that most of cancers present, and detectable in the 
PSA range 1-3 ng/ml, would still be detectable in a curable stage at re-
screening and after having shown that the overall detection rate remained 
unchanged in this PSA range 67, it was decided to omit DRE and TRUS as 
screening tests and to biopsy all men with PSA values in the 3.0-4.0 ng/ml 
range. In table 6 the incidence of prostate cancer of the 1st screening round is 
shown in different PSA ranges.  
 
Table 6 positive predictive value (PPV) and detection rate per PSA range in 
the 1st screening round of the ERSPC 
PSA range 
ng/ml 
No. men 
screened 
No. 
prostate 
cancer 
No. 
biopsies 
% PPV 
biopsy 
% PPV 
detection 
rate, PSA 
range 
0.0-0.9 7139 4 185 2.2 0.06 
1.0-1.9 6205 45 510 8.8 0.75 
2.0-2.9 2508 30 221 13.6 1.20 
3.0-3.9 1426 179 792 22.6 12.55 
4.0-10.0 2235 526 2006 26.2 23.53 
>10 457 230 403 57.1 50.33 
total/mean  19970 1014 4117 21.7 5.08 
 
After the initial cut-off of <4.0 ng/ml in 1994, Catalona et al. now recommend 
a PSA cut-off level of 2.6 ng/ml as an indictor for biopsy. They found a 
prostate cancer incidence of 22% in the 2.6-4.0 ng/ml PSA range (in biopsies). 
Tumors in this PSA range had favorable characteristics, they were 
significantly smaller and more often organ confined (88 vs. 63%) as compared 
to tumors detected in the PSA range 4.0 ng/ml and greater . Punglia et al.  
recently reported on the effect of verification bias, which occurs when the 
“relative” sensitivity and specificity is studied in a population which was only 
for a part exposed to the test (i.e. not everyone with an increased PSA value 
will undergo prostate biopsy to confirm prostate cancer). Verification bias 
masks the true sensitivity and specificity of PSA. Adjusting for verification 
bias (i.e. lowering the PSA threshold for biopsy recommendation from 4.1 to 
2.6 ng/ml in men younger than 60) simply significantly improved the 
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estimated sensitivity and specificity of the PSA test for a screening population. 
However, even after adjusting for verification bias, the bias still exists, if not 
all men were tested. In the prostate cancer prevention trial of Thompson et al.  
(discussed above) every man in the placebo group was offered a prostate 
biopsy after the 7-year study period, therefore this study was not subject to 
verification bias. In the PSA range ≤ 4.0 ng/ml, the prostate cancer incidence 
was 15% and of these tumors 15% contained Gleason pattern 4, which 
indicates that high grade cancer in the low PSA range is not a rare finding. 
Similarly, a side study performed in the screening arm of the ERSPC in the 
PSA range 2.0-3.9 ng/ml the prostate cancer revealed an incidence of 17% in 
sextant biopsies, and the detection rate was 14% four years after the initial 
screen . 
Detection and radical treatment of the large proportion of organ 
confined prostate cancers in this low PSA range, does not automatically lead 
to lower prostate cancer mortality rates: the high incidence of prostate cancer 
in sextant biopsies in the age range (61-91 years, with a median of 69 years) of 
the men in the study of Thompson et al. is not surprising, it includes the 
possibility that these biopsies identified autopsy cancers 68. Configuring this 
possibility, Hoedemaeker et al. reported organ confined tumors (pT2) in 93% 
of which 86% were small tumors (<0.5ml) in the PSA range <4.0 ng/ml in the 
ERSPC. Apart from being diagnosed clinically, half of the radical 
prostatectomy specimens contained Gleason pattern 4, in line with Thompson 
et al.  
To improve the test characteristics of PSA, various parameters related 
to PSA change were introduced (i.e. PSA velocity, PSA doubling time, PSA 
slope). PSA velocity was put forward as a promising screening tool by Carter 
et al. . They found a PSA velocity of 0.75 ng/ml per year significantly 
associated with clinical prostate cancer. However, in the screening arm of the 
ERSPC, PSA velocity was 0.62, 0.46 respectively 0.03 ng/ml per year in 
prostate cancer patients, men with negative biopsy outcome and men without 
a biopsy indication (PSA ≤3.0), respectively. When PSA velocity as well as 
PSA doubling time were tested in receiver operating characteristic analyses 
(ROC curves), the areas under the curve were only moderately greater than 
0.5 (equal to chance) and therefore of very limited use in predicting biopsy 
outcome in the screened population of the ERSPC . Particularly, in the low 
PSA range in the ERSPC, PSA velocity was not a predictive variable in a 
multivariate analysis to predict prostate cancer in sextant biopsies .  
When only the PSA <1.0 ng/ml range was considered, as in the 
Spanish section of the ERSPC, it was found that if these men were repeatedly 
PSA tested after a 4-year screening interval, only 4 prostate cancers were 
diagnosed. In concordance with this, within the Dutch section of the ERSPC 
0.9% of men with a PSA <1.0 ng/ml showed progression to PSA levels ≥3.0 
ng/ml, however if that occurred a PPV of 19% was found 69, (dr. F.H. 
Schröder, Erasmus medical center, Rotterdam, submitted)   
In the ERSPC, TRUS determined prostate volume was a negative 
predictor for biopsy outcome after multivariate testing; the smaller the 
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prostate, the higher the prostate cancer incidence . Therefore PSA density 
might be predictive for prostate cancer.  
In addition to PSA dynamics, other molecular forms of PSA have been 
under research. The ratio of free to total PSA improved the relative specificity 
in detecting prostate cancer in the PSA range 4-10 ng/ml by Catalona et al. 70. 
This was configured in several studies, including the Swedish part of the 
ERSPC . Pro-enzyme of PSA (Pro-PSA) and Benign PSA (BPSA) are formed in 
the peripheral and transitional zone of the prostate. The amount of pro-PSA is 
increased in prostate cancer whereas BPSA is increased in BPH patients . 
However when samples of the ERSPC were tested for Pro-PSA as an 
individual marker to distinguish between BPH and cancer it did not improve 
the specificity further than free PSA .  
 
Genetic abnormalities in prostate cancer 
Numerous genetic abnormalities have been described in prostate cancer, but 
only a few genes involved in progression of prostate cancer are shown to 
carry genetic alterations.  The most frequently occurring tumor suppressor 
genes in prostate cancer are PTEN and p53. Both represent markers of 
advanced prostate cancer. Loss of PTEN is associated with increased Gleason 
scores and increased risk of recurrence, while p53 gene mutations are most 
common in metastasized and androgen –independent prostate cancer. These 
markers provide no additional prognostic information to conventional 
prognosticators of prostate cancer 20. Genes involved in prostate cancers are 
genome-wide mapped by characteristic large chromosomal alterations (losses, 
gains, and translocations) in the tumor. Chromosomal losses are an indication 
for a localization of a tumor suppressor gene, whereas gains and 
translocations are an indication for an oncogene. The most frequent genetic 
changes in prostate cancer progression and/or prostate cancer recurrence are 
gain of the long arm off chromosome 8 and 11 (8q and 11q) and loss of the 
short arm of chromosome 8 (8p) . 
 
Conclusions 
Annual PSA testing was recommended since 1993 in the USA but, 11 years 
later in 2004, there is still no conclusive evidence that PSA screening is 
beneficial. When going through the points of Wilson and Jungner (Table 1) 
requirements 1-4 and 6 can be met. Point 5, a suitable screening test can be 
met partly, because the PSA test is a test with limited sensitivity. Better tests 
urgently need to be found. The ideal situation would be a test that 
distinguishes between significant or insignificant prostate cancer. The Natural 
history of prostate cancer is partly understood (point 6), however, we do not 
know what the natural history is of screen detected prostate cancer. Point 8, 
the policy of whom to treat as patients is discussed thoroughly in this 
introduction, because since increasingly more localized prostate cancers are 
diagnosed, over-diagnosis and therefore over-treatment accompanied with 
adverse side effect seriously influences quality of life. The answer if screening 
for prostate cancer reduces disease specific mortality and therefore can be 
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used continuously or as “a once and for all project” reflected in point 10 is still 
unknown. At the moment there is no scientific basis for population based 
prostate cancer screening outside randomized clinical trials designed to assess 
its effectiveness and identify men who might benefit from screening. 
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Abstract 
Objective: We evaluated the incidence of prostate cancer, high-grade prostatic 
intraepithelial neoplasia (PIN) and lesions suspicious for prostate cancer 
(LSPC) in sextant biopsies in two subsequent screening rounds at a 4-year 
interval and their predictive value for subsequent prostate cancer detection. 
Methods: In the Rotterdam section of the European Randomized Study of 
Screening for Prostate Cancer (ERSPC), 4117 men underwent sextant biopsy 
in the 1st screening round. The 2nd round was performed at a 4-year interval 
and biopsies were taken in 1840 men.  
Results: The incidence of prostate cancer, LSPC and PIN in the 1st, 
respectively 2nd round were 24.6, resp. 19.9% (p=0.001), 2.7, resp. 2.8% and 0.8, 
resp. 2.5% (p<0.0001). Prostate cancer incidence after repeat biopsy for LSPC 
in the 1st, resp. 2nd round was 36.7 and 17.0%, and after repeat biopsy for PIN 
13.3% in both rounds, respectively. Men with a benign biopsy in the 1st round 
had a significantly lower prostate cancer incidence in the 2nd round compared 
to men who did not undergo biopsy in the 1st round (10.7 vs. 22.7%, 
p<0.0001). 
Conclusions: The decrease of prostate cancer detection in the 2nd round was 
associated with an increase in the incidence of PIN. Strikingly, LSPC 
diagnosed during the 1st round, but not during the 2nd round were predictive 
for prostate cancer, while isolated PIN was never predictive for prostate 
cancer. PIN shoud not be an indication for repeat biopsy in a screening 
population. Importantly a 1st round benign biopsy outcome proved to be a 
negative predictor of subsequent prostate cancer detection.  
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Introduction 
Elevated serum prostate specific antigen (PSA) tests and to a lesser extent 
abnormal digital rectal examination (DRE) and transrectal ultrasonography 
(TRUS) are indicators for prostate biopsy. So far histopathologic examination 
of prostate needle biopsies is the only possibility to establish the diagnosis of 
prostate cancer. Some prostate biopsy lesions, like high-grade prostatic 
intraepithelial neoplasia (PIN), or lesions suspicious for prostate cancer 
(LSPC) have been postulated as lesions predictive for the subsequent 
detection of prostate cancer 72,73.  
A LSPC is characterized by a proliferation of prostatic glands with 
abnormal architectural patterns, but lacking sufficient cytonuclear atypia to 
make a definite diagnosis of prostate cancer 74. LSPC have been described by a 
wide variety of terms, including atypical small acinar proliferation (ASAP) 75. 
The incidence of LSPC is 1.5-4.8% of prostate biopsies 76,77 and the chance of 
finding prostate cancer on repeat biopsies ranges from 39%  up to 60% 78,79.  
PIN is characterised by atypical glandular cells with prominence of 
nucleoli lining larger acinar structures surrounded by an interrupted basal 
cell layer. The incidence of isolated PIN in prostate needle biopsy is 5% 24. The 
chance of finding prostate cancer on repeat biopsy after an initial diagnosis of 
isolated PIN is 23-50%. 80-83. The current opinion is that PIN represents a 
precancerous state for prostate cancer, and close follow-up of these cases is 
recommended.  
In the current study we analyzed the frequency of prostate cancer in 
sextant biopsies, PIN, and LSPC in sextant needle biopsies in two subsequent 
prostate cancer screening rounds after a 4-year interval. In addition, the 
predictive value of prostate biopsies with benign outcome, PIN or LSPC for 
subsequent detection of prostate cancer was evaluated. 
 
Material and methods 
In the Rotterdam section of the European Randomized Study for Prostate 
Cancer (ERSPC) 42,376 participants, aged 55-75, were randomized in a 
screening (n=21,210) and a control arm (n=21,166). The first round of 
screening (prevalence screen) took place from November 1993 until December 
1999. A total of 19,970 men actually underwent screening. Screening for 
prostate cancer in this study was done by PSA determination, DRE and TRUS. 
Systematic sextant prostate needle biopsy was recommended for participants 
who had either an elevated PSA level (≥ 4.0 ng/ml), abnormal DRE or 
abnormal findings on TRUS. The protocol was simplified on May 1997, when 
sextant biopsy was recommended if PSA was ≥3.0 ng/ml. Abnormalities on 
DRE and/or TRUS were no longer indicators for biopsy. Until March 1996, an 
interim screening was performed. One year after the 1st screening round men 
with benign biopsy outcomes at the prevalence-screening round were re-
invited at an interim screening round for PSA measurement. In this interim 
screening round there were 495 men biopsied. 
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The second screening round, using PSA ≥3.0 ng/ml as a cut-off value for 
sextant biopsy, started in November 1997 and is still ongoing. Until 
September 2003, 11,654 men were screened 
PSA determinations were done with a Hybritech Tandem E assay (Hybritech 
Beckman-Coulter Corp., San Diego, Cal), and after January 2000, the 
automated version was used (Beckman-Access, Beckman-Coulter Inc. 
Fullerton CA, USA). All men had signed informed consent prior to their 
participation to the screening study. 
Systematic sextant biopsies were obtained during longitudinal and 
cross-sectional ultrasonographic scanning of the prostate. A 7th biopsy was 
taken if a hypo-echogenic lesion was visible at TRUS. Repeat biopsy strategy 
for PIN was repeat sextant biopsy and a 7th if a hypo-echogenic lesion was 
visible at TRUS and for LSPC, 4 biopsies were taken from the region of the 
prostate were the lesion was diagnosed. One pathologist (T v/d K) reviewed 
all biopsies with cancer, PIN and LSPC in order to avoid inter-observer 
variation. During this review, the number and size of biopsies were recorded 
as well as proportion of tumor involvement, and proportion of each Gleason 
grade.  
 
Statsistical analysis 
Statistical analysis was done with the SPSS software package (SPSS Inc., 
Chicago, IL). P<0.05 was considered significant. Chi-square tests were used 
for ordinal variables, student T-test for linear variables, i.e. PSA and age. 
 
Results 
Prostate cancer incidence 1st, interim, and 2nd screening round 
In the 1st screening round 19,970 men had a PSA test, of whom 4117 
underwent sextant biopsy. In total, after repeat biopsies for PIN and LSPC 
were performed, 1014 men with prostate cancer were diagnosed (biopsy 
incidence 24.6%). One year thereafter, 514 men were re-invited for sextant 
biopsy in the interim screening round (including 15 men who did not show 
up for biopsy in the 1st screen). In this round 63 prostate cancers were 
diagnosed after performing repeat biopsies. After exclusion of 3 men with 
prostate cancer detected in the interim screening round who did not undergo 
sextant biopsy in the 1st round, it could be calculated that  prostate cancer 
incidence dropped in the interim screen, as compared to the prevalence 
screening round from 24.6 to12.1% (p<0.0001). So far, in the 2nd screening 
round 1840 men underwent sextant biopsy and 366 prostate cancers were 
diagnosed (incidence 19.9%), which was significantly lower compared to the 
biopsy detection rate in the 1st round (p<0.0001).  
In Table 1 the diagnoses of men biopsied in the 1st and 2nd screening rounds 
are shown.  
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Table 1 Biopsy Findings in 1st and 2nd Screening Round 
 initial biopsy  
n (%) 
 diagnosis after repeat 
biopsy n (%) 
 cancer detection 
rate n (%) 
 
biopsy 
diagnosis 
1st round  2nd round  1st round  2nd round  1st   round 2nd round  
Benign 3004 
(72.8) 
1391 
(75.6) 
3078 (75.1) 1457 (79.5) 60 (12.1)1 NA 
PIN 34 (0.8) 46 (2.5) 3 (0.0) 6 (0.0)  9 (13.3) 6 (13.3) 
LSPC 108 (2.6) 50 (2.7) 5 (0.0) 2 (0.0) 35 (36.5) 8 (17.0) 
PC 970 (23.6) 353 (19.2) 1014 (24.7) 367 (20.0) NA NA 
other 
malignancy2 
1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 
total (%) 4117 
(100) 
1840 
(100) 
41013 (100) 18323 (100) 1014(24.6) 367 (19.9) 
NA Not Available, PIN Prostatic Intraepithelial Neoplasia, LSPC Lesion Suspicious for 
Prostate Cancer, PC Prostate Cancer 
1Prostate cancer detection rate after repeat biopsy in interim screening round, selected from 
3078 benign biopsies in the 1st screening round 
2Leiomyosarcoma of rectal wall 
316 men in the 1st and 8 men in the 2nd screening round declined repeat biopsy  after a 
diagnosis of PIN or LSPC (see figure 1 and 2 ) 
 
PIN in two subsequent screening rounds 
In the 1st screening round 34 of 4117 biopsied men had a diagnosis of isolated 
PIN (0.8%). Thirty men underwent repeat biopsy, of whom 4 were diagnosed 
with prostate cancer (13.3%). In the remaining 26 men, who underwent repeat 
biopsy, only 2 men were again diagnosed with PIN and 2 other men with 
LSPC. 
In the 2nd round, 46 men were diagnosed with PIN (2.5%), 41 of whom 
underwent repeat biopsy. Six men were diagnosed with prostate cancer 
(13.3%). Of the remaining 35 men, four respectively one man were diagnosed 
with PIN respectively LSPC, after repeat biopsy. Except for one man who was 
biopsied 3 times and showing PIN each time, men with PIN in their repeat 
biopsy were not rebiopsied a 3rd time in the 1st and 2nd round. Compared to 
men who underwent repeat biopsy for an initially benign diagnosis, men with 
an initial diagnosis of PIN did not have a higher probability for detection of 
prostate cancer (12.1 vs. 13.3%). Although men with PIN in the 1st round were 
significantly older compared to men with benign diagnoses, this was not the 
case in the 2nd round. The incidence of PIN increased significantly from the 1st 
to the 2nd round (p<0.0001). Potential predictive factors for detection of 
prostate cancer after repeat biopsy, i.e. the length, bilaterality and multi-
focality of PIN in biopsy cores, age, PSA, DRE and TRUS findings, did not 
reach significance, neither in the 1st nor in the 2nd round.  
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Prostate cancer yield after repeat biopsy for a LSPC 
Hundred-eight men were diagnosed with a LSPC in the 1st round (2.6%). A 
total of 96 men underwent repeat biopsy and 35 of them were diagnosed with 
prostate cancer (36.5%). Compared with the biopsy detection rate of cancer in 
the interim screening round, prostate cancer incidence after repeat biopsy in 
men with a 1st round LSPC was significantly higher (p<0.0001). Two men 
diagnosed with PIN in their 1st biopsy were diagnosed with LSPC after repeat 
biopsy. 
In the 2nd round 50 men were diagnosed with LSPC (2.7%), 47 men 
underwent repeat biopsy and 8 of them were diagnosed with prostate cancer 
(17.0%), which was significantly lower, compared to the 1st screening round 
(p<0,0001). Similarly, when the prostate cancer incidence on repeat biopsy in 
the 2nd round was compared with the interim screening round prostate cancer 
incidence no significant differences could be found. 
Slightly more men had LSPC in the 2nd screening round compared to the 1st 
screening round. Men with LSPC had significantly higher PSA values (6.3 vs. 
4.5 ng/ml) compared to men with benign diagnoses at biopsy in the 1st round 
(p<0.0001), but not in the 2nd round. Despite higher PSA values in the 1st 
round in men with LSPC, their PSA level, age, DRE, and TRUS findings were 
not predictive for prostate cancer after repeat biopsy in both rounds. 
 
Prostate cancer yield during subsequent screening rounds after initial diagnosis of 
PIN or LSPC 
In Figure 1 and 2, the flowcharts of PIN and LSPC diagnoses in the 1st and 2nd 
screening round can be seen.  In total 2 out of 22 men diagnosed with PIN in 
the 1st round were diagnosed with prostate cancer in the follow-up. One man 
with an initial PIN diagnosis, followed by a lesion suspicious for malignancy 
after repeat biopsy in the 1st round was diagnosed with prostate cancer in the 
interim screen. Another man with PIN in his 1st sextant biopsy and benign 
diagnosis in his repeat biopsy was incidentally diagnosed with prostate 
cancer at transurethral resection of the prostate (TURP) 3 years later. Three 
men with a PIN-diagnosis in the 1st round were invited in the interim 
screening round. They had benign diagnoses after repeat biopsy for PIN in 
the 1st as well as in the interim screening round. Three men with a PIN 
diagnosis in the 1st round (of whom 2 also underwent screening in the interim 
screening round) had a benign biopsy outcome in the 2nd round.  
In total 7 out of 108 men with an initial LSPC diagnoisis in the 1st round 
were detected with prostate cancer after a 4-year follow-up. Four men with 
benign biopsy outcome after repeat biopsy for LSPC in the 1st round, were 
diagnosed with prostate cancer in the 2nd round. Three of the 4 had a benign 
diagnosis in their repeat biopsies. The 4th man was diagnosed with prostate 
cancer after repeat biopsy, prompted by a PIN-diagnosis in the 2nd round. 
One man did not undergo repeat biopsy in the 1st round, but was diagnosed 
with prostate cancer in the 2nd screening round. 
Two men with LSPC in the 1st round had an interval carcinoma just 
before the 2nd screening round. One of them declined repeat biopsy in the 1st 
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screening round. The other interval carcinoma was detected after a rising 
PSA.  
 
 
 
 
Figure 1 PIN in 1st and 2nd scfeening round 
 
 
 
 
Benign: benign diagnosis after repeat biopsy  
PC: prostate cancer 
LSPC: lesion suspicious for prostate cancer 
PIN: prostatic intraepithelial neoplasia 
PIN 1st round
1 PC
22 benign 4 PC
1 PC
2 LSPC 2 PIN
30 repeat biopsies 4 no repeat biopsies
PIN 34
PIN 2nd round
30 benign 6 PC 1 LSPC 4 PIN
41 repeat biopsies 5 no repeat biopsies
PIN 46
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Figure 2 LSPC in 1st and 2nd round 
 
 
 
 
 
 
 
Benign: benign diagnosis after repeat biopsy  
PC: prostate cancer 
LSPC: lesion suspicious for prostate cancer 
PIN: prostatic intraepithelial neoplasia 
 
 
 
 
 
 
 
LSPC 2nd Round
36 benign 8 PC 1 LSPC 2 PIN
47 repeat biopsies 3 no repeat biopsies
LSPC 50
LSPC 1st round
5 PC
57 benign 35 PC 3 LSPC 1 PIN
96 repeat biopsies
2 PC
12 no repeat biopsies
LSPC 108
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Prostate cancer yield after benign biopsy outcome in the first and/or interim screening 
round 
After (repeat) sextant biopsies in the first round, 3078 men had benign 
diagnoses, and 745 of them underwent a biopsy in the 2nd screening round. 
Prostate cancer was found in 86 men. However, one man was diagnosed with 
PIN and 5 men with LSPC in their first biopsy in the 2nd round. When 
excluding these 6 men, there was a chance of 10.7% of being diagnosed with 
prostate cancer in the 2nd round after a benign biopsy in the first round. The 
2nd round prostate cancer incidence in men who were biopsied in the 1st as 
well as in the interim screen, (n=192) was 10.9% after exclusion of 2 men who 
had initially LSPC in the 2nd round and prostate cancer after repeat biopsy. 
The prostate cancer incidence in men who were not biopsied in the 1st round 
was 22.7%, which was significantly higher (p<0.0001). Eight men were found 
with an interval carcinoma between the 1st and 2nd screening round. Of those 
men with a benign biopsy in the 1st round, significantly more men with 
abnormal DRE and TRUS in the 2nd round were at risk for detection of 
prostate cancer as compared to men with normal DRE and TRUS findings 
(p=0.004 and p=0.007). PSA, PSA-velocity and age however, were not 
predictive for prostate cancer after biopsy in the 2nd round. 
 
Discussion  
Here we report on the incidence of prostate cancer in sextant biopsies and the 
chance of finding prostate cancer after repeat biopsy for different lesions 
predictive of cancer studied in two subsequent screening rounds with an 
interval of 4 years. The prostate cancer incidence in sextant biopsies declined 
significantly from 24.6% to 19.9% in the 1st and 2nd screening round, 
respectively. This is associated with the previously reported drop in the 
amount and grade of tumor in sextant biopsies in the 2nd screening round 84. 
Also the proportion of potentially advanced prostate cancers (Gleason score 
≥4+3 in sextant biopsy) significantly decreased in the 2nd screening round 85. 
The incidence of PIN in sextant biopsies increased significantly from the 1st to 
the 2nd round (0.8% vs. 2.5%). Especially in the 1st screening round the 
proportion of isolated PIN is low as compared to data in literature. DeMarzo 
et al. recently published a PIN incidence of 5% 24. This was, however, after 
reviewing 439 cases where-in 6 cases of PIN were missed and another 6 cases 
were previously diagnosed as low-grade PIN. The PIN incidence before 
review was 2.7%, which is comparable to our 2nd round data. The incidence 
reported in our series was without reviewing and the actual PIN incidence 
might therefore be higher than reported here. As a result of reviewing sextant 
biopsies for PIN, its incidence is expected to increase, because the reviewer 
will be more focused on the detection of PIN instead of prostate cancer. Inter-
observer variation for diagnosing PIN is reported to be “moderate” (kappa 
value 0.61-0.81), 86 which could result in a higher PIN incidence by chance. 
Other explanations for the discrepant low PIN incidence in our study include: 
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1) in a population based screening lower PIN incidence rates may occur 
compared to a referred urological population. 2) ”only” sextant biopsies were 
performed, which represent a limited sample size. 3) Tissue 
preparation/staining variables may influence the pathologic features used to 
diagnose PIN 87.  
Since all PIN diagnoses were reviewed by one uro-pathologist (T.v/d 
.K) and biopsy and preparation methods were equal in the subsequent 
screening rounds, the observed rise of the PIN-incidence in the 2nd round may 
be considered realistic. An explanation for the increased frequency in PIN 
may be the aging of the screened population. Indeed, in an autopsy study, it 
has been shown that PIN occurs more commonly in older men 43, a 
phenomenon also observed during the prevalence screening round in our 
study (data not shown). The incidence of LSPC remained stable during the 
two subsequent screening rounds (2.6% to 2.7%). This incidence is 
comparable to previous literature data ranging from 1.5-4.8% 76,77. Generally, 
much less variation in the incidence of suspicious lesions is reported 
compared to PIN.  
During the 1st screening round LSPC was highly predictive for 
detection of prostate cancer after repeat biopsy. Strikingly, this was not the 
case for men diagnosed with a LSPC in the 2nd screening round, although the 
proportion of detected prostate cancers tended to be higher as compared to 
that in men with initially benign diagnosis in the first screening round 
undergoing biopsy one year later (17.0 vs. 12.1%). This difference was not 
significant. Men with PIN in the 1st and 2nd round were not at increased risk 
for detection of prostate cancer after repeat biopsy as compared to men with a 
previous benign biopsy diagnosis (13.3 vs. 12.1%). One other large study also 
has reported that PIN is not a risk factor for prostate cancer detection after 
repeat biopsy 88. The limited predictive value of isolated PIN is further 
illustrated by prostate cancer in only two men with a prior PIN diagnosis 
(and benign diagnosis after repeat biopsy) after a 4-year interval. If these two 
men were added to the men who were diagnosed with prostate cancer after 
repeat biopsy for PIN, there still would be no significantly increased prostate 
cancer risk for men with PIN in the 1st round. This implies that in this 
screening study the only lesion significantly predictive for subsequent 
prostate cancer is a diagnosis of LSPC, particularly in the 1st screening round.  
The finding that PIN and possibly LSPC in the 2nd round do not 
represent a significant risk factor for subsequent detection of prostate cancer 
is not comparable to previous literature, where PIN, respectively LSPC is 
reported to be associated with 23-51% 80-83, respectively 39- 60% 78,79 chance of 
prostate cancer after repeat biopsy. This may be due to differences in the 
populations under investigation. For example, the population of Park et al. 83 
in which the prostate cancer detection rate is 50% after repeat biopsy for PIN, 
does not represent a clear screening or referred urological population. 
However, the number of repeat biopsies and cores in their population (19% of 
the population had a 3rd sextant biopsy with at least 6-10 core biopsies) 
explains a higher prostate cancer incidence. The higher detection rate of 
53
 53
prostate cancer after repeat biopsy for LSPC reported by some authors 88 may 
similarly be the consequence of a different repeat biopsy protocol.  In our 
center, only 4 cores were taken, directed at the site where the LSPC was 
found. The intention of our repeat biopsies was just to confirm or to disprove 
that the previously detected LSPC represented an adenocarcinoma. Allen et 
al. 89 reported that prostate cancer was found on the same and adjacent sites 
of the atypical small canard proliferation in 85% of the time and the 
remaining were found at other sites. Extrapolating this data would imply that 
15% of cancers are missed by our biopsy strategy. This percentage 
corresponds well with the ``background`` prostate cancer incidence of 12.1% 
in men with prior benign diagnosis.  
 Another explanation for our lower prostate cancer incidence after 
repeat biopsy for PIN and LSPC could be down-staging and reduction of 
tumor volume in our cohort of men. Tumor stage in prostate cancer declined 
considerably after introduction of prostate cancer screening 62. The chance of 
diagnosing prostate cancer obviously decreases with lower tumor volumes 90. 
From literature we know that in up to 99% of cystoprostatectomies because of 
bladder cancer contained PIN, whereas in only half of these prostates also 
concurrent prostate cancer was diagnosed 91. This indicates that the “volume” 
of PIN involved glands in a prostate may be larger as compared to the 
volume of cancer in case screen-detected prostate cancers. Thus, during 
subsequent screening rounds the chance of finding prostate cancer on sextant 
biopsy decreases and the chance of finding PIN increases. Nevertheless, 
detection of PIN is subject to a considerable sampling bias as becomes 
apparent from the observation that in the minority (2 of 24, i.e. 8.3%) of men 
with an initial diagnosis of PIN, this lesion was found again during repeat 
biopsies.  
A large proportion of the men (i.e. 40.5%) who underwent sextant 
biopsy in the 2nd round of our screening study also underwent sextant biopsy 
in the 1st round. Strikingly, men with a benign biopsy outcome in the 1st 
round, including those who underwent a repeat biopsy, were at significantly 
decreased risk of prostate cancer compared to men who never had a sextant 
biopsy before (10.7 vs. 22.6% p<0.0001). This is comparable to the observation 
in men who underwent “repeat” biopsy in the interim screen:  Their prostate 
cancer incidence dropped to 12.1% (1 year after a benign diagnosis in the 1st 
round). The prostate cancer incidence in the 2nd round of men who were 
previously biopsied once (1st round) or twice (1st and interim screening 
round) was 10.7 vs. 10.9%, respectively. Apparently, a screening interval of 1-
or 4 years after a benign biopsy outcome did not influence the prostate cancer 
incidence in sextant biopsies. In literature a range from 10-30% prostate 
cancer incidence has been reported for repeat biopsies after a prior benign 
diagnosis 92-95. Djavan et al. found a 10% prostate cancer incidence after doing 
repeat biopsy (sextant biopsy and 2 additional transition zone biopsies) 
within 6 weeks, a comparable figure with ours, but Fleshner et al. reported a 
prostate cancer incidence of 30% after repeat biopsy. This high incidence may 
be attributed to the low number of biopsies (< 6 biopsy cores) in almost 20% 
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of the men during the initial biopsy procedure. Comparison of our data with 
literature is confounded by differences in biopsy procedures (i.e. different 
number of repeat biopsies, number of biopsy cores and regions in the prostate 
biopsy) and patient populations. Also the quality of the pathology 
performance may influence the biopsy detection rate of prostate cancer after 
an initial biopsy with benign outcome 96. 
 
Conclusions 
The significant decrease of prostate cancer incidence in sextant biopsies in the 
2nd screening round was associated with an increase in the proportion of 
biopsies with isolated PIN. Strikingly, during the 1st round, but not during the 
2nd round LSPC was highly predictive for subsequently detected prostate 
cancer, while PIN was not predictive for prostate cancer in repeat biopsy 
neither in the 1st nor 2nd round. This might be explained by downsizing of the 
tumor volumes in the 2nd round. No clinical variable could help predict the 
outcome of repeat biopsy diagnostics. Furthermore, an initially negative 
biopsy in the 1st screening round proved to be “protective” for prostate cancer 
in the 2nd screening round. DRE and/or TRUS abnormalities were now able to 
predict subsequent prostate cancer after an initially benign diagnosis. The 
finding of isolated PIN in a screened population had no predictive value for 
prostate cancer within 4 years and therefore this lesion by itself should not be 
considered an indication for repeat biopsy. For a diagnosis of LSPC in the 2nd 
screening round we continue to recommend a repeat biopsy, since a repeat 
biopsy is intended to clarify the nature of the previously diagnosed LSPC. 
Additionally, abolishment of repeat biopsies after a diagnosis of LSPC could 
increase the pressure on the pathologists to give a less ambiguous diagnosis.  
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Abstract 
Objective: To evaluate whether the incidence of atrophy reported on sextant 
biopsies is associated with subsequent prostate cancer detection. To obtain a 
more thorough analysis of the different categories and extent of atrophy a 
review of benign biopsies was performed.  
Methods: In the Rotterdam section of the European Randomized Study of 
Screening for Prostate Cancer (ERSPC) 4117 and 1840 men underwent sextant 
biopsy in the 1st and 2nd screening round (4-year interval), respectively. 
Sextant biopsy was prompted by elevated PSA. For review, randomly taken 
benign sextant biopsies (n=202) with a follow-up of at least 8 years were 
chosen. 
Results: Before review, atrophy was reported in biopsies in 11.4% and 8.7% in 
the 1st and 2nd round, respectively. Prostate cancer incidence during 8-year 
follow-up after an initial diagnosis of atrophy was 10.4%, which was not 
significantly higher than the 12.3% of cancers detected after a benign 
diagnosis without reference to atrophy. After review the incidence of simple 
atrophy, post atrophic hyperplasia and sclerotic atrophy in sextant biopsies 
was 91, 47 and 9%, respectively. Extensive atrophy was observed in 5% of 
biopsies. Only 2 (4.7%) men in the reviewed group had a subsequent 
diagnosis of prostate cancer in the 8-year follow-up. Additionally, prostatic 
intraepithelial neoplasia (PIN) was diagnosed in 3 men (7.0%) in the 2nd 
screening round.  
Conclusions: Atrophy, especially its simple form, is a very common lesion in 
prostate biopsies (94%). Atrophy in an asymptomatic population subject to 
screening was not associated with a higher prostate cancer or PIN incidence 
during subsequent screening rounds. 
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Introduction 
Prostate cancer is the most common non-cutaneous malignancy in the 
Western world4. So far histopathologic examination of prostate needle 
biopsies is the only possibility to establish the diagnosis of prostate cancer. 
Histological examination of prostate biopsies can be difficult and a conclusive 
diagnosis cannot always be rendered, since some lesions may resemble 
prostate cancer 24. A lesion suspicious for prostate cancer, and high-grade 
prostatic intraepithelial neoplasia (PIN) and, more recently, atrophy have 
been considered as lesions predictive for associated prostate cancer 72,73. It is 
hypothesized that atrophy is the consequence of chronic inflammation. 
Chronic inflammation has been linked to cancers other than prostate cancer 
(i.e. the liver (hepatitis C), stomach (Helicobacter pylori) and colon (colitis 
ulcerosa)). Also epidemiological evidence exists for a link between infections 
(i.e. sexual transmitted disease) and inflammation (prostatitis) and prostate 
cancer 97. The observation of reduced frequency of prostate cancer in men 
using non-steroidal anti-inflammatory drugs (NSAIDs) is consistent with the 
hypothesis that there is an association between inflammation and prostate 
cancer 98. 
Several forms of prostatic atrophy have been described. Ruska et al. 
distinguished two categories of atrophy, i.e. simple atrophy (SA) and post 
atrophic hyperplasia (PAH). A third form, sclerotic atrophy, was also 
suggested to represent a pre-neoplastic lesion, however this is a seldom found 
diagnosis 99. Because atrophy was believed to originate from inflammation, 
McNeal et al.100 used the term post-inflammatory atrophy for the above 
mentioned (SA and PAH) lesions 97. DeMarzo et al. introduced the term 
“proliferative inflammatory atrophy” (PIA) for PAH and SA, since both tend 
to be highly proliferative lesions, associated with inflammation. They also 
suggested that PIN lesions might arise from PIA 101,102.  
Atrophy has been linked to prostate carcinogenesis by some authors, 
because of its spatial relationship with cancer in radical prostatectomy 
specimens 103. Some molecular changes in prostate cancer and PIN are shared 
with atrophy; the frequency of p53 mutations in PAH was equal to the 
frequency in PIN, in a small numbers of cases 104. The incidence of atrophy in 
prostate biopsies is unknown. Nevertheless, a recent study reported the 
occurrence of atrophy in autopsy prostates: of the examined prostates 66% 
contained atrophy with inflammation and 22% contained atrophy without 
inflammation, respectively 105.  
This study focuses on the frequency of atrophy reported in sextant 
biopsies during two subsequent prostate cancer screening rounds with a 4-
year interval. To make a distinction between the different forms of atrophy, 
their extent in needle biopsies and their role as a predictor for prostate cancer, 
202 biopsies reported with a benign outcome (including atrophy), were 
reviewed. 
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Material and methods 
Study population 
Our study population consisted of 41,919 participants, aged 55 to 74 years, 
who were randomized to screening and non-screening. The prevalence 
screening was done between June 1994 until December 1999 and a total of 
19,970 men were actually screened. Screening for prostate cancer was done by 
PSA determination, digital rectal examination (DRE) and transrectal 
ultrasonography (TRUS). Systematic sextant needle biopsy was recommended 
for participants who had either an elevated PSA level (≥ 4.0 ng/ml) or 
abnormal DRE and/or abnormal findings on TRUS. After November 1997, 
sextant biopsies were suggested in all men who had a PSA value of 3.0 ng/ml 
or more, and DRE and TRUS were omitted as a screening tool. The 2nd 
screening round, using the PSA ≥3.0 ng/ml screening protocol after a 4-year 
interval, started in June 1998 and finished in December 2003.  
 
Diagnosis of atrophy without pathology review 
In the routine prostate cancer screening setting (before review), community 
pathologists could, in the absence of cancer, report atrophy as a separate 
diagnostic entity on sextant biopsies. However, no guidelines regarding the 
criteria for such a diagnosis are employed in the laboratory.  
 
Categories of atrophy after pathology review 
For review, one uro-pathologist (T.v.d.K), who was blinded for follow-up 
details, reviewed a random sample of sextant biopsies (n=202) with a benign 
outcome (including atrophy) for the incidence and category of atrophy. The 
sextant biopsies dated from 1995, in order to achieve a follow-up of at least 8 
years. The diagnostic entity “atrophy” was split up in three different 
categories, which are shown in figure 1: 1) Simple atrophy, 2) post atrophic 
hyperplasia, and 3) sclerotic atrophy. Each category was further graded in 
arbitrary extent categories: 1) no atrophy, 2) 1-3 biopsy cores containing one 
or more separate small (<5 mm) foci of atrophy, 3) >3 biopsy cores containing 
one or more separate small (<5 mm) foci of atrophy, 4) >5 mm of continuous 
atrophy (adjacent area) in 1 or 2 biopsy cores, 5) >5mm of continuous atrophy 
(adjacent area) in >2 biopsy cores. 
 
Statistical analysis  
Statistical analysis was done with the SPSS software package (SPSS 11.0 Inc., 
Chicago, IL). P<0.05 was considered significant. Chi-square tests were used 
for ordinal variables, student T-test for linear variables, i.e. PSA, age and 
prostate volume. Multinomial regression was used to evaluate the association 
between the extent of atrophy and age, PSA and prostate volume. 
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Figure 1 a Simple atrophy, with whole biopsy core involved, b Post-atrophic 
hyperplasia (black arrow), c Sclerotic atrophy, with whole biopsy core 
involved 
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Results 
Atrophy incidence before review 
In the 1st and 2nd screening round 4117 and 1840 men underwent sextant 
biopsy. Atrophy was reported in 11.4% (468) and 8.7% (160) of sextant 
biopsies in the 1st and 2nd round, respectively (p<0.0001). Of those 468 men 
reported with atrophy in the 1st round, 135 were again biopsied in the 2nd 
screening round. Prostate cancer was found in 14 (10.4%) men. Of those men 
whose 1st biopsy showed benign pathology without atrophy and biopsied 
again in the 2nd screening round (n=661), 12.3% were found to have prostate 
cancer, which was not statistically different from the prostate cancer incidence 
after an initially reported diagnosis of atrophy (10.4%). Thirty-nine patients 
were diagnosed with prostate cancer before the scheduled 4-year screening 
interval (interval carcinomas). Of these 39 patients, 5 and 34 had atrophy and 
benign diagnoses reported in the 1st screening round. If these numbers of 
patients were added to the 10.4% and 12.3% prostate cancer incidence in the 
2nd screening round, there still was no significant difference in prostate cancer 
incidence in men with atrophy as compared to those with benign diagnosis 
during the 1st round. The PIN incidence in the 2nd round in men with a 1st 
round atrophy and benign diagnosis was 5.4 and 3.3%, respectively, which 
was a non-significant difference. 
Men with a reported atrophy diagnosis were significantly older and 
had larger prostate volumes (59 vs. 51 ml) as compared to men with a benign, 
no atrophy biopsy diagnosis (p<0.001). PSA levels did not differ significantly 
between these two groups 
 
Atrophy incidence after review  
Two hundred-two consecutive sets of sextant biopsies from the 1st screening 
round reported as benign, including atrophy, diagnoses were reviewed for 
the presence of 3 different types of atrophy and their extent. The results are 
listed in table 1.  
 
Table 1 Different forms of atrophy in prostate needle biopsies 
 simple atrophy 
(SA)  
n (%) 
post atrophic 
hyperplasia 
(PAH) n (%) 
sclerosing 
atrophy  
n (%) 
no atrophy 
 
18 (9) 106 (53) 184 (91) 
1-3 cores with 
focal atrophy 
114 (56) 77 (38) 17 (8) 
>3 cores with 
focal atrophy 
42 (21) 4 (2) 1 (1) 
 
>5 mm atrophy 
in 1 or 2 cores 
21 (10) 12 (6) 0 (0) 
 
In total 94% of the men were diagnosed with some form of atrophy of which 
simple atrophy was the most common form. Extensive atrophy (a continuous 
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area of >5 mm in more than 2 cores) was seen in 5% of men, predominantly in 
the simple atrophy form. In total, 43 men with an atrophy diagnosis after 
review underwent biopsy in the 2nd screening round of whom two (4.7%) and 
3 (7.0%) men were diagnosed with prostate cancer and PIN. The 2 men 
diagnosed with prostate cancer had both simple-and post atrophic 
hyperplasia. The extent of atrophy in these two men was intermediate to large 
for simple atrophy (atrophy category 3 and 4 for man 1 and 2) and small for 
post atrophic hyperplasia (atrophy category 1 and 2 for man 1 and 2). No 
interval carcinomas or cancers diagnosed after the age of 75 were found in 
these men.  
Men with atrophy after review were significantly older, compared to 
men without atrophy (67 vs. 62 years of age, P=0.008). Although not 
significant, men with atrophy had higher prostate volumes and PSA levels 
compared to men without atrophy. Men with extensive (atrophy category 4 
and 5) post atrophic hyperplasia had higher PSA levels compared to men 
with extensive simple atrophy, however this was also not significant. The 
extent of atrophy was not significantly associated with a higher prostate 
cancer incidence. 
 
Discussion 
In this study we reported the incidence of atrophy before and after review 
and the prostate cancer incidence in sextant biopsies in the subsequent 
screening rounds after a 4-year screening-interval.  
Before review, the incidence of reported atrophy was 11.4% and 8.7%, 
in the 1st and 2nd screening round, respectively. The prostate cancer incidence 
in the 2nd screening round in men with a diagnosis of atrophy (10.4%) and in 
men with a benign (not explicitly atrophy) diagnosis (12.3%) in the 1st 
screening round, did not differ significantly. During the next year of follow-
up a limited number of additional carcinomas was detected which did not 
influence the outcome. 
Because the true incidence of atrophy and its different categories in 
prostate biopsies was unknown, 202 sextant biopsies reported as benign, 
including atrophy were reviewed. After review, 94.0% of these biopsies 
contained some form of atrophy. Due to the under diagnosis of atrophy on 
the routine pathology reports, we will focus on the results after review. After 
a diagnosis of atrophy during review, the prostate cancer incidence within the 
8-year follow-up was 4.7%, which was comparable to the prostate cancer 
incidence in men with benign biopsies, who also underwent a biopsy after a 
4-year screening interval. Apparently, neither before nor after review atrophy 
was associated with an increase of prostate cancer incidence. 
The incidence of atrophy after review reported here is comparable to 
the autopsy study of Billis et al. 105 who reported a total atrophy incidence of 
88% compared to 94% in our study. The prostate cancer incidence in their 
study was equal in prostates with and without atrophy and they concluded 
that atrophy was not associated with prostate cancer. This is in contrast to 
views expressed in recent literature, where it is hypothesized that atrophy, i.e. 
64
 64
PIA (PAH and SA) 101 may be a precursor or risk factor for prostate cancer. It 
was also suggested that PIA might progress to PIN. However, in our study 
we were also not able to find a significant association between a diagnosis of 
atrophy and the presence of PIN in subsequent screening rounds. It could be 
argued, however, that one or more categories of atrophy represent a lesion, 
which predisposes to prostate cancer on the very long run. According to this 
view only young men (e.g. < 40 years) with atrophy would be at risk for 
development of prostate cancer at older age. Direct evidence for this view will 
be hard to obtain. On the other hand, our findings do not contradict such a 
hypothesis although we would expect that the extent of atrophy at age > 55 
would be a manifestation of atrophy at young age. The lack of an association 
of (extensive) atrophy and subsequent prostate cancer might then be 
considered as an argument against the role of any kind of atrophy in prostate 
carcinogenesis.  
The dramatic discrepancy between the atrophy incidence before and 
after review can probably be explained by the possibility that the pathologist 
is less focused on the importance of the diagnosis, because in our institution 
atrophy was not regarded as a clinically relevant lesion for prostate cancer. In 
routine practice a diagnosis of atrophy might only be rendered, if this lesion 
was present in a prominent way due to the lack of guidelines for diagnosing 
atrophy. Also a high inter-observer variation will be present among 
pathologists for the diagnosis of atrophy due to the lack of guidelines for 
diagnosis atrophy.  
Men with atrophy were significantly older, compared to men with a 
benign, no atrophy diagnosis. As a result of this, we expect that the incidence 
of atrophy during the subsequent screening rounds in the ERSPC will 
increase. No significant differences were found in prostate volume and PSA 
between men with and without atrophy. As expected, because atrophy as a 
whole was not associated with the detection of subsequent prostate cancer, 
also the category and extent of atrophy was not associated with an increased 
prostate cancer incidence. 
In the absence of guidelines, consensus about diagnosing atrophy 
needs to be established worldwide, before linking atrophy with prostate 
cancer.  
 
Conclusions 
Atrophy is a common lesion and is present in 94% of sextant biopsies. An 
atrophy diagnosis in our asymptomatic population was not predictive for 
prostate cancer nor PIN in subsequent screening rounds (8 year follow-up). 
Neither the separate atrophy categories (i.e. simple atrophy, post atrophic 
hyperplasia, and sclerotic atrophy) nor their extent in sextant biopsies were 
associated with an increase in prostate cancer incidence in subsequent 
screening rounds as compared to men with benign diagnoses. 
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Abstract 
Objective: At the Rotterdam section of the European Randomized Screening 
program of Prostate Cancer (ERSPC) a cohort of 19,970 men aged between 55-
75 years is screened at an interval of 4 years. This includes a systematic 
sextant needle biopsy procedure in men with elevated PSA and/or positive 
DRE or transrectal ultrasound. Detection during the second screening round 
of a large number of cancers mainly composed of high grade (Gleason grade 
4/5) and/or a high amount of cancer might be considered as a failure to 
identify these tumors at an early stage during the prevalence screening.  
Patients and methods: Men diagnosed during the second screening round 
with a potentially advanced cancer (PAC), i.e. prostate cancer Gleason score 7 
(4+3, or 3+4 with a >30% cancer involvement) or 8-10 in their biopsy, were 
identified. Clinical data, including PSA values in de prevalence screen, biopsy 
history, clinical staging and follow-up were retrieved. In radical 
prostatectomy specimens the features of the tumor were further analyzed. 
Results: During the second screening round 503 cancers were detected in 
11,210 participants, including 30 (6.0%) with features of PAC in their 
diagnostic biopsy. Curative treatment was offered to 26 patients. 
Prostatectomy showed organ-confined cancer in 11 of 12 specimens, and 
tumor volumes ranged from 0.11-7.93 ml (median 1.05ml). PSA failure was 
noted in 6 of 22 patients offered a curative therapy.  
Conclusions: PAC is a rare finding in the 2nd screening round after a 4-year 
screening interval. A substantial proportion of 2nd round detected PAC 
represents organ-confined cancer. The data suggest that the currently 
employed screening protocol is sufficiently effective to detect > 95% of 
cancers at a stage before they have developed features that render them 
incurable.  
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Introduction 
In the western world the incidence of prostate cancer is increasing due to 
general availability of serum tests for prostate specific antigen (PSA) and 
aging of the population106. Early detection of prostate cancer by PSA testing 
may result in a decrease in mortality from prostate cancer, but definite 
evidence for this effect is not yet given. The European Randomized study of 
screening for prostate cancer  (ERSPC) is an international multi-center 
population based trial that investigates the impact op PSA testing for cancer 
mortality 107. Participants are randomized in a screening and control arm and 
final outcome of this study with regard to endpoint parameters like mortality 
from prostate cancer is not expected before year 2008. 
Analysis of intermediate parameters in order to assess the efficacy of 
the current screening protocol of the Rotterdam section of the ERSPC seems to 
be warranted for a few reasons. Previously, it was claimed that annual PSA 
testing in combination with digital rectal examination (DRE) would lead to 
the detection of all cancers at a curable stage 108. Indeed, the American Cancer 
Association recommends yearly PSA testing 109. The screening interval of 4 
years employed in the Rotterdam section of the ERSPC, may therefore be 
considered a too long time period. In addition, according to the ERSPC 
protocol the diagnosis of prostate cancer is established on a systematic sextant 
biopsy. This systematic sextant biopsy procedure has now become 
controversial, because it has been reported that about 30% of cancers are 
missed by this procedure 110. The earlier finding by the Rotterdam section of 
the ERSPC that the incidence of prostate cancer did not drop significantly in 
the 2nd round of screening (3.9%) as compared to the first screening round 
(4.3%) may support this view 84. Especially for large prostates and small 
tumors a more extended biopsy procedure is recommended 111. For above 
reasons it may be anticipated that in a screening program with a 4-year 
interval using systematic sextant biopsies prostate cancers may be missed, 
which could lead to the manifestation of clinically advanced prostate cancers 
during the 4-year interval or to their detection at the second screening round.  
In order to generate a simple parameter for the efficacy of screening for 
prostate cancer several attempts were made to categorize the outcome of 
prostate needle biopsies in subsets with a different prognostic impact 84,111-113. 
It was reported that among biopsies with Gleason score 7 those with 
dominant Gleason pattern 4 (4 + 3) indicate the presence of more adverse 
pathological findings compared to those with Gleason score 7 with a smaller 
pattern 4 component (3 + 4)112. An increased prostate cancer mortality in 
patients with Gleason score 7 and even higher in those with score 8-10 was 
reported compared to patients with Gleason score 6 in their biopsy 113. Some 
others demonstrated a relationship between extent of cancer in the biopsy and 
pathologic stage in the prostatectomy specimen 114,115. Thus, an arbitrary 
categorization model may be constructed defining “potentially advanced” 
prostate cancer (PAC) on the basis of Gleason score and amount of tumor 
present in sextant biopsy 84. Following such an arbitrary model, we 
considered the detection during the second screening round of a significant 
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number of prostate needle biopsies with PAC, defined by a predominance of 
Gleason pattern 4 and/or 5 or needle biopsies with >30% cancer involvement 
by Gleason score 7 (3 + 4) cancers as an indication for a potential inadequacy 
of our current screening protocol. 
In this study we analyzed the frequency of PAC in sextant biopsies 
during the second round of screening for prostate cancer and we compared 
these findings in the corresponding prostatectomy specimens and with 
clinical stage and follow-up. Furthermore, the screening history of these men 
was analyzed in order to find an explanation for failure of early identification 
of these potentially advanced cancers.  
 
Patients and Methods 
In the Rotterdam section of the ERSPC 42,376 participants, 55-75 years old, 
were randomized in a screening (n=21,210) and a control arm (n=21,166). In 
the first round, which took place from October 1991 until December 1998, a 
total of 19,970 were actually screened of whom 4,243 men underwent prostate 
biopsy. 
These numbers also include participants from the pilot study, in which in case 
of PAC the same screening protocol was used. Screening for prostate cancer 
in this study was done by PSA determination, digital rectal examination 
(DRE) and transrectal ultrasonography (TRUS). Systematic sextant prostate 
needle biopsy was recommended for participants who had either an elevated 
PSA level (≥ 4.0 ng/ml), abnormal DRE or abnormal findings on TRUS. The 
protocol was simplified on May 1997, when sextant biopsy was recommended 
if PSA was ≥3.0 ng/ml. Abnormalities on DRE and/or TRUS were no longer 
indicators for biopsy. The second screening round, using the latter screening 
protocol, started in October 1995 and is still ongoing. Until March 2003, a total 
of 11,210 of the expected 13,390 participants were screened of whom 2,607 
men had undergone prostate biopsy. Of the men with a negative biopsy in the 
1st screening round (n=3,151), 60% were screened in the 2nd round. Those men 
who were not screened anymore in the 2nd screening round either refused 
biopsy (12.6%), were too old (16.0%) or died (4.0%). In 7.4% of the men the 
reason was unknown. When there was an invitation for sextant biopsy in the 
2nd screening round, 12.6% of the participants did not undergo biopsy; 
including 10.9% refusals and 1.7% of the participants, who were not allowed 
to undergo a biopsy due to anticoagulation therapy. The expected number of 
participants in the second round is based on the total number of participants 
of the first round, after exclusion of 1) participants with prostate cancer 
already found in the first screening round, 2) those with an age over 75 and 3) 
those died during the 4-year screening interval.  
PSA determinations were done with a Hybritech Tandem E assay (Hybritech 
Beckman-Coulter Corp., San Diego, Cal), and blood samples were stored to 
allow repeat determinations. All men had signed an informed consent prior to 
their participation to the screening study. 
During the second round of the screening program two side studies were 
performed: 1) the impact of PSA doubling on the detection of (clinically 
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relevant) prostate cancers on 5,658 men. If PSA increased twice or more since 
the first screen, men were invited for sextant biopsy. 
2) Investigation of the incidence of prostate cancer in the PSA 2-4 ng/ml range 
performed on 885 men. Men in this side study were invited for sextant biopsy. 
The participants were also included in the analysis.  
 
Systematic sextant biopsies were obtained during longitudinal and cross-
sectional ultrasonographic scanning of the prostate. A 7th biopsy was taken if 
a hypoechogenic lesion was visible at TRUS. One pathologist (T v/d K) 
reviewed all biopsies with cancer in order to avoid inter-observer variation in 
Gleason grading. During this review, the number and size of biopsies were 
recorded as well as proportion of tumor involvement, and proportion of each 
Gleason grade.  
Slides from radical prostatectomies of participants with prostate cancer were 
retrieved from the archives of the pathology laboratories of the Erasmus 
Medical Center and surrounding hospitals of the Rotterdam region. There 
was one single protocol for total embedding of the prostates in use in all 
pathology laboratories allowing accurate measurements of tumor volume, 
grading and staging. After review tumor stage and Gleason score were 
determined. Tumor volume was measured by morphometry as described 
previously 116. For tumor staging of radical prostatectomy specimens the 1992 
TNM classification for prostate cancer was used 117. 
Using the database of the Rotterdam section of the ERSPC the needle biopsies 
of second round participants with Gleason score ≥4+3 or higher and those 
with Gleason score 7 (3+4) with more than 30% tumor involvement in their 
sextant biopsy were identified. Data on clinical stage, therapy and follow-up 
were retrieved from the ERSPC database. 
 
Statistical analysis 
Statistical analysis was done with the SPSS computer program. P<0.05 was 
considered significant. Chi-square tests were used for number of advanced 
cancers, paired sample T-test for comparing PSA levels of men with PAC at 
first and second screening round.  
 
Results 
Biopsy characteristics of potentially advanced cancers in 2nd screening round  
Until March 2003, a total of 503 cancers were detected in the second screening 
round, including 30 (6.0%) fulfilling the criteria of PAC (Table 1).  
 
Table 1 Frequency of cancers in the first and second screening round 
Round 1 2 
screened participants 21152 11210 
total cancers 1092 503 
PAC1 214 30 
Ratio cancer/PAC 19.6% 6.0% 
1PAC potentially advanced cancers (see text for definition) 
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During the prevalence screening a total of 1,092 prostate cancers were 
diagnosed in 21,152 participants, including 214 PAC (19.6%). The reduction of 
PAC detected in the 2nd round is highly significant (p<0.001). Of the 30 PAC 
found, 11 participants were derived from the PSA doubling time study, and 5 
participants from the PSA 2-4 ng/ml side study. Two PAC participants in the 
PSA doubling time side study had PSA levels <3.0 ng/ml in the 2nd screening 
round. These participants would not have been invited for sextant biopsy in 
the main study screening round. There were no participants with PAC in the 
PSA 2-4 ng/ml side study with PSA <3.0 ng/ml. 
In the second screening round 373 participants had Gleason score 6 (3+3) in 
their sextant biopsies, of these participants a total of 6 had >30% tumor 
involvement (1.6%). All these tumors were clinically organ confined; their 
median PSA values as compared to PAC were lower (3.0 vs. 4.7 ng/ml).  
The distribution of Gleason scores of PAC in the 2nd screening round is 
shown in Table 2.  
 
Table 2 Subdivision of potentially advanced cancers on the basis of Gleason 
score 
Gleason score on sextant 
biopsy 
PAC in 2nd round (n) 
3+4 8 
4+3 4 
4+4 12 
3+5 2 
4+5 1 
5+3 1 
5+4 1 
5+5 1 
Total 30 
 
There were 72 cancers with Gleason 3+4 in the second screening round of 
which 8 (11%) comprised more than 30% tumor of the biopsy length. Four 
and 15 participants with prostate cancer detected on biopsy had Gleason 
score 7 (4+3) and 8, respectively. Five out of the 8 participants with a PAC 
Gleason 3+4 underwent an additional 7th biopsy as a consequence of a TRUS 
detected hypoechogenic lesion. All these 5 biopsies were positive for tumor. If 
these hypoechogenic lesions were not biopsied selectively, 4 participants 
would not have been categorized as PAC.  
For convenience, the extent of cancer involvement of the needle biopsies was 
further broken up according to the following arbitrary system: A = 1 biopsy 
core positive cancer, B = 2 -3 biopsy cores positive for prostate cancer, C = ≥4 
biopsy cores positive for prostate cancer. Distribution of the biopsies 
according to this categorization is shown in Table 3.  
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Table 3 Categorization of PAC on the basis of proportion of tumor 
involvement of the sextant needle biopsies 
classification number of cases 
A 8 
B 10 
C 12 
Total 30 
 
In all but 1 participant in category A the sextant biopsies contained less than 
10% tumor.  If the 8 PAC of participants with Gleason score 7 (3 + 4) and  
>30% tumor involvement were excluded, 8 participants would be left in 
category B and 8 participants in category C. 
 
Development of PSA values in PAC patients during 1st and 2nd screening round 
The PSA values of participants with PAC in the second round increased 
significantly from the 1st to the 2nd round (P=0.008) (Table 4), with a median 
PSA doubling time of 5 years.  
 
Table 4 Serum PSA levels at first and second round of men with 2nd round 
PAC 
screening round PSA if PAC in 2nd round 
median (range) 
1 2.6 (0.8-9.7) 
2 4.7 (1.7-59.0) 
 
One patient had a more than 10-fold PSA increase. In Figure 1 the 1st and 2nd 
round log PSA values of the 30 participants can be compared individually. 
The median PSA velocity was 0.5 ng/ml per year, range 0.0-12.8 ng/ml per 
year. In 9 men (30%) the PSA velocity was above 0.75 ng/ml per year 
suggestive of a rapidly progressive cancer development.  
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Figure 1 Log PSA change in first and second screening round per individual 
Log PSA first and second round 
individually
0,1
1
10
100
1 2
screening round
 
 
History of patients with PAC in 2nd screening round biopsy 
In the 2nd screening round a total of 792 men with a previous negative 
outcome biopsy history during the prevalence screening underwent a sextant 
biopsy. Forty-nine out of these 792 men (6.2 %) had prostate cancer in the 2nd 
screening round, including 5 men with PAC. The initial biopsy reports of the 
5 men with PAC in the 2nd screening round were negative for prostate cancer 
and/or high-grade prostatic intraepithelial neoplasia (PIN). After review of 
these biopsy cores of the prevalence screen, no cancer was found. In one case, 
however, isolated HG-PIN in a single gland was found. On the whole 2nd 
screening round a 10-fold increase in PSA level was detected in two men at 
the 2nd screen. After repeating the PSA-determinations of the two (first round) 
sera, it was found that serum of one patient was mixed up. This patient 
actually had a (first round) serum PSA of 6.6 ng/ml instead of 0.8 ng/ml. As a 
consequence he was not invited for biopsy at the first round.  
One participant with a sextant biopsy category C PAC had an abnormal DRE 
in the first screening round and a PSA of 3.6 ng/ml. He did not show up for 
biopsy in the first round. 
 
Therapy and follow-up of patients with PAC during 2nd round 
Clinical TNM stage and therapy of patients with PAC is shown in Table 5. In 
21 patients the prostate cancer was organ confined (70%). Fifteen patients 
received radiotherapy, of whom 1 received adjuvant hormone therapy. 
Twelve patients underwent radical prostatectomy.  
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Table 5 Clinical stage and therapy of patients with 2nd round PAC 
clinical 
T- stage 
Prostatec- 
tomy 
Radio-
therapy 
watchful 
waiting 
endocrine 
therapy 
Radio-
therapy 
and 
endocrine 
therapy 
number 
of cases 
T1c 4 1 1   6 
T2a/b 6 4  23  12 
T2c 1 21    3 
T3a/b 1 52   1 7 
T3c  2    2 
total 12 14 1 2 1 30 
1PIN missed during prevalence screening 
2Including one man, refusing a biopsy at first round and one man receiving neo-adjuvant 
endocrine therapy.  
3Failure to detect elevated PSA during prevalence screening 
 
Patients who received radiotherapy had a higher clinical T-stage compared to 
radical prostatectomy patients. Two patients received hormone therapy. They 
had high PSA levels (42.0 and 59.0 ng/ml), cancer in every biopsy core 
(category C) and one patient developed lymph node metastasis. At a median 
follow up of 29 months (range 7-73) all PAC patients were alive. PSA values 
after therapy were known in 20 patients. There was PSA progression (PSA 
increase >0.2 ng/ml after one measurement) in 7 patients. The patient who 
was set on watchful waiting had a PSA increase from an initial PSA 5.4 ng/ml 
to 6.3 ng/ml during a follow up time of 39 months.  
 
Radical prostatectomy findings in PAC patients 
In Table 6 the pathologic features of the prostatectomy specimens of 12 
patients are given.  
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Table 6 Needle biopsy findings, PSA levels and prostatectomy findings in 
patients  
with 2nd round potentially advanced cancers.  
Downgrading from Gleason score 8 in the biopsy to Gleason score 7 in the 
radical prostatectomy was seen in 3 patients, and upgrading from Gleason 
score 7 (3 + 4) in the biopsy to Gleason score 9 in the prostatectomy occurred 
in 2 patients. Tumor volumes ranged from 0.11-7.93 ml, with a median value 
of 1.05 ml. In the 7 prostatectomy specimens matching with Gleason score 7 
(4+3) or Gleason score 8 (4+4) in the sextant biopsy most tumors were small 
(<0,6 ml) except two (1.46 ml and 2.07). The latter included a transition zone 
carcinoma of Gleason score 4 (2+2) of 1.21 ml and a peripheral zone Gleason 
score 8 cancer of 0.86 ml. Concerning the 4 patients with Gleason score 7 (3+4) 
cancer and >30% tumor involvement in their sextant biopsy it was noted that 
their tumor volumes ranged from 1.55-7.93 ml.  
Clinical T stage of all prostatectomy specimens under staged the tumor in 8 
patients and over-staged the tumor only in 1 patient. Second round PSA 
values in men who underwent radical prostatectomy specimens ranged from 
2.4-11.0 ng/ml, while a significant correlation of PSA with tumor volume was 
lacking (p=0.53). Median PSA velocity of PAC treated with radical 
prostatectomy was 0.5 ng/ml per year, which tended to be lower as compared 
to PAC not treated with radical prostatectomy (2.2 ng/ml per year p=0.06). 
 
Discussion 
Our study shows that PAC, defined by Gleason score ≥4+3 or more than 30% 
tumor involvement with Gleason score 3+4 in the sextant biopsy, occurs 
infrequently in the second screening round of the Rotterdam section of the 
ERSPC.  It is known that after onset of the PSA era the incidence of well-
differentiated cancers (Gleason score 2-4) decreased 118 and that of moderately 
pros
tate 
Gleason 
score 
Biopsy 
cate-
gory 
Gleason 
score 
RP1 
PSA- 
velocity 
(ng/ml 
per 
year) 
tumor  
volume 
(ml) 
clinical  
T-stage 
Patho-
logical 
T- 
stage 
1 4+4 B 4+5 0.39 0.55 T2a T2c 
2 3+4 C 4+5 0.38 7.93 T1c T3c 
3 4+4 A 3+4 0.43 0.11 T2a T2a 
4 4+4 A 3+4 0.34 0.58 T1c T2a 
5 4+4 A 4+3 0.28 0.24 T3a T2c 
6 3+4 C 3+4 0.14 1.55 T1c T2c 
7 4+4 B 4+4 0.36 1.46 T1c T2c 
8 3+4 B 3+4 0.46 5.15 T1c T2c 
9 3+4 C 4+5 0.98 6.91 T2a T2c 
10 3+5 B 4+5 0.21 0.29 T2b T2c 
11 4+3 A 3+4 0.46 0.63 T2a T2a 
12 4+4 A 3+5 1.6 2.08 T2c T2c 
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differentiated tumors (Gleason score5-7) increased because more prostate 
cancers were found through biopsy instead of coincidently by transurethral 
resection of the prostate 118,119. When early detection programs were 
introduced a relative decrease of poorly differentiated cancers (Gleason score 
8-10) was noted when comparing prostatectomy specimens before the PSA 
era and those from participants of the first screening round62. Recently, the 
Rotterdam section of the ERSPC reported a significant reduction in extent of 
tumor involvement of the biopsies and downgrading in the second screening 
round 84. The demonstration on a much larger series of 2nd round cancer 
containing biopsies of a significantly lower frequency of PAC (i.e. 6.0%) when 
compared with the first round (19.6%) confirms and extends our previous 
observation. The calculated long lead-time of prostate cancer, which is 10.3 
years at age 55-74 48, is in line with the observed decrease of PAC in the 2nd 
screening round. 
The employed criteria to define PAC were based on data from 
literature indicating that amount of cancer in the biopsies and extent of high 
grade Gleason 4/5 are important predictors of disease outcome 112,115. Others 
have questioned the potential to predict organ-confined disease at an 
individual basis on the basis of biopsy pathology variables of prostate cancer 
114. According to a previous study from the ERSPC, biopsy parameters may 
well be suitable for an estimation of the proportion of advanced cancers in the 
context of a large population-based study. In a previously developed 
categorization model based on a limited number of prevalence screening 
round prostate biopsies and matched prostatectomy specimens, we 
demonstrated that about 60% of biopsy defined “advanced” cancers had 
extra-prostatic extension 84. It is then remarkable that only one of 12 
prostatectomy specimens of men with a 2nd round PAC contained a pT3C 
cancer. This finding would suggest that employment of the same definition 
for PAC in the 2nd screening round as in the prevalence screening may rather 
have led to an overestimation of advanced cancers in the 2nd round. Three of 
four patients with a small focus Gleason score 8 cancer in one biopsy 
(category A) proved to have a comparatively low tumor volume in the 
prostatectomy specimen which was also downgraded to Gleason score 7. In 
contrast, two of three cases with extensive involvement of needle biopsies 
(category C) by Gleason score 7 cancer were associated with a large volume 
prostate cancer Gleason score 9 in the prostatectomy. On the other hand, it 
cannot be excluded that additional cancers with adverse features may be 
present among those biopsy-detected cancers, which did not fall within our 
arbitrary definition of PAC. Indeed, it is likely from previous data that 
additional cancers with adverse features are present among those biopsy-
detected cancers, which did not fall within our arbitrary definition of PAC 84. 
When we would include Gleason score 6 (3 + 3) cancers with ≥ 30% biopsy 
involvement in the 2nd round only 6 cases were identified. Radical 
prostatectomy was performed in 2 of the latter cases and revealed organ 
confined cancers with Gleason score 6. Summarizing, it may be inferred from 
the prostatectomy data that a substantial subset of second round cancers, 
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defined on the basis of findings in the prostate needle biopsy as PAC were 
organ confined although a comparatively large proportion of them (6 of 12) 
were composed of poorly differentiated cancer (Gleason score 8 or 9).  
 Failure to detect prostate cancer during the prevalence screening as a 
consequence of a missed abnormality in the biopsy, respectively serum PSA 
determination occurred in 2 patients. Another failure to detect a PAC during 
the prevalence screening was patient related (refusal of biopsy). The other 27 
PAC in the 2nd screening round had not been detected by the regular 
prevalence screening. The low tumor volume of 6 of the 12 PAC treated by 
radical prostatectomy (i.e.< 0.7 ml) may well have precluded their detection 4 
years before in the first screening round. On the other hand, a selection bias 
towards cancers with more favorable features, including small tumor volume 
may have occurred in those men with PAC in the 2nd round offered a 
prostatectomy as compared to those given radiotherapy.  
 The efficacy of our current screening protocol may not only be 
measured from the presence of PAC in the 2nd screening round, but also on 
the number of clinically manifest interval carcinomas, occurring during the 4-
year screening interval. A recent analysis at the Rotterdam section of the 
ERSPC revealed 25 interval carcinomas (not patient related) occurring 
between 1993 and 1996 120. More importantly, no advanced cancers (Gleason 
score 4+3) were found among these interval carcinomas.  
 If rapidly progressive prostate cancers with short doubling times 
would comprise a substantial proportion of the PAC, this would be another 
potential problem related with the current screening protocol with a four-year 
interval. We demonstrated that the median PSA velocity (PSAV) of the 
patients with PAC was 0.5 ng/ml per year. In literature a PSAV of 0.75 ng/ml 
year was considered predictive of the presence of clinical prostate cancer 
when PSA values were between 4.0 and 10.0 ng/ml 121. Only 30% of the 
patients with a second round PAC had a PSAV > 0.75 ng/ml. This indicates 
that PSAV is not a good predictor for PAC in this subset of patients. Of course 
it cannot be excluded that a number of potentially highly aggressive prostate 
cancers with low PSA levels are hidden in our screened population. It is 
uncertain whether a more frequent PSA testing protocol would be of benefit 
for their early detection.  
 The incidence of PAC reported here of about 2.0 per thousand 
participants in the second screening round seems to be reassuring for the 
efficacy of our current screening protocol, employing a 4-year interval for 
PSA testing and sextant biopsy procedure for definite diagnosis of prostate 
cancer. 
 
Conclusions 
A screening protocol employing a 4-year interval for PSA testing and sextant 
biopsy procedure for definite diagnosis of prostate cancer seems warranted, 
since 1) the mean lead time of prostate cancer is estimated to be 6-12 years for 
different age groups 48, 2) the frequency of clinically manifest interval cancers 
reported so far is negligible 120 and 3) a low incidence of potentially advanced 
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cancers is detected during the 2nd screening round. Furthermore, the 
performance of the adopted screening procedure seems to be good, since only 
2 of 30 2nd round PAC could be attributed to failure of diagnostic tests at the 
prevalence screening.  
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Abstract 
Objective: Focal cancer detected in needle biopsy is a common finding since 
PSA based screening is introduced. Clinical-pathologic features of patients 
with focal cancers, treated with radical prostatectomy (RP) or watchful 
waiting (WW), were analyzed in order to detect clinical predictors for 
progression during follow-up.  
Methods: Patients were selected from the European Randomized Screening 
study for Prostate Cancer (ERSPC). Focal cancer on sextant biopsy was 
defined as ≤3.0 mm involvement by cancer in one biopsy core lacking Gleason 
pattern 4 or 5. PSA doubling time was used in the WW group as a marker of 
disease progression.  
Results: The proportion of focal prostate cancers increased significantly from 
16% in the 1st to 29% in the 2nd screening round, 118 and 108 men were 
treated with RP and WW. Median tumor volume was 0.13 ml. PSA level and 
prostate volume predicted tumor volume in multivariate regression. A PSA 
density cut-off of ≤0.1 ng/ml/cm3 predicted organ-confined tumor (<0.5 ml) 
in 94% of the patients. Positive surgical margins were predictive for PSA-
recurrence. Four patients in the RP group had PSA recurrence in the follow-
up. PSA doubling time < 2, 3, or 4 years was noted in 4.9, 14.6 and 22.0% of 
patients in the WW-group, respectively. 
Conclusions: Median tumor volume was small (0.13 ml). A comparison 
between PSA recurrence in the RP group and PSA doubling time in the WW 
group showed a significantly more favorable outcome after RP if a PSA 
doubling time of <3 or 4 years was chosen as a marker for progression of 
disease in WW. A WW policy with delayed curative intent may be 
recommended in patients aged between 55-75 years with focal cancer and 
PSA density <0.1 ng/ml/cm3.  
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Introduction 
With frequent serum prostate specific antigen (PSA) testing and systematic 
biopsy of the prostate, the risk to detect clinically irrelevant prostate cancer 
increases. A high prevalence of co-morbidity coupled with the relatively slow 
progression of most prostate cancers 122 implies that competing causes of 
death may be substantial contributors to mortality in men diagnosed with 
prostate cancer. Therefore screening for prostate cancer introduces over-
detection (defined as: cancers that would not have been diagnosed in the 
absence of screening) and a lot of men might be over-treated. It was recently 
calculated that in a screening program with a 4-year interval, the proportion 
of cancers detected unnecessarily could be as high as 48% 48. Therefore it is 
important to make efforts to define clinically insignificant tumor on 
preoperative variables; wherein it is safe to apply watchful waiting (WW) and 
to avoid over-treatment associated with side effects, like radical 
prostatectomy (RP) or radiotherapy.  
Many authors have tried to establish a definition of an indolent or 
clinically insignificant tumor in RP specimens. Stamey et al. proposed that 
tumors <0.5 ml should be considered as clinically insignificant 123. This was 
based on the incidence of prostate cancer in unselected cystoprostatectomy 
specimens, in which 8% of the largest tumors were considered significant, 
because the cumulative prostate cancer incidence was calculated at 8%, and 
all others, which were smaller than 0.5 ml, were considered insignificant. 
Epstein et al. even proposed a cut-off value for clinical insignificant prostate 
cancer of 0.2 ml, because occasionally a prostate cancer in the 0.2-0.5 ml tumor 
volume range was non-organ confined 124. Other authors elaborated on this 
cut-off of 0.5 ml, because no other proper definition could be established for 
an insignificant tumor. In an editorial comment 10 years after his initial 
publication, Stamey et al. disposed the arbitrary cut-off of 0.5 ml and 
suggested that even larger tumor volumes and presence of high-grade cancer 
might be within the definition of insignificant tumors as well. Patient age is 
the most important predictor to decide whether a tumor might be clinically 
insignificant 125. Currently, the tumor volume of 0.5 ml, without Gleason 
pattern 4 or 5 is the most accepted definition for “insignificant” or minimal 
cancer. 
Increasingly, a small focus of well-differentiated cancer is detected in 
only one biopsy in men with an elevated PSA. The clinical relevance of such a 
finding is not entirely clear, since this finding may be the manifestation of 
either a minimal, moderate or even advanced cancer. Further predictive 
parameters are required to choose between a WW policy and immediate 
curative treatment. WW might be an option for those men with a high 
likelihood of “insignificant” or minimal cancer if close monitoring is possible. 
PSA measurement at follow-up visit is considered to be a useful monitoring 
instrument for this treatment. It has been shown that a rapid PSA increase 
(short PSA doubling time which is the time PSA needs to double) correlates 
with clinical progression 126,127. In this report we studied retrospectively if we 
could predict minimal cancer in RP specimens, based on focal cancer at 
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sextant biopsy and clinical preoperative variables. We also compared the 
outcome of patients with focal cancer treated with RP or managed with a WW 
policy. 
 
Material and methods 
Patients and screening strategies 
In the Rotterdam section of the European Randomized Screening Study for 
Prostate Cancer (ERSPC) 42,376, 55-75 years old, were randomized in a 
screening (n=21,210) and a control arm (n=21,166). The 1st round of screening 
(prevalence screen) took place from June 1994 until December 1999. Screening 
for prostate cancer was done by PSA determination, digital rectal examination 
(DRE) and transrectal ultrasonography (TRUS). Systematic sextant prostate 
needle biopsy was recommended for participants who had either an elevated 
PSA level (≥4.0 ng/ml), abnormal DRE or abnormal findings on TRUS in the 
1st round. Men with benign diagnoses in the 1st round were re-invited for an 
early re-screen round, wherein 510 men were biopsied. This policy was 
discontinued later on, in May 1997, because of the low sensitivity and low 
positive predictive value of DRE and TRUS in the PSA range <4.0 ng/ml 66. 
Also the favorable tumor characteristics in the PSA range 3.0-4.0 ng/ml 
warranted this protocol change 10. The protocol was simplified and sextant 
biopsy was recommended if PSA was ≥3.0 ng/ml, regardless of DRE and/or 
TRUS. All patients’ PSA levels at diagnosis were determined with the 
Beckman-Coulter Hybritech Tandem E Assay (Hybritech Incorporated, San 
Diego CA,) that was replaced since January 2000 by the automated version 
(Beckman-Access, Beckman- Coulter Inc. Fullerton CA, USA). 
The 2nd screening round, using the PSA ≥3.0 ng/ml screening protocol started 
in June 1998 and finished in December 2003. Until November 2003, 11887 men 
were screened. During this 2nd round of the screening program two side 
studies were performed 128. One studied the impact of PSA doubling on the 
detection of (clinically relevant) prostate cancers. If the PSA level increased 
twice or more since the 1st round, men were invited for sextant biopsy. The 
other investigated the incidence of prostate cancer in the PSA 2.0-4.0 ng/ml 
range. All participants in these side studies were included in our analysis.  
Systematic lateralized sextant biopsies were obtained during 
longitudinal and cross-sectional ultrasonographic scanning of the prostate. A 
7th biopsy was taken if a hypoechogenic lesion was visible at TRUS. Prostate 
biopsy cores were labeled and processed individually. One pathologist 
(T.H.v.d.K) reviewed all biopsies with cancer, PIN and lesions suspicious for 
malignancy in order to avoid inter-observer variation. During this review, the 
number and size of biopsies were recorded as well as proportion of tumor 
involvement, and proportion of each Gleason pattern. Focal cancer was 
defined as one single core positive for prostate cancer ≤3mm in sextant 
biopsy, containing no Gleason pattern 4 or 5.  
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Pathologic processing 
Slides from RP specimens were retrieved from the archives of the pathology 
laboratories of the Erasmus Medical Center and surrounding hospitals of the 
Rotterdam region. There was one single protocol for total embedding of the 
prostate in use in all pathology laboratories allowing accurate measurements 
of tumor volume, grading and staging 129. In short, after fixation, RP 
specimens were inked and serially sectioned at 4 mm intervals and totally 
embedded in paraffin blocks. After review, pathologic stage and Gleason 
score were determined. Tumor volume was measured by morphometry as 
described previously 130. Fifteen men were excluded in this analysis, because 
RP specimens could not be retrieved, were not totally embedded, or not 
embedded according to protocol in 7, 4 and 4 men, respectively. For tumor 
staging of RP specimens the 1992 TNM classification for prostate cancer was 
used 117 
 
Categorization of cancers in prostatectomy specimens and follow-up 
The combination of preoperative variables, tumor characteristics and outcome 
of surgery is predictive of the prognosis after RP 131-133.  We therefore created 
an arbitrary model that was based on the above-mentioned models. Since we 
included only men with a diagnosis of focal cancer in the needle biopsy we 
created two categories. 1) Minimal tumors: tumors <0.5 ml, containing no 
Gleason pattern 4 or 5, organ confined and negative surgical margins. 2) 
Moderate to advanced tumors: tumors ≥0.5 ml, or tumors containing any 
amount of Gleason pattern 4 or 5 or extra-capsular extension or positive 
surgical margins.  
 Patients in both therapy groups were seen at 3-month intervals within 
one year after therapy initiation, thereafter biannual controls were performed 
in the Erasmus medical center and surrounding hospitals. At each visit serum 
PSA was obtained and DRE performed. PSA doubling time was calculated in 
watchful waiting (WW) patients when they had at least 3 PSA values in the 
follow-up. PSA values obtained by other assays (in surrounding regional 
hospitals) were corrected for known differences with the Hybritech assay 
using the regression method of Passing and Bablok 134. Recurrence of disease 
was determined as PSA ≥0.2 ng/ml, postoperatively in patients who 
underwent radical prostatectomy (RP).  Median duration of follow-up in the 
RP and WW group was 45 (n=87) and 30 (n=82) months, respectively. 
 
Statistical analysis 
Statistical analysis was done with the SPSS software package (SPSS 11.0 Inc., 
Chicago, IL). P<0.05 was considered significant. Mann-Whitney tests were 
used for ordinal variables, T-test for linear variables, i.e. PSA and age. 
Multiple continuous regression was performed via the backward elimination 
method. The Kaplan-Meier method was used to calculate PSA-free recurrence 
curves and significant differences between curves were based on the log-rank 
statistic. 
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Results 
Prostate biopsies during subsequent screening rounds 
Prostate biopsies were obtained in two subsequent rounds and one early re-
screening round. In the 1st screening round 1014 prostate cancers were 
diagnosed, including 157 focal cancers (15.5%). In the early re-screen, which 
was performed one year after the 1st round in men with an initial benign 
biopsy outcome, 19 (30.1%) of the prostate cancers were focal cancers. In the 
2nd round 546 cancers were detected and 159 (29.1%) of them were focal. 
Thus, a total of 335 focal cancers were detected in this population based 
screening program. When patients within the same screening protocol (PSA 
≥3.0 ng/ml indication for sextant biopsy) in the 1st and 2nd round were 
compared, the ratio focal cancer/all cancers increased significantly in the 2nd 
round from 15.5 to 29.1% (p=0.03). Employing the original screening protocol 
(PSA ≥4.0) without positive DRE or TRUS as indicator for sextant biopsy, the 
ratio focal cancer/ all cancer in the 1st and 2nd screening round was 12.8% and 
32.8% (p=0.0001). The choice of therapy for patients with focal cancer was RP, 
WW, radiotherapy or hormonal therapy in 118, 108, 93, and 2 patients, 
respectively. In 14 men the therapy is as yet unknown.  
 
Radical prostatectomy and watchful waiting policy 
The characteristics of patients in the RP and WW groups are shown in Table 1.  
 
Table 1 Characteristics of patients who underwent radical prostatectomy and  
watchful waiting   
variable RP (n=103) WW (n=108)  p-value 
 median (range) median (range)  
age (years) 62.8 (55-72) 68.6 (57-77) <0.0001 
PSA at diagnosis 
(ng/ml) 
4.4 (0.9-21.0) 3.7 (1.2-24.8) 0.007 
PSAd (ng/ml/cm3 
prostate) 
0.10 (0.03-0.48) 0.09 (0.03-0.56) NS 
Gleason score 6 (4-6) 6 (2-6) NS 
prostate volume 
(ml) 
41 (17-154) 40 (14-130) NS 
cT-stage N (percentage) N (percentage)  
T1C 65 (63.1%) 63 (58.3%)  
T2A 27 (26.3%) 38 (35.2%)  
T2B 2 (1.9%) 0  
T2C 7 (6.8%) 1 (0.9%)  
T3A 2 (1.9%) 0  
unknown 0 6 (5.6%)  
RP radical prostatectomy 
WW watchful waiting 
NS not significant 
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Hundred-three RP specimens suitable for tumor volume measurement were 
included in our analysis. No patient was treated with adjuvant or neo-
adjuvant therapy. Hundred-eight patients with focal cancer were managed 
with a WW policy. Patients managed with WW were significantly older and 
had lower PSA values. The co-morbidity, as expressed by ASA score, 
(Association of Anesthetists-score ranging from class1 (Normal healthy 
patient) towards class 5 (patient dies without intervention 135) of men on a 
WW policy remained equal in two subsequent screening rounds and was 
rarely (3%) score 3 (patient with severe systemic disease) (data not shown) or 
above. Impalpable disease in the RP and WW-group was diagnosed in 63.1%, 
respectively 58.3%, of the patients. Clinically two extra-capsular prostate 
cancers were diagnosed in the RP-group. Three patients in each group had a 
7th positive biopsy core, directed at a hypoechogenic area.  
 
Tumor volume in radical prostatectomy specimens 
Median tumor volume in focal prostate cancer was 0.13 ml (range 0.00-8.93 
ml). Out of these patients, 61.2% had a tumor volume <0.2 ml and 78.6% <0.5 
ml.  
Confining the analysis to men screened according to the initial screening 
protocol (PSA ≥4.0 ng/ml), revealed a tumor volume <0.2 ml in 52.4%. 
Median tumor volumes in the 1st, early re-screen and 2nd screening round 
(0.16, 0.18 and 0.07 ml) did not differ significantly. Tumor volume per PSA 
range can be seen in Table 2. 
 
Table 2 Median tumor volume according to PSA ranges  
 tumor volume ml 
(range) 
  
PSA range 
(ng/ml) 
1st round (n=56) Interim screening 
round (n=7) 
2nd round 
(n=40) 
0-2.9 0.09 (0.0-0.4) 0.1 (n=1) 0.07 (0.0-0.6) 
3-3.9 0.05 (0.0-0.5) NA1 0.17 (0.0-2.2) 
4.0-9.9 0.21 (0.0-2.3) 0.94 (0.0-1.0) 0.04 (0.0-1.1) 
≥10.0  0.37 (0.0-0.6) 0.06 (n=1) 1.08 (0.0-8.9) 
Total 0.16 (0.0-2.6) 0.18 (0.0-1.0) 0.07 (0.0-8.9) 
NA not available 
 
Also after analysis of patients submitted to the same screening algorithm (i.e. 
PSA ≥3.0 ng/ml) the median tumor volume in the 1st and 2nd round did not 
differ significantly (0.17 vs. 0.08 ml). Comparison in the 2nd screening round 
of tumors in patients with PSA <3.0 and those with PSA ≥3.0 revealed no 
significant difference in median tumor volume (0.07 vs. 0.08 ml). Eighteen 
patients underwent sextant biopsy in an earlier round. Tumor volume of 
patients who underwent sextant biopsy in an earlier round had somewhat 
smaller median tumor volumes (0.08 vs. 0.10 ml, not significant). When all 
preoperative clinical variables (i.e. Gleason score, clinical stage, length of 
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tumor in sextant biopsy, PSA, prostate volume and age) were multivariately 
tested with linear regression, only PSA and prostate volume were significant 
predictors of tumor volume (p<0.0001 for both variables). A larger prostate 
volume predicted a smaller tumor volume. When all postoperative (RP 
Gleason score, pathologic stage, positive surgical margins) variables were 
added to the multivariate analysis, prostate volume and PSA continued to be 
predictive for tumor volume, but also a positive surgical margin and stage 
pT4 were significant predictors for tumor volume (p=0.006 and p<0.001). 
When we combined PSA and prostate volume and used PSA density ≤0.1 
ng/ml/cm3 (n=48) as a cut-off value, 94% of the 48 patients had a tumor 
volume of <0.5 ml and organ-confined cancer in the RP specimen. In Table 3, 
PSA density in relation to tumor volume is shown. Both patients who were 
converted to RP after 9 and 10 months of WW had Gleason score 5 organ-
confined cancers (pT2c). One of these patients had a tumor volume of 0.24 ml.  
 
Table 3 Tumor volume according to PSA density ranges 
PSA density range (ng/ml/cm3) tumor volume ml (range) 
≤0.10 0.08 (0.0-2.2) (n=48)  
0.11-0.15 0.10 (0.0-2.2) (n=31) 
≥0.16 0.45 (0.0-8.9) (n=24) 
 
Pathological findings in prostatectomy specimens   
No patients with focal cancer undergoing RP had tumor positive lymph 
nodes. In 3 men, it was not possible to find the prostate cancer in the RP 
specimen, even after additional sectioning and exclusion of mix-up of biopsy 
material by molecular analysis. Positive surgical margins were present in 15 
RP specimens, 4 patients did have positive surgical margins in case of tumor 
volumes <0.5 ml (Gleason score 6). The pathological stages are listed in Table 
4.  
 
Table 4 Pathologic stage of focal prostate cancer, including two patients who 
were initially managed with watchful waiting 
pathologic stage n percentage (%) 
no prostate 
cancer 3 2.9 
pT2a 40 38.1 
pT2b 1 1.0 
pT2c 56 53.3 
pT3a 3 2.9 
pT4 2 1.9 
Total 105 100 
 
Five patients had extra capsular disease, including 2 with invasion of the 
bladder neck. One patient with stage pT3a was clinically diagnosed with a 
cT3a prostate cancer, whereas 3 pT3 patients were clinically diagnosed with 
cT1c stage. Tumor volume of patients with extra-capsular disease ranged 
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widely (i.e. from 0.37 to 8.94 ml). Sixteen patients were diagnosed with a 
Gleason pattern 4 component in their carcinoma (Gleason score 3+4 (n=14), 
4+3 (n=1), 4+4 (n=1)) in the RP specimen. In 9 patients Gleason pattern 2 was 
dominant in the RP specimen. When patients in the RP-group were 
categorized, 67 (65%) cancers were considered as minimal tumors (<0.5 ml, no 
Gleason pattern 4 or 5, organ confined and negative surgical margins) and 36 
(35%) were considered moderate to advanced tumors (≥0.5 ml, with Gleason 
pattern 4 or 5, ≥pT3a and or positive surgical margins). The proportion of 
minimal and moderate to advanced tumors was equal in both rounds. In 6 of 
11 patients with a tumor volume >1 ml, more than 50% of the tumor was 
composed of Gleason pattern 2 carcinoma localized in the transition zone.  
 
Follow-up 
Follow-up of the RP-group was available in 87 men, with a median follow-up 
of 45 months (range 3-96). Four patients (4.6%) showed PSA recurrence. 
Despite PSA recurrence, no evidence for local recurrence or (lymph node) 
metastasis was found. The median time to PSA recurrence was 53 months (4-
99 months). PSA levels were stable in 3 patients without adjuvant therapy 
(0.3, 0.5 and 0.7 ng/ml for 63, 88 and 44 months, respectively). The other 
patient with PSA recurrence shortly thereafter died of a cancer other than 
prostate cancer. PSA progression in the RP-group was significantly associated 
with positive surgical margins (p=0.02) in multivariate analysis. All other 
variables (i.e. age, Gleason score at sextant biopsy or RP, pathologic stage, 
PSA, volume, and tumor volume) were not significantly related to PSA 
progression after RP. The 5-year PSA progression free survival Kaplan Meier 
curve of minimal and moderate tumors was 98 and 93% (not significant), 
respectively (Figure 1).  
 
 
 
90
 90
Figure 1 PSA free survival in minimal and moderate tumor in the RP-group 
 
 
Follow up of patients managed with a WW policy was available in 82 
patients, and median follow-up was 30 months (5-86). No patient had a cT-
stage increase at follow-up. PSA doubling time can be seen as a marker of 
progressive disease in the follow-up of WW patients. A PSA doubling time 
shorter than 2, 3, or 4 years occurred in 4, 12, and 18 patients, respectively. In 
figure 2 Kaplan Meier curves of “failure” in WW-patients are shown (i.e. 
using a failure cut-off of 3 different PSA doubling times (<2, 3, or 4 years)). If 
patients changed therapy they were censored at the time of treatment. The 
chance of failure to PSA doubling times < 2, 3, and 4 years within 5-year 
follow-up in WW-patients was 5, 13 and 17%, respectively. Median PSA 
doubling time was 7.4 years (range: negative (PSA decreased)-63 years).  
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Figure 2 Different PSA doubling times as marker for progression in watchful 
waiting patients. 
 
PSA dt PSA doubling time 
 
Negative and PSA doubling time >10 years were seen in 54.3% of the patients. 
One patient in the WW-group had a Gleason score 8 in his follow-up biopsy 
associated with a PSA doubling time of 4 months. Follow-up biopsies in other 
patients were not recorded. Histologically proven lymph node metastasis was 
seen in one patient, already known with PSA-progression. There was no 
clinical parameter (PSA, PSA-density, age, Gleason score, age, length of 
tumor, clinical stage) significantly associated with PSA doubling time <2,3, or 
4 years. Four and one deaths have been recorded during the study in the RP 
and WW group, respectively. However, these patients died of intercurrent 
diseases and prostate cancer was not a contributing factor. 
 
Conversion from watchful waiting to other therapy 
Eighteen patients (21%) changed therapy after a median of 15 months (6-87). 
The main reason for therapy change was a progressive PSA (PSA doubling 
time was <4 years in 12 patients). Therapy change to RP was patients wish' in 
one case and one patient changed to hormonal surgery therapy after lymph 
node metastasis was diagnosed. In 4 patients reasons for therapy change was 
unknown. Thirteen, 3 and 2 patients underwent radiotherapy, hormonal 
therapy, and RP, respectively. These patients showed no disease progression 
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(defined as: PSA ≥0.2 ng/ml postoperatively or two increasing PSA values 
after radiotherapy) after therapy change.  
 
Discussion 
In this study we show that in a screened population a significant proportion 
of men was diagnosed with a “focal” prostate cancer in sextant needle 
biopsies. Its incidence significantly increased to almost 30% of all cancers in 
the 2nd screening round. This increase could be observed both under the 
conditions of the initial screening protocol (PSA ≥4.0 ng/ml) and those of the 
final screening protocol (PSA ≥3.0 ng/ml). This data is similar to findings at 
the Swedish section of the ERSPC, where the ratio of focal cancer/all cancers 
increased significantly in subsequent screening rounds at a 2-year interval 114.  
In 79% of the men with focal cancer, undergoing RP, a cancer <0.5 ml was 
found in the RP specimen. Earlier studies demonstrated that the amount of 
cancer in the needle biopsy couldn’t predict accurately the tumor volume in 
the RP specimen 114,136. In a similar way, focal cancer in a prostate needle 
biopsy cannot predict accurately a minimal cancer in the corresponding RP 
specimen. Allan et al. 137 defined focal cancer as 0.5 mm in one core and no 
Gleason pattern 4 or 5. They found in a series of 54 patients a minimal cancer 
in 71% of RP. Furthermore, they reported extra-prostatic extension and 
positive surgical margins in 3, respectively 5 patients with focal cancer. 
Apparently, using a more restricted definition of focal cancer (i.e. 0.5 mm 
instead of 3 mm) does not improve the predictability of minimal cancer organ 
confined cancer.  
Predictive parameters for tumor volume after a diagnosis of focal 
cancer in our study were PSA level and prostate volume. When PSA and 
prostate volume were combined as PSA density, using a cut-off value of 0.1 
ng/ml/cm3, 94% of the patients had tumor volumes smaller than 0.5 ml and 
every tumor was organ confined. After employment of a PSA density cut-off 
value of 0.15 ng/ml/cm3, Epstein et al. 124  noted in 86% of patients with focal 
(stage T1c) cancers a tumor volume <0.5 ml, including two patients with 
extra-prostatic disease. If exclusively focal T1c carcinomas from our study 
were considered with PSA density of 0.15 ng/ml/cm3, only 78% of patients in 
our study had a tumor volume <0.5 ml and one had extra-prostatic disease. 
Indeed, addition of clinical staging parameters did not improve the prediction 
of tumor volume in these focal cancers. Other authors also demonstrated that 
both PSA-density and PSA level were predictive for tumor volume in case of 
focal cancers 137,138.   
Tumors in RP specimens after a diagnosis of focal cancer tended to be 
smaller in the 2nd screening round. This is in line with our previous 
observation that the tumor involvement in needle biopsies during the 1st 
round was more extensive as compared to those in the 2nd screening round, 
which would imply that during subsequent screening rounds a downsizing of 
prostate cancers would occur 84.  
Three patients (2.9%) with focal cancer in the 2nd screening round 
lacked a detectable cancer upon RP (pT0 stage cancer) even after additional 
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sectioning and exclusion of mix-up of biopsy material by molecular analysis. 
This considerably higher percentage as compared to the incidence of 0.3% 
mentioned recently in literature 139 may be attributed to the highly selected 
group of our patients. Strikingly, also in the latter paper most pT0-stage 
prostate cancer patients had only one positive needle biopsy core. Obviously, 
focal cancer increases the risk to encounter a pT0 prostate cancer in a 
subsequent RP specimen. 
Despite the occurrence of 5 deaths in the patients diagnosed with focal cancer, 
we did not observe disease specific mortality neither in the RP nor WW-group 
during the 3-year follow-up period. Histologically proven metastasis to the 
lymph nodes was noted in one patient in the WW-group, but this did not 
occur in the RP-group. As may be expected, patients with a focal cancer 
treated by RP rarely showed PSA- progression (4.6%). In this selected group 
of patients, positive surgical margins were the only variable significantly 
associated with PSA progression. In the follow-up of focal cancers managed 
by a WW policy, PSA doubling time is a frequently used variable to monitor 
prostate cancer. In literature different PSA doubling time cut-offs have been 
proposed as progression marker in WW patients. McLaren et al. 127 noted 
clinical progression (defined by increased clinical T-stage) in 80% of patients 
within 2 years of follow-up with a PSA doubling time of <3 years. Clinical 
progression was observed in 50% of patients after 2.5 years if PSA doubling 
time was >3 years. Stephenson et al. 126 reported  that clinical progression of 
WW patients was significantly related to PSA doubling time less than 4 years. 
On the basis of these studies a cut-off PSA doubling time <4 years may be 
chosen as the most optimal marker for progressive disease in WW.  This 
somewhat arbitrary cut-off value could be used to compare the frequency of 
“PSA progression” of patients on WW policy with those treated by RP. 
Employing PSA doubling time <4 years “PSA progression” was observed 
significantly more frequently in the WW-group as compared to PSA 
recurrence in the RP-group: the proportion of patients with a 5-year PSA 
progression-free interval after RP, respectively the proportion of patients in 
the WW-group with a PSA doubling time >4 years was 96 and 67% 
(p=0.0005), respectively. Despite this significant difference a definite 
conclusion cannot be drawn because no established criteria for “PSA” 
progression in WW patients are available. If for example, another cut-off 
value of PSA doubling time <2 years as arbitrarily employed by Choo et al. 140 
would be applied, no significant 5-year difference in PSA progression 
between the RP and WW-group had been observed. Indeed, only 4 patients of 
our WW series (4.9%) had a PSA doubling time < 2 years. On the other hand, 
some advocated PSA doubling times even longer than 4 years as a marker for 
“PSA progression”. Stephenson et al.126 reported that a PSA doubling time 
<10 years correlated with disease progression on repeat biopsy and DRE, 
whereas in our screening study the mean PSA doubling time was 6.1 years in 
men with negative biopsy outcome in the second screening round (average 
PSA doubling time of 25 years in men who did not undergo biopsy in two 
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subsequent screening rounds) 141. No clinical variable available at diagnosis 
could predict a PSA doubling time <4 years in the follow-up in our study.  
In this study, 22% of men on WW policy after a diagnosis of focal 
cancer changed therapy and 67% of them did so because of PSA progression. 
Fifteen of the latter patients (83%) were given curative treatment. All 
converted patients had stable PSA values afterwards. Two patients converted 
to RP after following a WW policy. They had organ confined disease with 
Gleason score 5 prostate cancer. Carter et al. 142 saw organ-confined disease in 
11 out of 13 patients who underwent RP after a WW policy. It should be noted 
that these authors defined disease progression as adverse pathological 
findings in follow-up needle biopsies and their inclusion criteria for watchful 
waiting were different. The limited proportion of men opting for therapy 
conversion (i.e. 22%) demonstrates that our follow-up protocol (i.e. biannual 
PSA testing) for WW is rather acceptable to most men.  
A substantial proportion (32.2%) of patients with focal cancer opted for 
WW. In the entire screened population, the proportion of men opting for a 
WW policy increased from 10.0% in the 1st round to 24.4% in the 2nd screening 
round. A possible explanation for this finding might be the significantly older 
age in the 2nd screening round. The co-morbidity was low in the two 
subsequent screening rounds and equal in both rounds in our patient 
population at time of initiation of WW. The increase of focal cancers and 
lower PSA levels of WW patients compared to men who underwent RP, as 
shown here, and the less aggressive tumors in the 2nd screening round 85 
might also be responsible for the increase in WW-patients.  
 
Conclusions 
Patients with focal cancer in their sextant biopsy have a definite, but small 
risk of PSA progression after RP (4.6%). The positive predictive value of focal 
cancer for a minimal cancer in the RP was 94% using a PSA density cut-off of 
≤0.1 ng/ml/cm3. PSA progression occurred more frequently in the WW-
group (when PSA doubling time of <3 and 4 years was used as a cut-off value 
for PSA progression) compared to the RP-group. Nevertheless, delayed 
therapy with curative intent after a WW policy in patients with focal cancer, 
especially in those patients with low PSA-density levels might be an 
acceptable option. However, definite criteria for disease progression in WW 
patients urgently need to be established.  
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Abstract 
Objective: To evaluate the features of prostate cancer detected during two 
subsequent screening rounds in relation to changes in therapy choice.  
Methods: Data were retrieved from the European Randomized Study of 
Screening for Prostate Cancer, section Rotterdam (ERSPC). Men, ages 55-75 
years were prostatic specific antigen (PSA) tested at an 4-year interval. A total 
1548 sextant biopsies were recorded for Gleason score and tumor extent and 
550 radical prostatectomy specimens were evaluated for Gleason score, 
pathological T-stage and tumor-volume.  
Results: Gleason score, involvement of biopsy by tumor, clinical stage and 
PSA level were more favorable in patients of the second round compared to 
those of the first round. The number of men choosing for watchful waiting 
increased from 98 (10%) to 123 (22%) in the first and second round, 
respectively (p< 0.0001). In patients undergoing radical prostatectomy, 
median tumor-volume in the first and second screening round was 0.65 and 
0.45 ml (p=0.001). Minimal cancer (cancer <0.5 ml, organ confined, no Gleason 
pattern 4 or 5) was found in 122 (31.6%) in the first and 60 (42.6%) in the 
second screening round (p=0.03). The 5-year PSA progression free survival 
after radical prostatectomy was 87%.  
Conclusions: In the second screening round, after radical prostatectomy, 
42.6% fulfilled the criteria of minimal cancer, reflecting a high level of over-
treatment. The 5-year PSA progression free survival in patients with a 
minimal cancer was high (94%) and suggests that a more conservative 
approach is warranted in these men. Their proper identification however 
remains difficult.  
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Introduction 
Prostatic specific antigen (PSA) testing is mainly responsible for the changing 
incidence in prostate cancer in many countries. Presently, two large 
randomized clinical trials of screening for prostate cancer are ongoing, one in 
Europe (European Randomized Study of Screening for Prostate Cancer, 
ERSPC) and another in the USA (Prostate Lung Colorectal and Ovary cancer, 
PLCO). The answer with adequate evidence whether screening reduces 
mortality from these randomized clinical trials will probably not be available 
before 2008. Until this time the debate on screening for prostate cancer will 
continue. The goal of the ERSPC is to evaluate whether population based 
screening reduces mortality from prostate cancer at an acceptable price in 
terms of quality of life and costs 1. As a consequence of screening a higher 
proportion of localized prostate cancer is diagnosed and therefore the 
opportunity for curative therapy has increased 143. However, the considerable 
increase in incidence/mortality ratio in areas where screening is prevalent 
also led to concerns with regard to the necessity of immediate curative 
therapy with accompanying severe side effects such as erectile dysfunction or 
incontinence for urine and faeces. The number of radical prostatectomies and 
radiotherapy treatments in The Netherlands has increased dramatically over 
the last decade 144. Growing awareness of potential over-treatment, that is 
treatment of men with prostate cancer who may not benefit from therapy, has 
prompted watchful waiting as an alternative (prior) to immediate curative 
therapy.  Hoedemaeker et al. 84 already reported more favorable tumor 
characteristics when 25% of men in the second round were screened implying 
a higher risk of over-treatment. After full completion of the second round of 
the ERSPC (Rotterdam), clinical staging parameters of detected prostate 
cancers as well as the histopathological tumor characteristics of sextant 
biopsies and corresponding radical prostatectomy specimens in two 
subsequent screening rounds were analyzed and related to therapy choice 
and follow-up data with regard to PSA failure.  
 
Material and Methods 
Patients and screening strategies 
In ERSPC, section Rotterdam, 42,376 men, 55-75 years old, were randomized 
to a screening (n=21,210) and a control arm (n=21,166). Ethical approval of the 
study was obtained from the Dutch ministry of health (committee on the 
population screening act, WBO committee nr. 325291). The first screening 
round (November 1993 - December 1999) was initially done by PSA 
determination, digital rectal examination (DRE) and transrectal 
ultrasonography (TRUS). Sextant needle biopsy was recommended for 
participants who had either an elevated PSA level (≥4.0 ng/ml), abnormal 
DRE or abnormal findings on TRUS. The protocol was simplified on May 
1997, when sextant biopsy was recommended if PSA was ≥3.0 ng/ml, 
regardless of DRE and/or TRUS findings.   
During the second screening round (June 1998 - December 2003), using 
the PSA ≥3.0 ng/ml protocol, two side studies were performed. One studied 
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the impact of PSA doubling time on the detection of (clinically relevant) 
prostate cancer. If PSA doubled and rose above PSA  ≥1.0 ng/ml, men were 
invited for sextant biopsy. The other investigated the incidence of prostate 
cancer in the PSA 2.0-4.0 ng/ml range and the level of free PSA and human 
kallikrein 2. All participants in these side studies were included in our 
analysis.  
Prostate biopsy cores were labeled and processed individually. One 
pathologist (T.H.v.d.K) reviewed all biopsies with cancer, high-grade 
prostatic intraepithelial neoplasia and lesions suspicious for malignancy in 
order to avoid inter-observer variability. During this review, the number and 
size of biopsies were recorded as well as the absolute amount of tumor 
involvement, and the proportion of each Gleason pattern.  
 
Pathologic processing 
Slides from radical prostatectomy specimens were retrieved from the archives 
of the pathology laboratories of the Erasmus Medical Centre and surrounding 
hospitals of the Rotterdam region. There was one single protocol for total 
embedding of the prostate in use in our hospital and in some but not all 
surrounding pathology laboratories, allowing accurate measurements of 
tumor-volume, grading, and staging 129. In short, after fixation, radical 
prostatectomy specimens were inked and serially sectioned at four mm 
intervals and totally embedded in paraffin blocks. Two uro pathologists 
(T.H.v.d.K and G.J.L.H.v.L) determined pathologic stage (tumor, node, 
metastases (TNM) classification of 1992) 145 and Gleason score 146. If no 
prostate cancer could be found, additional sections were made and molecular 
analysis was performed to exclude mixing up of material. Tumor-volume was 
measured by morphometry as described previously 130. Radical prostatectomy 
in the first and second screening round was performed in 400 and 179 patients 
respectively. No patients had lymph node metastasis on frozen section 
material and therefore no radical prostatectomies were abandoned. There was 
one patient included in this study with a lymph node metastasis on paraffin 
section, diagnosed as pT4N1M0 stage prostate cancer, and no adjuvant 
treatment was given. Of 386 (96%) and 164 (92%) patients the radical 
prostatectomy specimens from the first and second screening round could be 
retrieved. Tumor-volume was measured in 488 (i.e. 338 from the first and 150 
from the second round) radical prostatectomy specimens, which were 
embedded according to protocol. Gleason score was determined in all, but 
two radical prostatectomy specimens because of neo-adjuvant endocrine 
therapy (which falsely induces a higher Gleason score). 
Two patients in the first round received neo-adjuvant endocrine 
therapy for practical reasons (i.e. patients’ holiday). No other neo-adjuvant 
therapies were given. Seven patients received adjuvant radiotherapy within 6 
months after radical prostatectomy in the first round, of whom one developed 
PSA progression.  
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Categorization of cancers in prostatectomy specimens and follow-up 
Tumors were categorized according to a previously reported arbitrary model 
that was based on tumor characteristics 130, comprising three categories: 1) 
Minimal tumor: tumor-volume <0.5 ml, containing no Gleason pattern 4 or 5, 
organ confined, 2) Moderate tumor: tumor-volume ≥0.5 ml, or organ confined 
tumor containing any amount of Gleason pattern 4 or 5 or tumor with extra-
capsular extension without Gleason pattern 4 or 5, and 3) Advanced tumor: 
Tumors with extra-capsular extension containing Gleason pattern 4 or 5, 
seminal vesicle invasion or bladder neck invasion.  
Biannual controls were performed in the Erasmus Medical Centre or in 
surrounding hospitals. At each visit serum PSA was determined and DRE 
performed. Recurrence of disease (PSA failure) was defined as two 
subsequent PSA levels of ≥0.2 ng/ml, postoperatively. Metastasis was 
determined by a bone scan.  
 
Statistical analysis 
Statistical analysis was done with the SPSS software package (SPSS 11.0 Inc., 
Chicago, IL). P<0.05 was considered significant. Pearson chi squared tests 
(two sided) were used for ordinal variables, student’s t test (Mann Whitney 
test for non-parametric data) for linear variables. Multinomial regression was 
used for tumor category. The Kaplan Meier method was used to calculate 
PSA progression free survival curves in different categories and significant 
differences between curves were based on the log rank statistic. Patients were 
censored if follow-up ended or patients died. Univariate and backward 
multivariate Cox regression analysis was used to create a model for 
prediction of PSA progression for linear and ordinal variables. 
 
Results 
Prostate cancer detection rates and therapy choice 
The detection rate of prostate cancer in the first and second screening round 
was 5.1 and 4.4%, respectively (p=0.0005) (Table 1).  
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Table 1 Prostate cancer incidence, PSA range, and number of radical 
prostatectomies performed 
Round one 
PSA (ng/ml) 
Number of 
men 
screened (n) 
Number 
of 
biopsies 
(n)  
Cancer 
(n) 
Prostate 
cancer 
detection 
rate (%) 
RP 
performed 
n (%)  
<3.0  15852 918 79 0.5 41 
3.0-3.9 1426 791 179 12.6 80 
4.0-9.9 2235 2005 526 23.5 229 
>10.0 457 403 230 50.3 51 
total 19970 4117 1014 5.1 401 
round two      
<3.0  10026 693 109 1.1 34 
3.0-3.9 949 830 174 18.3 50 
4.0-9.9 1362 1215 235 17.3 84 
≥10.0 183 166 32 17.5 11 
total 12520 2904 550 4.4 179 
PSA Prostatic Specific Antigen 
RP Radical Prostatectomy 
 
When the analysis was limited to men screened at a cut-off level of PSA ≥3.0 
ng/ml, the prostate cancer detection rate in the first and second screening 
round was 5.0 and 3.0%, respectively (p<0.0001). In the first screening round 
the prostate cancer detection rate increases with higher PSA ranges, which is 
not the case in the second screening round (Table 1). The proportion of men 
who underwent radical prostatectomy was 39.4 and 32.5% in the first and 
second round, respectively (p=0.002) (Table 2). The decrease in performed 
radical prostatectomies in the second round was most prominent in the PSA 
range ≥4.0 ng/ml. The proportion of men who underwent radiotherapy 
decreased drastically in the second round (48.5 vs. 35.6%). On the opposite, 
the proportion of men who were managed by watchful waiting more than 
doubled from 9.7% in the first to 22.4% in the second round.  
 
Tumor characteristics in two screening rounds 
Clinical characteristics are given in Table 2. In all cancers detected, clinically 
extra-prostatic disease (clinically (c)T3-T4) was significantly less frequent in 
the second round and the proportion of impalpable (cT1C) cancers increased 
significantly in the second screening round. Parallel with the clinical stage 
migration a grade migration was noted as manifested by the reduction of 
sextant biopsies with Gleason score ≥7 cancers from 35.4% in the first round 
to 20.7% in the second round (p<0.0001). The percentage of patients with a 
Gleason score ≥7 cancer who underwent radical prostatectomy was 26.3 and 
27.7% in the first and second screening round, respectively. In round one, 
patients who underwent radiotherapy had the worst pre-treatment tumor 
characteristics, next to patients treated with endocrine therapy. In round two, 
however, pre-treatment tumor characteristics (Gleason score, cT-stage and 
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PSA) of patients undergoing radiotherapy were similar to those undergoing 
radical prostatectomy. The overall percentage of tumor involvement in 
sextant biopsies was significantly lower in the second round (20.7% vs. 11.1, 
p<0.0001), a phenomenon that also held true for patients who underwent 
radical prostatectomy in the second screening round (data not shown). 
Notably, in men who had a negative biopsy outcome in the first round 
but a positive outcome in the second round the percentage of tumor 
involvement in sextant biopsy was smaller as compared to men who were not 
biopsied before (5.1 vs. 10.4% p=0.001). 
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Table 2 Characteristics of patients in different therapy groups 
1st round all men  RP WW RT ET 
biopsy Gleason category n(%)    
<7 647 (63.8) 291 (72.8) 86 (87.8) 265 (53.9) 5 (21.7) 
7 278 (27.4) 87 (21.8) 8 (8.2) 170 (34.6) 12 (52.2) 
>7 82 (8.1) 18 (4.5) 4 (4.1) 54 (11.0) 6 (21.7) 
unknown 7 (0.7) 4 (1.0) 0 3 (0.6) 0 
cT-stage n (%)    
T1c 356 (35.3) 167 (41.8) 56 (57.1) 128 (26.0) 5 (21.7) 
T2 467 (45.6) 199 (49.8) 34 (34.7) 231 (47.0) 3 (13.0) 
T3-4 190 (18.5) 34 (8.5) 8 (8.1) 133 (27.0) 15 (65.2) 
age 66.1 63.5 69.4 68.8 69.1 
PSA 5.7 5.3 4.4 6.5 41.0 
total n (%) 1014 400 (39.4) 98 (9.7) 492 (48.5) 23 (2.3) 
unknown therapy 1     
 
2nd round  all men  RP WW RT ET 
biopsy Gleason category n(%) 
<7 436 (79.3) 130 (72.6) 115 (93.5) 149 (76.0) 4 (50.0) 
7 96 (17.5) 42 (23.7) 7 (5.7) 39 (19.9) 3 (37.5) 
>7 18 (3.2) 7 (4.0) 1 (0.8) 8 (4.1) 1 (12.5) 
cT-stage5 n(%)    
T1c 339 (61.6) 109 (60.9) 95 (77.2) 110 (56.1) 1 (25.0) 
T2 191 (34.7) 64 (36.2) 26 (21.1) 77 (39.3) 7 (87.5) 
T3-4 20 (0.7) 6 (3.4) 2 (1.6) 9 (4.6) 0 
age (median) 67.1 64.9 69.8 68.7 67.8 
PSA (ng/ml) 3.9 4.1 3.4 4.1 6.4 
total n (%) 550 179 (32.5) 123  (22.4) 196 (35.6) 8 (1.5) 
unknown therapy 44     
RP Radical Prostatectomy  
WW Watchful Waiting 
RT Radiotherapy 
ET Endocrine Therapy 
cT-stage Clinical T-stage 
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PSA Prostatic Specific AntigenTumor features in radical prostatectomy specimens 
Details are shown in Table 3.  
 
Table 3 Characteristics of radical prostatectomy specimens 
 1st round 2nd round  p-value 
pT-stage1   p=0.07 
pT0 1 (0.3) 3 (1.8)  
pT2a 73 (28.9) 41 (25.0)  
pT2b 9 (2.3) 5 (3.0)  
pT2c 211 (54.7) 86 (52.3)  
pT3a 62 (16.1) 20 (12.2)  
pT3b 4 (1.0) 2 (1.2)  
pT3c 8 (2.1) 6 (3.7)  
pT4 17 (4.4) 1 (0.6)  
total  386 (100) 164 (100)  
Gleason score   p=0.11 
<7 241 (62.4) 103 (62.8)  
=7 130 (33.7) 49 (29.9)  
>7  13 (3.4) 12 (7.3)  
unknown 2 (0.5) na  
tumor category    p=0.03 
minimal  122 (31.6) 
) 
70 (42.6)  
moderate 193 (50.0) 73 (44.5)  
advanced 71 (18.4) 21 (12.8)  
positive surgical 
resection margins 
positive 
98 (25.6) 36 (22.0) p=0.39 
 
 
pT-stage Pathological T-stage 
 
Four radical prostatectomy specimens showed no prostate cancer (pT0). The 
proportion of radical prostatectomy specimens with extra-prostatic disease 
decreased from 23.6% in the first to 17.7% in the second round. The 
proportion of men with organ confined prostate cancer (≤pT2 stage) with 
positive resection margins was 18 and 15% in the first and second round, 
respectively. The proportion of radical prostatectomy specimens with Gleason 
score ≥7 in the first and second round was 37.0 and 37.2% respectively. Of the 
minimal tumors 9.7% had a positive surgical margin. The proportion of 
advanced tumors decreased in the second screening round. 
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Tumor-volume, proportion of minimal tumor in relation to PSA range 
is shown in Table 4.  
 
Table 4 PSA at diagnosis related to tumor-volume and percentage minimal 
tumor 
PSA range 
(ng/ml)  
median, mean tumor-
volume in ml (range) 
1st screening round 
n=342 
% 
minimal 
tumor 
median, mean tumor-
volume in ml (range) 
2nd screening round 
n=154 
% 
minimal 
tumor 
<3.0 0.28, 0.32 (0.00-1.09) 67 0.28, 0.38 (0.00-1.80) 56 
3.0-3.9 0.58, 0.72 (0.00-3.10) 45 0.43, 0.63 (0.00-2.17) 31 
4.0-9.9 0.77, 1.08 (0.00-13.48) 27 0.63, 1.06 (0.01-7.93) 46 
≥10.0 1.82, 2.16 (0.00-7.99) 13 1.33, 2.04 (0.00-8.94) 36 
total 0.65, 1.06 (0.00-13.48) 33 0.45, 0.86 (0.00-8.94) 43 
PSA Prostatic Specific Antigen 
 
Tumors in the second screening round were significantly smaller compared to 
the first round (p=0.001) with a significant relationship between PSA level at 
diagnosis and tumor-volume in the first and second screening round 
(p<0.0001 for both rounds, and R2 = 0.15 and 0.12). In the first round the 
proportion of minimal tumors decreased with increasing PSA range, but not 
in the second round. A weak correlation was found between increasing age 
and larger tumor-volumes (R2 =0.03). 
Multinomial regression (pseudo R2 = 0.33) demonstrated PSA range 
(p<0.0001), percentage tumor involvement in sextant biopsy category 
(p<0.0001), and biopsy Gleason category (p<0.0001) as preoperative 
predictors for tumor category (minimal, moderate, and advanced tumors) in 
the first screening round. Age was univariately associated with tumor 
category in both rounds. In the second round PSA range was not predictive 
for tumor category anymore (p=0.11).   
 
Follow-up after radical prostatectomy 
The follow-up was known in 383 and 127 patients and median (range) follow-
up was 67 (0-112) and 31 (0-67) months in the first and second screening 
round. PSA progression occurred in 60 patients (10.9%) with a mean time to 
progression of 52 months (95% CI 50-54 months). Metastases occurred in five 
patients (four with advanced and one with a moderate tumor) after a median 
follow-up of 44 months. Univariate Cox regression analysis revealed positive 
resection margins, pT-stage, age, tumor-volume, radical prostatectomy and 
biopsy Gleason score, percentage tumor involvement (all p<0.0001), number 
of cancer positive cores (p=0.001), and PSA (p=0.007) as predictors for PSA 
progression. Clinical T-stage and prostate volume were not predictive in 
univariate analysis. In multivariate Cox regression, positive resection margins 
(p=0.001), age (p=0.001), biopsy Gleason score (p=0.001), and pT-stage 
(p=0.037) significantly predicted PSA progression after radical prostatectomy.  
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The 5-year PSA progression free survival rates for minimal, moderate, 
and advanced tumor was 94, 89, and 67% (log rank p<0.0001), respectively 
(Figure 1).  
 
 
  
Figure 1 
 
PSA progression free survival of 3 tumor categories
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Of the minimal tumors 10% had a positive resection margin, which was 
significantly related to PSA progression (p=0.04). Kaplan Meier curves of 
different age categories and PSA progression free survival is shown in 
Figure 2. 
The category minimal tumor includes tumors <0.5 ml without Gleason 
pattern 4. Considering a broader definition of minimal cancer, including 
Gleason patterns ≥4 (n=55), 19% showed positive surgical margins and 9% 
showed extra-prostatic disease, indicating more aggressive disease. In stage 
pT3 tumors the 5-year PSA progression free survival was higher in negative 
surgical margins compared to positive resection margins (93 vs. 75%, log rank 
p=0.0003).  
 
Number of patients at risk 
Minimal    174           152              101               39                4                - 
Moderate  244            204   149               66               10               - 
Advanced   85            65               45           26                 8                -   
p<0.0001 
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Figure 2 
 
PSA progression free survival of
age categories
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Discussion 
The observation of more favorable characteristics of cancers detected on 
biopsies during the second screening round as reported earlier 85 is now 
further confirmed after comparison of tumor features in radical prostatectomy 
specimens of first and second screening round patients. Although down-
staging of prostate cancers in radical prostatectomy specimens of the second 
round compared to the first round did not reach significance, both a 
significant shift to lower tumor category (i.e. increase of minimal cancers) and 
decreased volume of second round cancers was noted. This category 
improvement of prostate cancers in radical prostatectomy specimens in the 
second screening round occurred in spite of the marginal improvement of 
clinical and biopsy characteristics in the subset of patients undergoing radical 
prostatectomy as compared to the considerable improvement in pre-treatment 
variables of all prostate cancers detected in the second round. Thus, during 
subsequent screening rounds the decrease in volume of cancer already 
observed in needle biopsies 84, continued. 
In the ERSPC, the over-diagnosis was calculated at 48% as a 
consequence of an estimated lead time of eleven years 48. If a minimal cancer 
Number of patients at risk 
<60       165             100             85              49              10               - 
60-65    171             142             97              42                7               - 
65-70    195       155            101             34             5               -        
70-75   31         24             13                6                -                -
p<0.0001 
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is considered as a cancer of which the diagnosis is not of benefit to the patient, 
over-diagnosis in our screened population would occur in at least three to 
four out of ten patients, their radical prostatectomy may have been an over-
treatment or the treatment has been carried out too early in the development 
of cancer. This can as yet not be proven. However, we know that the cancer 
specific survival of untreated highly differentiated prostate cancer is 89 and 
72% after 15 and 20 years, respectively 19. Generally it is felt that prediction of 
a minimal cancer is not reliably possible at the individual level 114, although 
Gleason score in the biopsy and percentage of tumor involvement in sextant 
biopsies by tumor can predict tumor category at a statistically significant 
level. Importantly, we noted that the PSA range did not predict tumor 
category anymore during the second round, which can be explained by that 
larger tumors are detected in an initial screening round, and in a subsequent 
round tumors are smaller and four years is too short for remaining cancers to 
re-grow to the same volume and the PSA driven biopsy indication is 
dominated by non-cancer disorders. Which further supports the notion 
arising in countries with an intense PSA screening (i.e. USA) that repeat PSA 
testing is less sensitive for tumor detection 141,147. 
In a previous study of focal cancer (≤3 mm of cancer in one biopsy 
core, without Gleason pattern 4 or 5) detected in participants of the ERSPC, 
we demonstrated that 66% (n= 74) of men with a focal cancer had a minimal 
cancer in the radical prostatectomy specimen 15. In men with a PSA density of 
≤0.1 ng/ml per ml prostate volume 94% of the cancers detected in their 
radical prostatectomy specimen was a minimal cancer148. Thus, a combination 
of focal cancer and PSA density of ≤0.1 ng/ml per ml prostate volume could 
be used as an indicator of minimal cancer, and in these men watchful waiting 
could be safely recommended. However, for young men with a potential 
minimal cancer immediate curative treatment might be preferred in order to 
avoid the psychological burden of repeated PSA tests and biopsies. 
Only a small fraction of men detected with prostate cancer during 
screening fulfils the combined criterion of focal cancer and low PSA density 
(7.9 and 18.2% in first and second round respectively). In the current study 
35% (n=196) of all tumors detected in radical prostatectomy specimens of first 
and second round were minimal cancers, and only 70 of them (36%) had a 
pre-treatment biopsy diagnosis of focal cancer. the majority of minimal 
cancers thus had been diagnosed with a more extensive cancer than “focal 
cancer” at biopsy. If the definition was widened to ≤6 mm of tumor in three-
biopsy cores still 58% of the tumors were categorized as minimal.  
Apart from well know parameters for PSA progression (pT-stage, 
Gleason score and positive resection margins) age was an independent 
predictor for PSA progression after radical prostatectomy (Figure 2). For this 
striking observation we have no explanation. Although older patients have 
larger tumors and higher PSA levels at diagnosis, if age was excluded in the 
multivariate Cox regression analysis, no other than the above-mentioned 
variables were significantly associated with PSA failure. Freedland et al. 149 
recently published the same remarkable finding on age related PSA failure 
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after radical prostatectomy, for which they also could not offer a proper 
explanation. It remains to be seen whether in these older men, with a higher 
PSA recurrence rate, the prostate cancer specific mortality will be higher as 
compared to men whose prostate cancer is detected and treated at a younger 
age, since other competing causes of death in the older age group may lead to 
increasing overall mortality. The proportion of men undergoing radical 
prostatectomy was significantly lower in the second round. The smaller 
proportion of radical prostatectomy and radiotherapy performed in the 
second round was due to the more frequent choice for watchful waiting. The 
increasing choice for watchful waiting treatment (i.e. 22% during the second 
round) might be encouraged by the more favorable tumor characteristics 
(lower Gleason score, cT-stage and PSA level) in the second round. Other 
factors that stimulated the choice of watchful waiting are growing awareness 
of over-diagnosis by urologists and the aging (although without increasing 
co-morbidity150) of the screened cohort. It remains to be seen how often men 
choosing for watchful waiting will revert to curative therapy in the course of 
time. As yet this is rather limited in the ERSPC Rotterdam as only 16% of 
patients who initially opted for watchful waiting changed therapy (83% with 
curative intent) 150.  
Despite the focus on over-diagnosis in this study, it should be realized 
that in the second screening round 13% of patients have an advanced tumor 
(pT3-T4 with Gleason pattern 4 or 5) in their radical prostatectomy specimen. 
This could among other things indicate that the screening interval of four 
years employed in this study is too long. In another study with a 6-month 
screening interval 151, using PSA ≥4.0 ng/ml as a screening tool, 77%, 
respectively 70% of men with a diagnosis of cancer in the initial, respectively 
subsequent screening round were treated with radical prostatectomy, but the 
proportion of  advanced cancers (pT3-T4 and pT2 with positive surgical 
resection margins) decreased only marginally from 33% at the initial to 27% at 
the subsequent screening round. The proportion of poorly differentiated 
cancers (Gleason score >8) in radical prostatectomy specimens in the latter 
study was 11 and 6% at initial and subsequent screening round, respectively. 
This outcome suggests that even screening at much shorter intervals does not 
necessarily lead to substantially less advanced cancers. Probably other factors, 
like biopsy compliance, number and (lateralized) location of needle biopsies 
also strongly influence the efficacy of screening.  
In the current study, the 5-year PSA progression free survival of 
minimal cancer (after radical prostatectomy) was 94%. We consider failure of 
surgery (positive resection margins) for the most part responsible for the PSA 
failures, because of the significant difference in PSA progression free survival 
in minimal cancer with or without positive resection margins (p=0.04). The 
overall 5-year PSA progression free survival was 87%, which was high 
compared to other studies, reporting 5-year PSA progression free survival of 
80 and 78% 152,153.  
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Conclusions 
After completion of two screening rounds at the Rotterdam section of the 
ERSPC it is apparent that tumor characteristics are more favorable in the 
second compared to the first screening round. The number of men choosing 
for radical prostatectomy or radiotherapy in the second round decreased at 
the benefit of watchful waiting. Within the current screening protocol about 
one third of patients treated for prostate cancer with radical prostatectomy 
had a minimal cancer, with very favourable follow up results. It is 
questionable whether these patients should have received immediate curative 
therapy. Observation is likely to reduce over-treatment, especially in older 
men. Considering predictors for tumor category, urologists might recommend 
watchful waiting for men with a Gleason score 6 or lower prostate cancer and 
low tumor involvement, specifically in men with a low PSA density.  
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Abstract 
Objective: To compare tumor characteristics at the time of diagnosis of 
cancers detected in the screening and control arm at the Rotterdam section of 
the European Randomized study of Screening for Prostate Cancer (ERSPC). 
Methods: Data were retrieved from the Rotterdam section of the ERSPC. Men 
were randomized to the screening arm (n=21,210) or the control arm 
(n=21,166). Men randomized to screening were offered PSA testing every 4 
years. Through linkage with the cancer registry, men randomized to the 
control arm were detected. The biopsy Gleason score was determined in 1,591 
and 373 patients in the screening and control arm, respectively. TURP, radical 
prostatectomy (RP) and cystoprostatectomy were evaluated for Gleason score, 
pathological (p)T stage and tumor volume. 
Results: More prostate cancers were detected in the screen arm (15.9 vs. 4.2 
per 1000 man years, p<0.0001). Clinical (c)T stage, biopsy and RP Gleason 
score distribution were significantly less favorable in the control arm. 
Proportion of men with advanced disease (i.e. T4/N1/M1), but not their 
incidence in man years absolute number was significantly (p< 0.0001) higher 
in the control arm (11.0%; 4.6 per 100,000) as compared to the screening arm 
(3.8%; 6.0 per 100,000). Incidental prostate cancers accounted for 9.3% of all 
cancers detected in the control arm. The 5-year PSA progression free survival 
after RP was 68% in the control arm and 89% in the screening arm (p<0.0001).  
Conclusions: Prognostic features of patients with prostate cancer detected in 
the control arm are less favorable as compared to those detected in the 
screening arm. However, in both arms equal number of men present with 
advanced prostate cancer. 
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Introduction  
The changing incidence in prostate cancer in the Western world is mainly due 
to PSA driven testing and the increase in life expectancy. PSA screening is 
thought to be a powerful tool to detect prostate cancer in an early stage, while 
curable (1). The primary goal of the European Randomized study of Screening 
for Prostate Cancer (ERSPC) is to evaluate whether population based 
screening reduces mortality from prostate cancer at an acceptable price in 
terms of quality of life and costs(2, 3). It is expected that at the end of 2009 
conclusive data on the influence of screening on prostate cancer mortality by 
comparison of both trial arms of the ERSPC will be available.  
Comparison of histopathological features of prostatectomies performed on 
men of the  screening arm of the ERSPC with those of a historical control 
group (4) of the same hospital demonstrated a decreased frequency of lymph 
node positive disease and a relative increase in proportion of Gleason score 8-
10 cancers. However, a comparison of pathological features of all cancers 
detected in the screening and control arm of the Rotterdam section of the 
ERSPC was not reported previously.  
Incidentally identified prostate cancer can be detected in 
approximately 10% of trans-urethral resection of the prostate (TURP) 
specimens. Tumors classified as pT1a diagnosed at TURP are considered as 
clinically indolent and with low biological potential with favorable follow-up 
and therefore they are usually managed by watchful waiting (5).  Detection of 
a substantial proportion of pT1a prostate cancers in the control arm may 
increase the prostate cancer specific survival in the control arm. Incidental 
prostate cancer may be detected in about 40% of cystoprostatectomy 
specimens obtained from men treated for a bladder cancer. These prostate 
cancers mostly have prognostically favourable features (6). 
The present analysis of histopathological features of cancers detected within 
the control and trial arm of the Rotterdam section of the ERSPC was 
performed to demonstrate whether population based screening for prostate 
cancer would lead to the increased detection of prostate cancers with 
favourable characteristics. In addition, this kind of analysis could reveal the 
proportion of clinically silent advanced cancers in the population.   
 
Material and methods 
Patients and screening strategies 
In the Rotterdam section of the European Randomized Screening Study for 
Prostate Cancer (ERSPC) 42,376 men, 55-75 years old, were randomized to a 
screening (n=21,210) and a control arm (n=21,166). The follow-up of prostate 
cancer detection in the control arm was complete until the 1st of July 2003. 
Information on prostate cancer of men in the control arm was obtained 
through a record linkage with the Dutch cancer registry. Prostate cancer 
incidence was calculated per 1000 man-years. Man-years were calculated as 
the interval between dates of randomization to the cut-off date of 1st of July-
2003. The cut-off date was overruled if death, prostate cancer diagnosis or the 
age of 75 occurred before the cut-off date. In the screening arm, 36 prostate 
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cancers were diagnosed after the age of 75 years (outside screening protocol) 
and 108 cases were detected within the 4-year screening intervals (interval 
cancers). In the control arm 107 men were older than 75 years of age at 
prostate cancer diagnosis. Patients detected as interval cancers and patients 
diagnosed with cancer older than 75 years of age (in both arms) were 
excluded in this study. A manuscript describing the features of interval 
cancers is in preparation. 
The details of the screening algorithm of the screened population have 
been described elsewhere(7). In short, initially men were offered a PSA test, 
digital rectal examination (DRE) and transrectal ultrasonography (TRUS). 
Sextant needle biopsy was recommended for participants who had either an 
elevated PSA level (≥ 4.0 ng/ml), abnormal DRE or abnormal findings on 
TRUS. The protocol was simplified on May 1997, when sextant biopsy was 
recommended if PSA was ≥ 3.0 ng/ml, regardless of DRE and/or TRUS 
findings.   
Patients of the screening arm were selected from the 1st, interim 
(performed one year after the 1st round in men with benign 1st round biopsy 
outcome), 2nd and 3rd screening round. Both the 2nd and 3rd rounds were not 
completed at the cut-off date. All diagnoses were based on histological 
examination. Slides from TURP and radical prostatectomy specimens, Millin 
prostatectomies, cystoprostatectomies, and prostate biopsies of the ERSPC 
participants were retrieved from the archives of the pathology laboratories of 
the Erasmus Medical Center and surrounding hospitals of the Rotterdam 
region. One single protocol for total embedding of the prostate was in use in 
all pathology laboratories allowing accurate measurements of tumor volume, 
grading and staging (8). In case of full compliance with the protocol, the 
tumor volume was measured. In short, radical prostatectomy specimens were 
inked and serially sectioned at 4 mm intervals and totally embedded in 
paraffin blocks. After review, pathologic stage (TNM 1992 classification)(9) 
and Gleason score(10) were determined by two uro-pathologists (T.H.v/d K. 
and G.J.L.H.v L.). Tumor volume was measured by morphometry as 
described previously(9). Tumor volume could be determined in 44 and 470 
radical prostatectomy specimens of the control and screening arm, 
respectively. Ten radical prostatectomy specimens and 4 TURP specimens of 
patients in the control arm could not be retrieved. Five men initially 
diagnosed with prostate cancer in the control arm did not have cancer after 
review. Even after immunohistochemistry was performed on these slides, 
prostate cancer could not be diagnosed. High-grade prostatic intra-epithelial 
neoplasia (PIN) and a lesion suspicious for prostate cancer was diagnosed in 
two and one man, respectively. These cases were excluded from analysis. 
Treatment decisions were not under the control of the ERSPC trial. 
Statistical analysis was done with the SPSS software package (SPSS 11.0 Inc., 
Chicago, IL). P<0.05 was considered significant. Student T-test was used for 
linear variables, i.e. PSA and age. The Mann-Whitney U test was used for 
non-parametric data (tumor volume). The Kruskall-Wallis test was used for 
ordinal data. The Kaplan-Meier method was used to calculate PSA-
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progression free survival curves and significant differences between curves 
were based on the log-rank statistic.  
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Results 
Prostate cancer incidence  
Until July 2003, a total of 1,596 and 464 of prostate cancers were diagnosed, 
which corresponded to a cumulative incidence of 7.5% and 2.2% in the 
screening and control arm, respectively. In man-years, the incidence in the 
screen and the control arm was 15.9 and 4.2 per 1000 men years, respectively 
(p<0.0001).  
 
Pretreatment tumor characteristics 
Patients in the control arm had significantly higher PSA levels at prostate 
cancer diagnosis and a lower proportion of clinical T1c prostate cancer, 
compared to the screening arm (Table 1).  
 
Table 1 Patient, pre-treatment and tumor characteristics 
 
Screening arm n (%)
n=1596 
Control arm n (%) 
n=464 
p-value 
Age (years) 66.5 67.9 p<0.0001 
PSA (ng/ml) mean, median 
(range) 
8.6, 4.9  
(0.3-315.7) 
57.2, 11.0  
(0.3-1500.0) 
p<0.0001 
clinical T stage n (%)   
T1c 685 (42.9) 117 (25.2) 
T2 530 (33.2) 112 (24.1) 
T3 196 (12.3) 71 (15.3) 
T4/N1/M1 36 (2.3)  47(10.1) 
 
 
 p<0.0001
Unknown/ other (TURP 
detected) 
149 (9.3) 88/29 (19.0)/(6.2)  
Biopsy 
 Gleason score * n (%) 
   
<7 1111 (69.6) 153 (41.0) 
=7 378 (23.7) 126 (33.8) 
>7 102 (6.4) 93 (5.2) 
 
p<0.0001 
Total 1591 (100) 373 (100)  
Unknown 5 45  
*Does not include TURP and cystoprostatectomy in the control arm (n=54) 
The distribution of Gleason scores of sextant biopsies in the control arm 
showed a significantly higher proportion of Gleason score >7 cancer 
compared to the screening arm. The absolute number of (clinically) advanced 
disease (T4N0M0/TXN1M0/TXN0M1) was higher in the control arm (47 vs 
36).  
 
119
 119
Therapy and pathological tumor characteristics 
Table 2 lists the therapy choices of patients of the screening and control arm.  
 
Table 2 Therapy choices of patients from the screening and control arm 
 
 
Screening arm n 
(%) 
Control arm n 
(%) 
p-value 
radical prostatectomy 595 (37.3) 84 (18.1) P<0.0001 
Radiotherapy 713* (44.7) 171* (36.9)  
watchful waiting 231 (14.5) 63 (13.6)  
endocrine therapy 33 (2.1) 71 (15.3)  
Other 1 (0.1) 2 (0.4)  
Unknown 23 (1.4) 73 (15.7)  
Total 1596 (100) 464 (100)  
*one patient in both screening and control arm received palliative treatment.  
 
Curative therapy (i.e. radiotherapy and radical prostatectomy) was offered to 
81.9 and 54.7% of patients in the screening and control arm, respectively. 
Radical prostatectomy was performed in 37.3 and 18.1% of the patients in the 
screeing and control arm, respectively. Radical prostatectomy was abandoned 
because frozen sections on lymph nodes were positive for prostate cancer in 3 
and 7 patients in the screening and control arm, respectively. Apart from 
advanced disease diagnosed by clinical examination (36 in the screening arm 
and 47 in the control arm), an additional 24 and 4 patients in the screening 
and control arm were diagnosed pathologically with stage T4 disease 
(invasion of the bladder wall), lymph node-or distant metastases. The total 
number of patients with advanced disease was 60 in the screening and 51 in 
the control arm (6..0 vs. 4.6 per 100,000 man years). The proportion of 
advanced disease (pathological (pT)stage T4/N1) in the radical 
prostatectomies was only slightly higher in the control arm (4.9 vs. 4.2%).  
In radical prostatectomy specimens of the control arm 53.5% of the 
cancers were Gleason score ≥7, a significantly higher proportion as compared 
to the 34.6% of cancers in the screening arm (Table 3).   
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Table 3 Tumor characteristics of radical prostatectomy specimens  
radical prostatectomy 
Gleason score n (%) 
Screening arm n (%) 
n=595 
Control arm n (%) 
n=84 
p-value 
<7 355 (46.5) 37 (45.7) 
=7 182 (32.4) 34 (42.0) 
>7 24 (4.3)  10 (12.3) 
 
p=0.001 
  
Total 561 (100) 81 (100)  
unknown 34  3  
Pathological tumor stage 
n (%)    
pT2# 438 (77.4) 53 (65.4) 
pT3a/pT3b 93 (16.4) 19 (23.5) 
pT3c 11 (1.9) 5 (6.8) 
pT4/N1 24 (4.2) 4 (4.9) 
p=0.07 
unknown 29 3  
 
Median tumor volumes determined in 40 radical prostatectomy specimens in 
the control arm were significantly larger (3.9 ml) compared to those found in 
prostatectomies of the screening arm (1.0 ml) (p<0.0001). Of 27.0% of the 
prostatectomy specimens of men of the screening arm the prostate cancers 
were stage pT2, Gleason score 6 with a volume < 0.5 ml as compared to 11.4% 
of those of the control arm (p < 0.01). 
TURP specimens with pT1a cancer and the cystoprostatectomy specimens 
with cancer (except one) were Gleason score 6 or lower. The cancers found in 
the cystoprostatectomy specimens as well as the prostatectomies performed 
according to Millen for BPH were organ confined.  
 
Follow up 
Follow up data in the screening and control arm were known for 97% and 
93% of patients who underwent radical prostatectomy. Median follow-up 
after radical prostatectomy or prostate cancer diagnosis in case of TURP or 
cystoprostatectomy in the screening and control arm was 61 and 42 months, 
respectively (range 0-126). PSA progression occurred in 71 resp. 21 (12 and 
25%) and distant metastasis in 3 resp. 6 (3.8% and 1.1%) of patients in the 
screening and control arm after radical prostatectomy, respectively. The 5-
year PSA progression free survival was 89 and 68% in the screening and 
control arm, respectively (log rank p<0.0001). However, a log rank test from 
randomization date to PSA progression showed no statistically significant 
difference (p=0.13). Three patients with an incidental diagnosis of prostate 
cancer (1 pT1a, and 2 pT1b), developed metastatic disease. One of 8 patients 
who underwent a cystoprostatectomy developed PSA progression.  
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Discussion 
The significantly higher prostate cancer detection rate in the screening arm 
(15.9 per 1000 man years) as compared to the control arm (4.2 per 1000 men 
years) is associated with a shift in clinical stage and Gleason score distribution 
of detected cancers. Our data of the diagnostic samples (needle biopsies, 
TURP) of both arms of the trial now provide direct evidence that the cancers 
detected in the screening arm have more favorable characteristics as 
compared to those in the control arm. A similar stage and grade shift during 
subsequent screening rounds for prostate cancer screening was previously 
reported by different ERSPC centers(11-13). Indeed, the difference in 
prognostic factors between screening and control arm seems to increase 
further with subsequent screening rounds. In the 1st screening round the 
proportion of men with a lymph node metastasis was 1.7% of all cancers 
detected, whereas in the 2nd round this was reduced to 0.2% (data not shown).  
The observation of more favorable tumor characteristics in the 
screening arm as compared to the control arm was also shown in the radical 
prostatectomy specimens, although treatment bias may have reduced the 
differences. Patients in the control arm showed a significantly reduced PSA 
progression free survival after radical prostatectomy, as compared to patients 
treated in the screening arm (p<0.0001) (Figure 1).  
 
Figure 1 PSA progression free survival screen versus control arm after radical 
prostatectomy 
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Number of patients at risk 
screen    572           492             367                195              74                 4 
control    77             53              23                   4                 2                 0 
p<0.0001 
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However, when comparing PSA failure rates from randomization date,  
instead of from date of surgery, no statistical significant difference was found 
(p=0.13). The latter analysis would compensate for lead-time bias (time 
between screen-detected and clinically detected prostate cancer). Since lead-
time bias in our study was calculated to be 10 years (120 months) (14) and the 
mean time from randomization to prostate cancer diagnosis in this study was 
49, respectively 101 months in the screening, respectively control arm, this 
would imply a lead-time of only 52 months. This shorter lead-time may arise 
from opportunistic screening and incidentally diagnosed prostate cancers in 
the control arm. Therefore analyzing the data from randomization date only 
in part corrects for lead-time bias.  
If the control arm would include a large number of patients offered 
curative treatment for a clinically significant, but not advanced prostate 
cancer this could jeopardize the demonstration of a difference in prostate 
cancer survival between the control and screening arm. Although the 
proportion of incidental prostate cancers detected in the control arm is rather 
high (9.3%) they also include advanced cancers (that is: 6 TURP’s with a 
Gleason score >7, 1 patient with pT1a with distant metastasis). Information of 
opportunistic screening is not yet complete, but more information is 
underway. In an earlier report on PSA testing in the control arm of the ERSPC 
until 1997, it was shown that a large proportion of men in the control arm had 
a PSA test (20.2%)(15). However, only 6% of that total proportion of men 
underwent prostate biopsy and finally 3.0% of these men in the control arm 
were diagnosed with prostate cancer as a consequence of their increased PSA 
(effective contamination).  
The proportion of men with clinically advanced cancers, likely to be 
beyond reach of curative treatment (T4/N1/M1) was higher in the screening 
arm compared to the control arm (6.0 vs 4.6 per 100,000 man years). This 
unexpected difference might be explained by two reasons 1) more prostate 
cancers are diagnosed in the screening arm, which automatically leads to a 
more intense search for metastases. 2) More radical prostatectomies are 
performed in the screening arm, which in Rotterdam and surrounding 
hospitals is always preceded by a bilateral lymph node dissection for 
investigation of metastases increasing the chance of detecting (lymph node) 
metastases. In addition, clinical T-stage of prostate cancer is frequently 
underestimated, and therefore the pathological stage might increase after 
radical prostatectomy (28% of tumors staged as cT3 became pT4/N1/M1 after 
radical prostatectomy). Importantly, our observations show that about half of 
the asymptomatic advanced prostate cancers could be detected by clinical 
examination (36 of 60). Since about an equal number of advanced prostate 
cancers was found in the screening and control arm, one must assume that a 
large proportion of advanced prostate cancer remains clinically latent for a 
longer period of time.  
The pilot trials performed in the area of Rotterdam suggested  a 
reduction of prostatic cancer specific mortality in the screening arm (16). We 
cannot confirm this in the current study, since follow-up is short (61 and 42 
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months in screening and control arm), in contrast to the data of the pilot trials 
(10 years). I.e. Bill-Axelson et al.(17) showed that in clinically detected 
prostate cancer there was no difference in incidence of metastases at a 5-year 
follow-up period between men treated with radical prostatectomy and 
watchful waiting. In addition, the median time for PSA recurrence after 
radical prostatectomy in the screening and control arm was 3 and 5 years, 
respectively. In a previous report it was stated that at biochemical recurrence 
after radical prostatectomy, the median time to metastasis was 8 years, and 
from metastasis to death was 5 years (18). This implies that the mean age of a 
man diagnosed in our study at the time of prostate cancer death would be 82 
or 81, (mean age at radical prostatectomy in screening and control arm is 64 
and 65 years of age) and therefore the chance of dying from a competing 
cause of dead is high and correspondingly, the chance of dying from prostate 
cancer after treatment with radical prostatectomy would be small. 
 
Conclusions 
The prostate cancer detection rate in the control arm is significantly lower 
compared to its rate in the screening arm. Tumors in the screening arm do 
have favorable tumor characteristics compared to the control arm. Advanced 
disease is almost equally divided between the two arms. Patients treated with 
radical prostatectomy in the control arm have significantly worse tumor 
characteristics and accordingly a lower PSA progression free survival rate. In 
the control arm 9.3% of the cancers were detected incidentally  
 
 
 
 
 
 
 
 
124
 124
References 
1. Catalona WJ, Loeb S. The PSA era is not over for prostate cancer. Eur Urol 
2005;48:541-545. 
2. The European Randomized Study of Screening for Prostate Cancer (ERSPC). 
rationale, structure and preliminary results. BJU Int. 2003 Dec;92 Suppl 2 2003:1-123. 
3. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. Prostate 
cancer mortality reduction by screening: power and time frame with complete enrollment in 
the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 
2002;98(2):268-73.  
4.  Hoedemaeker RF, Rietbergen JB, Kranse R, Schroder FH, van der Kwast TH. 
Histopathological prostate cancer characteristics at radical prostatectomy after population 
based screening. J Urol 2000;164(2):411-5 
5. Bostwick DG. The pathology of incidental carcinoma. Cancer Surveys 
1995;23(preventing prostate cancer: screening versus chemoprevention):7-18. 
6. Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Beltran A, Bostwick D. 
Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric 
comparison with clinically detected cancer in totally embedded specimens.  Human Pathol 
2005; 36: 646-654  
7. Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch 
centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003;92 Suppl 2:48-54. 
8. Hoedemaeker RRE, Ruizeveld de Winter JA, Van der Kaa CA, van der Kwast TH,. 
Processing radical prostatectomy specimens. a comprehensive and standardized protocol. J 
Urol Pathol 1998;9:211-222. 
9. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso 
M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38. 
10. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 
1992;23(3):273-9. 
11. Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, et al. 
Pathologic features of prostate cancer found at population-based screening with a four-year 
interval. J Natl Cancer Inst 2001;93(15):1153-8. 
12. Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, et al. Second 
round results of the finnish population-based prostate cancer screening trial. Clin Cancer Res 
2004;10(7):2231-6. 
13. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, 
population-based study of biennial screening using serum prostate-specific antigen 
measurement to detect prostate carcinoma. Cancer 2004;100(7):1397-405. 
14. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. 
Lead times and overdetection due to prostate-specific antigen screening: estimates from the 
European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 
2003;95(12):868-78. 
15. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH, et al. 
Effective PSA contamination in the Rotterdam section of the European Randomized Study of 
Screening for Prostate Cancer. Int J Cancer 2003;105(3):394-9. 
16. Schroder FH, Roobol MJ, Damhuis RA, de Koning HJ, Blijenberg BG, Van der Kwast 
TH, et al. Rotterdam randomized pilot studies of screening for prostate cancer--an overview 
after 10 years. J Natl Cancer Inst 2005;97(9):696. 
17. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. 
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 
2005;352(19):1977-84. 
18. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural 
history of progression after PSA elevation following radical prostatectomy. JAMA 
1999;281(17):1591-7. 
 
125
 125
Part 4 
Chapter 8 
Gleason score, age and screening: modeling dedifferentiation in 
prostate cancer 
 
Gerrit Draisma  
Renske Postma (equally first) 
Fritz H. Schröder 
Theodorus H. van der Kwast  
Harry .J. de Koning  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
accepted: International journal of cancer
126
 126
 
Abstract 
Objective: Tumor differentiation as measured by the Gleason score is highly 
predictive of the course of prostatic cancer after diagnosis. Since the 
introduction of the prostate-specific antigen (PSA) test tumors are diagnosed 
with a favorable tumor stage and differentiation grade. Does screening with 
PSA just detect more tumors with favorable characteristics or is 
dedifferentiation actually being prevented by early detection and consequent 
treatment? We used data from the Rotterdam section of the European 
Randomized study of prostate cancer screening (ERSPC) and a simulation 
modeling to answer this question. 
Methods: We analyzed the clinical stage and Gleason score of 2041 tumors 
diagnosed in the ERSPC-Rotterdam trial in relation to age at diagnosis. We 
fitted two MISCAN simulation models to the observed data: one model where 
dedifferentiation occurs before the tumor becomes screen-detectable and 
another where dedifferentiation occurs during the screen-detectable pre-
clinical phase. The hypothesis that dedifferentiation occurs during the screen-
detectable phase was tested by comparing the goodness of fit of both models. 
Results: High Gleason scores were significantly associated with age in the first 
screening round. The percentage of Gleason scores less than 7 decreased from 
76% in men aged 55-59 to 57% in men aged 70-74; Gleason scores greater than 
7 increased from 9% to 32%. In the second round and control arm no 
significant association between Gleason scores and age was found. Only the 
MISCAN model where dedifferentiation occurs during the screen-detectable 
phase reproduced the relation between Gleason score and age. 
Conclusions: This study provides epidemiological evidence of 
dedifferentiation as a major mechanism of tumor progression in prostate 
cancer. Furthermore dedifferentiation occurs during the screen-detectable 
phase and consequently may be prevented by screening with PSA. 
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Introduction 
In the western world the incidence of prostate cancer is increasing due to 
general availability of serum tests for prostate specific antigen (PSA) and 
aging of the population 5. Early detection by PSA testing and curative 
treatment of prostate cancer may result in a decrease in mortality from 
prostate cancer 159, but definite evidence for this effect is not yet given. 
Nevertheless, trial results show that TNM stage and Gleason score of screen-
detected tumors compare favorably to those of clinically diagnosed tumors in 
the control arms of the trials 84,157. It is tempting to deduce that detection by 
screening and consequent treatment prevent tumor growth and 
dedifferentiation. However, the very favorable characteristics of screen-
detected cancers might be due to length bias sampling: tumors with favorable 
characteristics probably grow more slowly and have more chance of being 
detected; moreover these tumors might never give rise to clinical symptoms 
and therefore not show up in unscreened/non-screened populations 48. In the 
following we concentrate on Gleason score, as it is highly predictive of 
treatment success (progression free survival) and prostate-specific survival 
after diagnosis 19. 
Screening can only prevent dedifferentiation if it occurs in cancers that 
are detectable by the screening test: screening cannot affect dedifferentiation 
that has taken place before the tumor has become screen-detectable. Evidence 
on the natural history of prostate cancer is scarce. Dedifferentiation in the 
screen-detectable phase is supported by a recent publication of Johansson et 
al. 19 who followed-up over 200 prostate cancer patients managed by watchful 
waiting. Some of these patients do have a higher Gleason score after repeat 
biopsy several years after watchful waiting was initiated. Epstein et al.161 also 
noted dedifferentiation in watchful waiting, but because of the small number 
of cases, and the short time between successive biopsies the authors attribute 
the observed change of Gleason score to biopsy variability.  In contrast, 
Thompson et al. reported a detection rate of prostate cancer of 15% in men 
with PSA levels below a cut-off point of 4 ng/ml. In these men 15% Gleason 
scores ≥7 were found, suggesting that high Gleason scores already exists 
before a tumor becomes detectable by the PSA screening. Also the 
widespread screening with PSA in the US has caused a shift to earlier-stage 
disease, and a markedly lower incidence of distant disease, but it has (not 
yet?) lead to a shift to lower grade disease 162. 
This study aims at modeling the natural history and dedifferentiation 
of prostate cancer using detailed information from 2041 cancers diagnosed in 
ERPSC-Rotterdam. We investigated whether our date show a relation 
between Gleason score, clinical T-stage and age at diagnosis as reported in 
163,164. We used the findings to discriminate between two MISCAN simulation 
models: a model where dedifferentiation occurs only before the screen-
detectable phase and a model where dedifferentiation occurs also during the 
screen-detectable phase. A significantly better fit to observed data of the 
second model is a strong indication of dedifferentiation that could be 
prevented by early detection and treatment.
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Patients and methods 
In ERSPC, section Rotterdam, 42,376 men, 55-75 years old, were randomized 
to a screening (n=21,210) and a control arm (n=21,166). Ethical approval of the 
study was obtained from the Dutch ministry of health (committee on the 
population screening act, WBO committee nr. 325291). The first screening 
round (November 1993 - December 1999) was initially done by PSA 
determination, digital rectal examination (DRE) and transrectal 
ultrasonography (TRUS). Sextant needle biopsy was recommended for 
participants who had either an elevated PSA level (≥4.0 ng/ml), abnormal 
DRE or abnormal findings on TRUS. Men with a benign biopsy result in the 
first round were invited for a recall visit after 1 year (interim screening 
round). The protocol was simplified on May 1997, when sextant biopsy was 
recommended if PSA was ≥3.0 ng/ml, regardless of digital rectal examination 
(DRE) and transrectal ultrasonography (TRUS). During the second screening 
round (June 1998 - December 2003), performed 4-years after the first screening 
round, the PSA ≥3.0 ng/ml protocol was used. Information on the diagnosis 
of prostate cancer in men randomized to the control arm and of cancers 
diagnosed outside the screening program in the screen arm was obtained 
through a record linkage with the Dutch cancer registry. The registry and 
subsequent linkage leads to a delay of 1 to 2 years in the reporting of these 
tumors. In this study we used a cut-off date of 1-July-2002 for inclusion of 
cancers diagnosed outside the screening program, i.e., cancers in the control 
arm and interval cancers in the screening arm. 
 
Pathologic processing 
Slides from prostate biopsies, transurethral resection of the prostate (TURP) 
specimens and cystoprostatectomy specimens were retrieved from the 
archives of the pathology laboratories of the Erasmus Medical Center and 
surrounding hospitals of the Rotterdam region. Biopsies from the 
surrounding hospitals varied from 2 to 12 cores per biopsy. One uro-
pathologist (T.H.v.d K) reviewed all biopsies with cancer, PIN and lesions 
suspicious for malignancy in order to avoid inter-observer variation. The 
grading of prostate cancer used in the ERSPC is the Gleason score system 17, 
which is based on growth patterns present in the tumor, classified from 
pattern 1 to 5. The Gleason score system combines the two most prominent 
patterns. Therefore Gleason scores range from 2-10, with score 2 indicating 
the best differentiated tumors and score 10 the poorest. Tumors with Gleason 
score 2-6 are considered well differentiated, with 7 moderately and with 
Gleason score 8-10 poorly differentiated. Internationally it is agreed that a 
needle biopsy is not graded under Gleason score 6 18. In addition to Gleason 
score, the number and size of biopsies were recorded as well as proportion of 
tumor involvement (only in the screened population). During this review, the 
number and size of biopsies were recorded as well as proportion of tumor 
involvement (only in the screened population), and proportion of each 
Gleason pattern. In the first screening round and in the control arm Gleason 
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scores are missing for 4 and 77 patients, respectively. As control arm biopsies 
were reviewed at random, no bias due to missing scores is to be expected. 
 
MISCAN modeling and statistical analysis 
The MISCAN prostate model has been described earlier 48. In short MISCAN, 
an acronym for micro-simulation screening analysis, is a simulation model 
that uses a semi Markov process to generate the transitions from one tumor 
stage to the next in individual men. The natural history model used in this 
study is shown in Figure 1.  
 
Figure 1 The MISCAN prostate cancer model. Prostate cancer develops from 
no cancer via one or more screen-detectable pre-clinical stages to a clinically 
diagnosed tumor. In each pre-clinical stage a tumor may grow to the next T-
stage, dedifferentiate to a higher Gleason score or give rise to symptoms and 
be clinically diagnosed. Screening may detect tumors earlier in one of the pre-
clinical stages. In model I all dedifferentiation occurs before the pre-clinical 
detectable phase (as indicated by the arrows on the left); in Model II 
dedifferentiation occurs also in the pre-clinical phase. 
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Tumors are characterized by T-stage (T1 impalpable, T2 palpable, confined to 
the prostate and T3+ palpable, with extensions beyond the prostatic capsule) 
and differentiation grade (Gleason score < 7, 7 and > 7). Parameters in the 
model are transition probabilities and dwelling times. These are estimated by 
numerical minimization of the deviance between observed data and 
corresponding model predictions. We constructed two MISCAN models for 
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the trial data: in Model I we assumed that Gleason score is determined before 
entering the pre-clinical phase, and does not change after the time the tumor 
has become screen-detectable; in Model II we assumed that dedifferentiation 
may take place in the screen-detectable phase. Predictions from both models 
were compared to: baseline incidence in 1990 (before the introduction of PSA 
screening in the Netherlands); baseline cT-stage distribution (Rotterdam 
cancer registry data 1992); cancer incidence, stage and Gleason score 
distribution in the control arm of the ERSPC Rotterdam; 1st and 2nd screening 
round detection rates and cT-stage and Gleason score distribution of screen 
detected cancers; incidence, cT- stage and Gleason score distribution of the 
interval cancers (cancers diagnosed in the screening arm after a negative 
screening test). For modeling purposes, cases detected in the interim 
screening round were counted as being detected in the 1st screening round. 
For cancers in the control arm and interval cancers we used a cut-off of July 2, 
2002 for inclusion and calculating men-years. Goodness of fit of both models 
was based on the calculated deviance of observed from predicted age specific 
incidence and detection rates, and age specific distributions of cT-stage and 
Gleason scores; a likelihood ratio test was used to decide whether goodness of 
fit of Model II was significantly better than that of Model I. 
Ordinal regression was used to test the significance of the association between 
Gleason score and age at diagnosis and clinical T-stage (cT-stage)165. 
 
Results 
Prostate cancer incidence 
In ERSPC Rotterdam, 19970 men were screened in the first round and 1013 
cancers detected (detection rate 5.1%); if we include the 65 cancers found in 
the interim screening round, in total 1078 cancers were found in the first 
round (detection rate 5.4%) In the second round 12529 men were screened 
and 550 cancers detected (detection rate 4.5%), (of which 393 before July 2002). 
Up to July 2002 473 men were diagnosed with cancer in the control arm, and 
128 men were diagnosed in the screening arm outside the screening program. 
Cumulative incidence in July 2002 after a mean follow-up of 5 years was 7.5% 
in the screened arm and 2.2% in the control arm.  
 
Gleason scores 
The Gleason score distribution by age group, study arm and mode of 
diagnosis is given in Table 1 and illustrated in Figure 2.  
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Tables 
Table 1 Gleason scores by age of diagnosis of cancers diagnosed in ERSPC 
Rotterdam 
study 
group 
age 
category  
Gleason score total rate 
  <7  =7  >7  unknown    
  n %3 n %3 n %3 n %4 n  
control 
arm1,2 
          incidence 
per 103 
men-
years 
 55-59 19 67.9 4 14.3 5 17.9 1 3.6 29 1.7 
 60-64 37 50.7 17 23.3 19 26.0 9 12.3 82 2.7 
 65-69 53 41.7 46 36.2 28 22.0 10 7.9 137 5.1 
 70-74 57 42.9 40 30.1 36 27.1 20 15.0 153 6.7 
 75+ 26 46.4 17 30.4 13 23.2 16 28.6 72 8.3 
 total 192 46.0 124 29.7 101 24.2 56 13.4 473 4.5 
screening 
arm 
          detection 
per 103 
tests 
round 1            
 55-59 125 75.8 31 18.8 9 5.5 1 .6 166 28b 
 60-64 161 70.6 56 24.6 11 4.8 0 .0 228 45 
 65-69 212 60.9 107 30.7 29 8.3 2 .6 350 77 
 70-74 148 56.5 82 31.3 32 12.2 0 .0 262 87 
 75+ 4 66.7 1 16.7 1 16.7 1 16.7 7 167 
 total 650 64.4 277 27.5 82 8.1 4 .4 1013 54 
interim 
round 
           
 55-59 8 80.0 1 10.0 1 10.0   10  
 60-64 8 72.7 3 27.3 0 .0   11  
 65-69 13 81.3 3 18.8 0 .0   16  
 70-74 18 72.0 7 28.0 0 .0   25  
 75+ 3 100.0 0 .0 0 .0   3  
 total 50 76.9 14 21.5 1 1.5   65  
round 2            
 55-59 15 75.0 5 25.0 0 .0   20 21 
 60-64 139 81.3 27 15.8 5 2.9   171 29 
 65-69 146 77.2 36 19.0 7 3.7   189 49 
 70-74 135 79.4 30 17.6 5 2.9   170 72 
 total 435 79.1 98 17.8 17 3.1   550 44 
1including Gleason scores of 40 TURP specimens, 6 cystoprostatectomy specimens and 2 
Millin prostatectomies 
2Follow-up up to July 2002 
3% of cases with Gleason score known, 4% of total cases 
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Figure 2 Proportion of Gleason score category per age category 
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Gleason score distribution of screen-detected cancers (70% Gleason score less 
than 7) is more favorable than that of cancers diagnosed in the control arm 
(46% less than 7) and more favorable in the second round (79% less than 7) 
than in the first round of screening (65% less than 7). In the control arm the 
Gleason scores of TURP, Millin and cystoprostatectomy specimens are 
included. When we excluded these specimens and take only biopsy Gleason 
score, the proportion of Gleason score <7 was 43%. 
Interestingly, Gleason score is related to age at diagnosis (Table 1 and Figure 
1). In the first screening round and in the control arm older men have higher 
Gleason scores. Univariate ordinal regression showed that the association is 
significant (p=0.011) in the first screening round, but not in the control arm. A 
multivariate analysis, correcting for clinical T-stage, showed that both age and 
T-stage were predictive for the Gleason score. There was no significant 
relation between clinical T-stage and age, neither in the screening arm nor in 
the control arm (data not shown). 
 
133
 133
Modeling 
Table 2 compares the observed cT-stage and Gleason score distributions with 
the predictions from Model I and II.  
 
Table 2 Percentage distribution of clinical T-stage and Gleason score in 
ERSPC Rotterdam as observed and predicted by MISCAN Model I (no 
dedifferentiation in detectable pre-clinical phase) and Model II 
(dedifferentiation in pre-clinical phase). 
 clinical T-Stage Gleason score  
Population T1 T2 T3+ G<7 G=7 G>7 
Observed       
baseline 1991 0.14 0.59 0.27    
control arm 0.42 0.31 0.28 0.46 0.30 0.23 
screening arm round 1 0.36 0.46 0.18 0.65 0.27 0.08 
screening arm round 2 0.62 0.35 0.04 0.79 0.18 0.03 
Screening arm interval cancers 0.59 0.26 0.15 0.72 0.16 0.13 
model I       
baseline 1991 0.18 0.53 0.28    
control arm 0.27 0.50 0.23 0.60 0.28 0.12 
screening arm round 1 0.40 0.44 0.16 0.67 0.24 0.08 
screening arm round 2 0.59 0.34 0.07 0.70 0.23 0.07 
Screening arm interval cancers 0.35 0.53 0.12 0.65 0.24 0.11 
Model II       
baseline 1991 0.20 0.52 0.28    
control arm 0.28 0.49 0.23 0.53 0.28 0.20 
screening arm round 1 0.39 0.45 0.16 0.65 0.27 0.07 
screening arm round 2 0.61 0.34 0.05 0.79 0.18 0.03 
Screening arm interval cancers 0.43 0.45 0.12 0.60 0.21 0.19 
 
Both models accurately predict the clinical stage distribution of tumors 
detected by screening in the first and second round. However the models 
predict a more favorable distribution than observed predictions at baseline, 
and a less favorable distribution than observed in the control arm and interval 
cancers. With respect to Gleason scores both models reproduce the 
distribution observed in tumors detected the first round of screening, but 
Model II reproduces the observed differences between the various study 
groups more closely than Model I. Figure 3 compare the predictions from 
both models with the observed age-specific Gleason score distributions. 
Model I predicts only a modest difference between the study groups and 
detection modes, and no association between Gleason score and age; Model II 
predictions fit the observed data significantly better. The difference in 
goodness of fit is statistically significant (Difference in deviance of 100 with 6 
extra parameters; p<0.0001). Still it is interesting to note that Model I predicts 
a more favorable distribution of Gleason scores in screen-detected cancers.  
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Figure 3 Gleason score by age group and study population as observed and 
predicted by a model without (Model I) dedifferentiation in the screen-
detectable phase and a model with (Model II) dedifferentiation. The graphs 
indicate the cumulative proportions of Gleason scores less than 7 and less 
than or equal to 7. The dashed lines indicate the observed distribution, and 
the solid lines indicate the predicted distribution. Error bars indicate the 
standard error of the predicted proportions. 
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Discussion 
In this report we studied tumor development and dedifferentiation by 
examining the association between clinical T-stage, Gleason score and age of 
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diagnosis in ERSPC Rotterdam. We did find a significant relation between 
Gleason score and age in the 1st screening round. The relation is also present, 
but not significantly, in the tumors found in the control arm, but not in the 
second round of screening. The results are compatible with the MISCAN 
simulation model that assumes that dedifferentiation occurs for a large part 
during the phase in which the tumor is screen-detectable, and not with the 
model that assumes that the differentiation grade is already determined when 
the tumor has become detectable by screening.  
Prostate cancer is a heterogeneous and often multi-focal cancer, which 
is marked by different Gleason patterns in one tumor. Two mechanisms can 
explain the presence of high-grade and low-grade components in prostatic 
tumors: 1) during their development prostatic tumors dedifferentiate, and 
progress from well differentiated (low Gleason score) to poorly differentiated 
(high Gleason scores) or 2) the combination of low and high grade evolves 
from pluri-potent stem cells that shed throughout the prostate and grow in 
different sites of the prostate to form a heterogeneous cancer 166. In the second 
case Gleason score is determined early in the development of the tumor. Both 
mechanisms might also occur at the same time.  
The findings in this study give support to the first mechanism: tumors 
progressively dedifferentiate during their development, which results in the 
association between age and high Gleason score observed in the data, most 
clearly in the first screening round. This might be explained that tumors in 
older patients had a longer time of development and had more chance to 
dedifferentiate. In the second round, most tumors are newly developed and 
consequently have lower Gleason scores and no relation with age can be seen. 
The fact that 80% of the tumors had a Gleason score less than 7 in the second 
screening round, indicates that a 4-year screening interval is not sufficient for 
dedifferentiation towards higher-grade for most tumors. In the control arm 
diagnosis is delayed in comparison with the screening arm and tumors had 
more time to dedifferentiate. This results in a greater proportion of high 
Gleason scores in the control arm. 
The finding that older men have more poorly differentiated prostate 
cancers than younger men has been reported before 163,164. Dedifferentiation 
has been studied by comparing the differentiation of metastases to that of the 
primary tumor. Cheng et al. 167 examined 242 men with regional lymph node 
metastases who underwent radical prostatectomy and bilateral 
lymphadenectomy. In 45% of the cases, Gleason score of lymph node 
metastases was higher than the primary tumor Gleason score, and in only 
12% the Gleason score of the primary tumor was higher. They concluded that 
there is a trend toward histological dedifferentiation when prostate carcinoma 
metastasizes to regional lymph nodes. Similarly, Brawn et al. 168 reported that 
in the majority of patients with widespread metastasis the metastases tended 
to be more poorly differentiated than the primary tumors. It could be argued 
however, that these observations are the consequence of a higher potential for 
metastasis of poorly differentiated tumor cells, rather than dedifferentiation. 
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Repeated samples in time from individual patients are the most direct 
way to study dedifferentiation. An early study of Brawn in 1983 169 reported 
dedifferentiation between two subsequent transurethral resection of the 
prostate (TURP) specimens with an interval of 3 to 11 years, in 65% of 54 
patients. Another 33% showed equally well or only little less differentiated 
prostate cancer (Anderson score was used). In this study, the majority of 
patients received hormone therapy, which artificially produces the 
appearance of a higher Gleason score 21. Another study reported 
dedifferentiation in 68% of tumors not treated with hormones between two 
subsequent TURP procedures with a mean interval of 2.4 years 170. Wheeler et 
al. 171 analyzed 49 patients who were initially treated with radiotherapy. After 
local recurrence of prostate cancer, a statistically significant shift to higher 
grades was seen. Multiple logistic regression analysis revealed that the only 
predicting factor for dedifferentiation was time since diagnosis. The above-
mentioned studies related to a very select group of patients. Only few men 
will undergo a repeat TURP, and patients selected for repeat TURP might 
have worse prostate cancer characteristics than men who are sufficiently 
treated by a single TURP. Similarly, the patients who had recurrence after 
radiotherapy (3.9%) in the study of Wheeler et al. are a very select group. Not 
every patient in this study underwent repeat biopsy and dedifferentiation 
could only be studied in patients with poor tumor characteristics (local 
recurrence, urinary obstruction). 
Several investigators have studied dedifferentiation in repeat biopsies 
in patients choosing for watchful waiting instead of curative treatment. 
Tumor characteristics in these patients might be more representative of the 
favorable characteristics of tumors found in screened populations. Adolfsson 
and Tribukait 172 studied cytological differentiation in 78 patients with at least 
2 fine needle aspiration biopsies taken at an interval of 2 years more. 
Progression to less differentiated tumors was seen in 18 patients (23%). 
Johansson et al. 19 reported dedifferentiation in 17% of 178 prostate cancer 
patients with localized disease managed by watchful waiting who underwent 
repeat fine needle biopsy. Epstein et al. 161 reported about patients who were 
managed by watchful waiting, selected according to the Epstein criteria 124 for 
insignificant cancer: a Gleason score less than 6; less than 3 cores positive for 
prostate cancer, not occupied by more than 50% of cancer; and a PSA density 
less than 0.15 ng/ml/cm3. The protocol indicated yearly prostate biopsy. 
Seventy patients underwent at least two subsequent biopsies, of whom only 9 
(13%) showed an increase in Gleason score from less than 7 to 7 or more. But 
in only one 1 case the increase in Gleason score was observed in a repeat 
biopsy taken after an interval of more than 24 months. The authors conclude 
that the higher score might be the result of sampling a higher-grade 
component initially not sampled. 
Not only tumor grade is related with age of diagnosis. In an earlier 
study (Postma, submitted) we found that age of diagnosis is a predictor for 
biochemical recurrence, independent Gleason score, pathological stage and 
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surgical margin status. Older age seems to be associated with poor prognosis 
with respect to prostate cancer treatment. 
 
Conclusions 
Our results, based on 2101 tumors diagnosed in the ERSPC trial, section 
Rotterdam support the hypothesis of dedifferentiation during the screen-
detectable, pre-clinical phase of prostatic tumors. This means that 
dedifferentiation may be prevented by screening and subsequent curative 
treatment. Because of the prognostic value of Gleason score, this information 
is crucial and an indication of the potential of screening with PSA to reduce 
prostate cancer mortality. Final proof of the latter point may require more 
follow-up than five years to show up, as by July 2002 the cumulative 
incidence of high grade tumors of Gleason scores greater than 7 is equal in 
both arms: 101 per 21,166 participants in the control arm, and 101 per 21,210 
in the screening arm. 
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Abstract 
Objective: Prostate cancer is known for its highly heterogeneous histological 
appearance, which is predominantly seen by the pathologist as well 
differentiated and moderately differentiated adenocarcinoma, i.e. Gleason grade 
3 or 4. The heterogeneous aspect may arise from dedifferentiation or from 
different stem cells. It is presently not clear, whether the histological 
heterogeneity is also reflected in the genomic composition of a tumor.  
Methods: Patients were selected from the screening arm of the European 
Randomized Study of Screening for Prostate Cancer section Rotterdam 
(ERSPC), a PSA based screening program for prostate cancer. Tumors with 
volumes 1.0-1.5 ml and a Gleason score of 3+3 or 3+4 were selected. The 
cancer DNA’s were retrieved from formalin-fixed and paraffin-embedded 
tissues allowing optimal recognition and selection of target cells. Comparative 
genomic hybridization with a 3500-element BAC array was used to detect 
differences in the genetic content of Gleason patterns 3 and 4.  
Results: 17 Gleason patterns (10x G3, 7x G4), derived from 11 radical 
prostatectomies, were investigated. A total of 1155 gains and 583 losses were 
discriminated in 10 G3 areas, 768 gains and 497 losses were detected in 7 G4 
regions. Frequent losses included chromosome arms 6q, 8p and 13q, frequent 
gains were seen on 7q and 8q. There were no significant differences between 
Gleason patterns 3 and 4, or between Gleason grades within one cancer.  
Conclusions: Histological heterogeneity, defined by Gleason grades 3 and 4, 
does not have a genomic counterpart, as measured by array-based CGH. 
Furthermore, these asymptomatic screen detected prostate carcinomas have 
genetic signatures comparable with those commonly seen in symptomatic 
cancers.  
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Introduction 
Prostate cancer is the most common cancer in males in the western world and 
the second most leading cause of cancer-related death in the Western world 4. 
Whether screening for prostate cancer is of benefit for the male population 
has not yet been established by randomized controlled trials. The European 
Randomized Study of Screening for Prostate Cancer (ERSPC) investigates 
whether PSA based screening reduces prostate cancer related death. Although 
preliminary results are promising considering a stage and grade shift towards 
more favorable prostate cancers, final results will not be here until 2008 or 
later 84. Concern has raised about over diagnosis in prostate cancer screening 
48. It is difficult, however, to distinguish which cancer is clinically significant 
or not. Histopathologically, prostate cancer is marked by heterogeneity and 
multi-focality . The heterogeneity and multi-focality might arise from 
dedifferentiation of cancer cells. For example, a prostate cancer with Gleason 
score 6 (3+3) might become a Gleason score 7 (3+4) tumor through clonal 
evolution, in which part of the Gleason pattern 3 dedifferentiates into Gleason 
pattern 4. Another hypothesis that might explain the histological 
heterogeneity is based on the concept of different cancer stem cells, which 
grow individually and collide to one tumor in time. The multi-focal 
appearance of prostate cancer would be in favor of the stem cell concept. The 
first hypothesis, however, is supported by the fact that older patients do have 
higher Gleason scores at diagnosis . In addition, patients followed by 
watchful waiting have a higher Gleason score after repeat biopsy several 
years later 19. Patients with Gleason score 7 prostate cancers have higher 
therapy failure than Gleason score 6 patients 173. It is therefore important to 
investigate, whether dedifferentiation occurs in prostate cancer. If so, 
screening might prevent dedifferentiation towards poorly differentiated 
tumors with a poor prognosis. Ruijter et al.174 demonstrated genetic 
heterogeneity in some but not all focal tumor lesions, indicating a multi-focal 
origin is one mechanism for prostate cancer origin, but there could be several 
other mechanisms that are likely to operate. However, a comparative genomic 
hybridization (CGH) based investigation did not reveal genetic heterogeneity. 
A FISH study of a prostate cancer tissue micro-array revealed significant 
differences in HER2/neu amplification or chromosomal gains between Gleason 
grades 3 and 4 . 
In this study, radical prostatectomy specimens of patients with Gleason score 
6 and 7 were examined with array-based CGH. The following questions were 
addressed: 1) Is there a difference between Gleason patterns 3 or 4 in general? 
2) Are there genomic differences between Gleason patterns within the same 
tumor? 3) What is the genetic “signature” of screen detected asymptomatic 
prostate cancers? 
 
Material and Methods 
Patient selection 
Patients were derived from the screen arm of the European Randomized 
Study of Screening for Prostate Cancer (ERSPC). In the ERSPC, section 
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Rotterdam, 42,376 men, 55-75 years old, were randomized to a screening 
(n=21,210) and a control arm (n=21,166). There was a 4-year screening 
interval. The study started on November 1993. Sextant needle biopsy was 
recommended for participants who had an elevated PSA level (≥4.0 ng/ml), 
abnormal DRE or abnormal findings on TRUS. The protocol was simplified 
on May 1997, when sextant biopsy was recommended if PSA was ≥3.0 ng/ml, 
regardless of DRE and/or TRUS findings.   
 
Tissue specimens 
Patients detected with prostate cancer in the screen arm who underwent 
radical prostatectomy were selected. One pathologist (T.H.v/d K.) reviewed 
all the prostatectomy specimens, in order to determine pathological T stage, 
surgical margin status and Gleason score. Radical prostatectomy specimens 
were embedded according to a protocol described earlier 129, allowing 
accurate measurements of tumor volume, exact location of  the tumor, 
grading, and staging. In short, after fixation, radical prostatectomy specimens 
were inked and serially sectioned at four mm intervals and totally embedded 
in paraffin blocks. Tumors with a Gleason score of 6 or 7 and a total volume 
between 1.0 and 1.5 ml were collected for DNA extraction. The radical 
prostatectomy specimens suitable for analysis are shown in Table 1.  
 
Table 1 clinico-pathological data 
patient Gleason score  surgical 
margin 
biochemical 
progression 
1 3x 4x + + 
2 3x 4x + + 
3 3 4x - + 
4 3x 4x + - 
5 3x 3 - - 
6 3x 3x - + 
7 3x 3 - - 
8 3x 4x - - 
9 3x 4x + + 
10 3x 4 + - 
11 3 4x - - 
X Gleason pattern included in the analysis 
 
The area of interest was marked on the glass slide and taken over on the 
paraffin block and punched out. After punching a new slide was made for 
control of the right area for tumor sampling. Isolation of DNA from the 
formalin-fixed, paraffin-embedded material was performed using the 
Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN) in 
accordance with the manufacturer’s instructions.   
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Array-based CGH  
The array-based CGH procedure was performed as previously described . 
Slides containing triplicates of ~3500 large insert clones spaced at density over 
the full genome were produced in the Leiden University Medical Center. The 
particular BAC set used to produce these arrays is distributed to academic 
institutions by the Welcome Trust Sanger Institute (UK) at no cost, and 
contains targets spaced at ~1 Mb density over the full genome, a set of 
subtelomeric sequences for each chromosome arm, and a few hundred probes 
selected for their involvement in oncogenesis. Information regarding the full 
set is available in the ‘‘Cytoview’’ window of the Sanger Center mapping 
database site, Ensembl . Insert clones were isolated from the bacteria, using 
the Wizard SV 96 Plasmid DNA Purification System (Promega, Leiden, the 
Netherlands) in combination with the Biomek 2000 Laboratory Automation 
Workstation (Leiden Genomic Technology Center facilities - LGTC, the 
Netherlands). DNA amplification, spotting on the slides and hybridization 
procedures were based on protocols previously described . We used 
commercially available female genomic DNAs (Promega, Leiden, the 
Netherlands) as test DNA. Test and reference DNAs were labeled with Cy3- 
and Cy5-dCTPs (Amersham Bioscience, Roosendaal, the Netherlands), 
respectively. After hybridization, the slides were scanned with a ScanArray 
Express HT (Perkin Elmer Life Sciences, Boston, MA, USA) to collect 16-bit 
TIF images through Cy3 and Cy5 filter sets. The spot intensities were 
measured by means of the GenePix Pro 5.0 software (Axon Instruments, 
Leusden, the Netherlands). Further analyses were performed using Microsoft 
Excel 2000. Spots outside the 20% confidence interval of the average of the 
replicates were excluded from the analyses.  
Log2 ratios of chromosomal gains and losses were listed by an algorithm 
using flexible thresholds based on the standard deviation (SD) of the data sets 
of the specimens. SD’s over windows of five consecutive BACs were 
averaged, sliding along the chromosomes one BAC at a time.  Thresholds for 
gains and losses were defined empirically at +/- 2.5 x SD. This procedure 
resulted in a sample-dependent detection of genomic alterations with less 
interference of “noise” from deparaffinized formalin-fixed DNA samples. In 
addition, sex-mismatch with male or female reference DNA was used as an 
internal CGH control. Only samples showing a clear sex-mismatch were 
included in the evaluation. Subsequently, X- and Y-mapped BAC clones were 
excluded from the frequency overviews of the (sub)groups. Frequency plots 
were smoothed for better visualization of gains and losses by a moving 
average over windows of five consecutive BAC’s, chromosome by 
chromosome.  Critical areas in CGH of paraffin-derived DNA’s, i.e. 
(sub)telomeric and pericentromeric regions, and distal chromosome 1p and 9q 
were excluded from analysis. BAC clones with aberration frequencies above 
or below 15% were listed as gains and losses, respectively. Single BAC clone 
alterations were removed, as they are likely to represent artefacts. 
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Statistical analysis 
Fisher’s Exact Test of unsmoothed data was applied for comparison of gains 
and losses between tumor sub-groups using SPSS 11.0 software (SPSS Inc., 
Chicago, IL). A p-value of  <0.05 (two-sided) was considered as statistically 
significant.  
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Results 
Eleven radical prostatectomies were taken from the screening arm of the 
European Randomized Study of Screening for Prostate Cancer section 
Rotterdam (ERSPC). Adenocarcinomas with a tumor volume of 1.0-1.5 ml and 
a Gleason score of 6 (3+3; n=3) or 7 (3+4; n=8) were selected. The cancer 
DNA’s were retrieved from formalin-fixed and paraffin-embedded tissues 
improving recognition and selection of target cells. Comparative genomic 
hybridization with a 3500-element BAC array (aCGH) was applied to detect 
differences in the genetic content of 17 Gleason patterns (10x G3, 7x G4) from 
the 11 patients. A total of 1155 gains and 583 losses were discriminated in 10 
G3 areas (116 and 58 per area, resp.), 768 gains and 497 losses were detected 
in 7 G4 regions (110 and 71 per area, resp.). Frequent losses included 
chromosome arms 6q, 8p, and 13q, frequent gains could be seen on 7q and 8q. 
Overviews of the alterations can be seen in Figure 1 and Table 2.  
 
Table 2 Genetic data in chromosomal order (overlapping alterations in bold). 
Gleason 3 pattern Gleason 4 pattern 
Loss 
4q24-q25  
 6q14.1-q14.2, 6q15-q16.1 
8p12-p21.2, 8p22-p23.2 8p11.21, 8p12-p23.3 
 10q23.31 
11q22.1 11q22.1 
13q14.13-q14.2 13q13.2-q32.1, 13q32.3-q34 
Gain 
1q32.1  
3q21.2-q21.3 3p21.31 
7q21.11, 7q21.13, 7q22.1, 7q33-q34 7q33-q24 
 8q11.23-q12.1, 8q22.1 
 9p21.32-p21.33 
10q22.1-q22.2  
11q13.3-q13.4 11q12.3, 11q13.2-q13.5 
17q21.2-q21.31 17q21.2-q21.31 
22q12.1-q12.2 22q12.1-q12.2 
 
There were no significant differences between Gleason patterns 3 and 4. 
Neither were differences observed between the two dominant Gleason grades 
within one cancer (Figures 2 and 3).  
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Figure 1 Overview of gains and losses of Gleason patterns 3 and 4. The top 
panel shows the combined data, the middle panel G3, and the bottom panel 
G4.  
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Figure 2 Log2ratios along the genome illustrating genomic imbalances (raw 
data) of the two G3 patterns of within one tumor.  
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Figure 3 Log2ratios along the genome depicting genomic imbalances (raw 
data) of G3 (upper) and G4 (lower) patterns within tumor 1.  
Discussion 
In this study we compared prostate cancers composed of well-differentiated  
(Gleason score 6; grades 3+3) and moderately differentiated (Gleason score 7; 
grades 3+4) tumors. We did not observe significant differences between 
Gleason patterns 3 and 4, nor did we see in Gleason patterns 3 of Gleason 
score 6 and 7 tumors. Thus, we cannot support the hypotheses of 
dedifferentiation or multiple cancer stem cells in prostate cancer. It should be 
mentioned that our number of samples is limited, which might have some 
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impact on the results. However, the spectrum of gains and losses were in 
accordance with those reported in the literature.  
Loss of heterozygosis (LOH) analyses have shown frequent loss on 
chromosome arms 3p, 6q, 7q, 8p, 9p, 10pq, 13q, 16q, 17q, and 18q . CGH 
analysis applied to a panel of both primary and recurrent tumors revealed 
losses of 8p and 13q in over 30% of cases, whereas recurrent tumors showed 
gains of 8q and of chromosomes 7 and X, as well as loss of 8p in over half of 
cases 175. A CGH study of a panel of lymph node metastases showed loss of 
8p, 10q, 13q, 16q, and 17p, as well as gain of 1q, 3q, 8q and 11p sequences in 
50% or more of tumors . Some of these alterations could already be 
distinguished in early stages of prostatic cancer, measuring <0.5 ml. In these 
tumors, abnormalities with chromosomal losses were most frequently seen in 
13q (31%), 6q (23%) and Y (15%), and gains on 20q (observed in 15% of the 
tumors) . These abnormalities were also seen in our set of tumors, with even 
more extended abnormalities. Paris et al. performed aCGH on a primary and 
metastatic tumors to investigate, which markers present in primary tumors 
might be predictive of tumor progression.  Specific loss at 8p23.2 was 
associated with advanced stage disease, and gain at 11q13.1 was found to be 
predictive of postoperative recurrence independent of stage and grade . FISH 
revealed numerical alterations of chromosomes 7, 8, 10, 16, 17, 18, X, and Y , 
as well as deletions and amplifications of specific chromosomal regions, e.g. 
8p22  and the MYC region on 8q24 .  
A limited amount of data is available of (cyto)genetic heterogeneity of 
prostate cancers. Flow cytometry revealed significant degrees of variation in 
DNA ploidy within individual cases . Another flow cytometry study showed 
that foci with different ploidy were infrequent in early prostatic carcinomas . 
Intra-tumoral heterogeneity was distinguished by LOH analyses of multifocal 
cancers . Different patterns of allelic imbalance were also discerned between 
multiple foci of preneoplastic lesions in the prostate . Furthermore, mutation 
analysis of TP53 showed heterogeneity in intratumor distribution of primary 
cancers , whereas the PTEN gene displayed mutational heterogeneity among 
different metastatic sites . In situ hybridization with centromeric DNA probes 
showed considerable heterogeneity within cases of prostatic adenocarcinoma . 
However, a drawback of all these investigations is the low number of genetic 
targets making it difficult to differentiate between a monoclonal or polyclonal 
origin of tumors. We applied a genome-wide approach to answer questions 
concerning genetic variation in prostate cancer. In a previous study using 
aCGH we did not find significant differences between Gleason 3 and 4 areas 
in symptomatic prostatic carcinomas . This is in accordance with the present 
study comprising asymptomatic cancers with a tumor volume of 1.0-1.5 ml. 
The prostate carcinomas in this study were screen detected cancers. Tumors 
detected by PSA screening mostly do have more favorable tumor 
characteristics compared to tumors diagnosed after symptoms have 
developed 176. Further, one third of the cancers diagnosed in subsequent 
screening arms of the Rotterdam screening study were of focal nature 148. 
Although asymptomatic our 11 cancers had tumor volumes between 1.0-1.5 
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ml, which is relatively large, and nearly half of the patients showed 
biochemical recurrence during follow-up. Therefore, we conclude that a 
subgroup of screen detected prostate cancers with  a genotype, commonly 
found in prostatic adenocarcinomas, might have an aggressive phenotype. 
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Abstract 
Objective: Asymptomatic prostate cancer and early stages of prostate cancer 
are encountered frequently nowadays due to surveillance and screening 
programs. For these cancers watchful waiting and biochemical treatment 
modalities, e.g. COX-2 inhibitors, might be good alternatives for radical 
surgery.  
Methods: A tissue micro-array was constructed comprising asymptomatic 
prostate cancers from the Rotterdam screening study of 100 patients (mean 
age 63.7 years, range 55-73 years) with varying tumor volumes (mean 1.0 ml, 
range 0.2-4.5 ml) and 10 men who underwent trans urethral resection of the 
prostate (TURP) without prostate cancer. Proliferation was defined by Ki67 
protein immunohistochemistry, anti-apoptotic features were determined of 
COX-2, Bcl-2, Bcl-xl and iNOS, and pro-apoptotic activity was measured by 
Caspase-3 immunostaining.  
Results: In general, low or virtually absent apoptosis-related protein 
expression was detected in luminal epithelium of both cancers and normal 
controls. Only Ki67 and iNOS showed significant higher expression in the 
carcinomas (p=0.03 and 0.001, respectively) compared to benign prostate 
tissue. No significant associations were found between proliferative and 
apoptotic activity of all our markers and tumor volume, Gleason score or 
pathological T-stage. 
Conclusions: Anti-apoptotic activity in screen detected prostatic carcinomas is 
low. It suggests that the use of apoptosis modulators would be of limited 
value in the treatment of asymptomatic prostate cancers detected in screening 
programs.  
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Introduction  
Prostate cancer is the most common non-cutaneous cancer in males in the 
Western world. Since the introduction of Prostate Specific Antigen (PSA) 
testing in the last decade, prostate cancer incidence increased dramatically 1. 
Due to PSA testing a lot of cancers are diagnosed which would never be 
detected clinically 2. Consequently, prostate cancer prevention programs have 
been subject to discussion. In the Prostate Cancer Prevention Trial, finasteride, 
which induces lower intraprostatic dihydrotestosteron levels, caused a 25% 
reduction in prostate cancer prevalence compared to men who were 
randomized in the placebo group 3. This was the first indication that prostate 
cancer might be prevented.  
Apoptosis, or programmed cell death, is involved in normal tissue in 
order to keep normal homeostasis through the elimination of redundant or 
potentially deleterious cells 4. Genetic lesions in cells may lead to diminished 
apoptosis and play a general role in tumorigenesis. Cells with DNA damage 
might escape cell cycle checkpoints, in which they otherwise would have 
gone into apoptosis. Now these cells can not be cleared, divide freely and a 
tumor may develop. The execution of apoptosis involves the activation of 
caspases by pro-apoptotic signals released from damaged mitochondria. In 
this respect the Bcl-2 family, which plays a role in maintaining mitochondrial 
integrity, is important. It is assumed that deficiencies in these mechanisms 
that regulate the apoptotic process may in another way contribute to tumor 
development.  For example, when Bcl-2 is highly expressed cells do not go 
into apoptosis, but stay alive and might proliferate 4-6.  
Androgen dependent prostate cancer cells undergo apoptosis in 
response to androgen withdrawal. Prostate cancer cells develop multiple 
apoptosis blocking strategies during progression from normal epithelial cells 
to androgen independent cancer cells 7,8. It has been reported that loss or 
alterations of apoptotic regulatory genes (which induce programmed cell 
death) play a role in prostate cancer progression. For instance, loss or 
inactivation of tumor suppressor genes such as p53 and PTEN, or over-
expression of anti-apoptotic proteins Bcl-2, COX-2 and Bcl-xl contribute to 
progression of prostate cancer 9. Following therapy with androgen ablation, 
p53 and Bcl-2 expression change and the apoptotic index increases in a large 
proportion of cases. Failure of apoptotic response as measured by the 
apoptotic index correlates with relapse 10. A chemoprevention trial targeted at 
induction of apoptosis has been set up (ViP) with rofecoxib (a COX-2 
inhibitor) to prevent prostate cancer 11. COX-2 inhibition has been shown to 
induce apoptosis in several prostate cancer cell lines 12. However, rofecoxib 
was withdrawn of the market because of cardiovascular side effects 13.  
In this study a tissue micro-array was constructed containing 100 
asymptomatic screen detected prostate cancers with tumor volumes ranging 
from 0.2 to 4.5 ml. Ki67, COX-2, Bcl-xl, Bcl-2, Caspase-3, and iNOS protein 
expression patterns were tested by means of immunohistochemistry. The 
following questions were addressed: 1) What is the level of apoptosis in 
screen detected prostate cancer? 2) Does the level of apoptosis warrant 
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treatment with medication that induces apoptosis? 3) Is there a relation 
between tumor volume, Gleason score and pathologic stage and the apoptotic 
profile?  
 
Patients and Methods 
Patients and screening strategies 
Data were retrieved from the Rotterdam section of the European Randomized 
Study of Screening for Prostate Cancer (ERSPC). Men, 55-75 years old, were 
randomized to a screening (n=21,210) and a control arm (n=21,166). They 
underwent screening every four years (starting from November 1993) until 
the age of 75. Screening was performed by PSA determination, and systematic 
sextant prostate needle biopsy was recommended for participants who had an 
elevated PSA level (≥3.0 ng/ml). Once diagnosed treatment was based on 
advise of the urologist and patients wish. For this study patients diagnosed in 
the screen arm and treated with radical prostatectomy were selected. Radical 
prostatectomy specimens were completely paraffin embedded and sliced 
according to protocol allowing accurate measurements of tumor volume, 
histological grading (Gleason score), and pathologic staging 14.  
 
Construction of the tissue micro-array 
Hundred radical prostatectomy specimens were collected for the tissue micro-
array (TMA). Ten trans-urethral resection of the prostate (TURP) specimens, 
wherein prostate cancer was not detected after thorough sectioning, were 
used as normal controls. The tissue micro-array was constructed as described 
by Kononen et al. 15. Six cylindrical tissue cores were taken of each of the 10 
control samples. Of the 100 radical prostatectomy specimens a total of 534 
tissue cores were collected in the TMA. Of each patient 4 to 10 core biopsies 
were inserted in the TMA depending on the number of different Gleason 
grade areas (range 2-4).  Total tumor volume categories included < 0.5 ml 
(n=25), 0.5-1.0 ml (n=25), 1.0-2.0 ml (n=25), > 2.0 ml (n=25). The pathological 
characteristics of the prostate cancer specimens within our tissue micro-array 
are listed in Table 1.  
 
Tables 
Table 1 Characteristics of the 100 prostatic cancers. 
tumor volume (mean; ml) 1.0 (range 0.2-4.5) 
pathological stage (pT)  
pT2 83 
pT3 15 
pT4 2 
Gleason score  
<7 62 
7 37 
>7 1 
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Immunohistochemistry 
Immunohistochemistry was performed on 4-µm-thick tissue sections of the 
TMA adhered to aminoacetylsilane (AAS) coated slides (Starfrost, Berlin, 
Germany). Immunostaining was performed using the ChemMate Envision kit 
(DAKO, Zoetermeer, The Netherlands). After de-paraffinization microwave 
(700 W) pretreatment was performed for 15 minutes using citrate buffer 
(10mM citric acid monohydrate, pH 6.0), except for PSA. The following 
antibodies, diluted in phosphate-buffered saline/5% were used: Ki67 antigen 
(Immunotech, Miami, FL; diluted 1/200), COX-2(Vector, Burlingame, CA; 
diluted 1/200), Bcl-xl (Zymed laboratories Inc, San Francisco, CA; diluted 
1/200), Bcl-2 (DAKO; diluted 1/100), Caspase-3 (DAKO; diluted 1/400), and 
iNOS (BD-transduction lab; diluted 1:800). As a positive control PSA antibody 
(DAKO; diluted 1/1600) was used, as a negative control the primary antibody 
was omitted.  
 
Scoring and statistical Analysis 
The immunostaining results of the TMA were scored per tissue core by two 
independent investigators. Moderate or intense brown nuclear/cytoplasmic 
staining was considered positive. The percentage of brown stained cells was 
determined in at least 50 prostate epithelial cells by each investigator. For the 
statistical analysis SAS-8 and Statistical Package for Social Sciences software 
11.0 were used (SPSS, Chicago, IL). A p-value <0.05 was considered 
significant.  
 
Results 
A tissue micro-array was constructed comprising asymptomatic screen 
detected prostate cancers of 100 patients (mean age 63.7 years, range 55-73 
years) with varying Gleason scores (4-9) and tumor volume (0.2 -4.5 ml; see 
Table 1)). The majority of these cancers was low-grade, i.e. Gleason score <7 
(62%), and/or low-stage, i.e. pT2 (83%). Protein immunohistochemistry was 
used to evaluate proliferative and apoptotic activity in the luminal epithelial 
compartment. Proliferation was defined by Ki67, anti-apoptotic features were 
determined of COX-2, Bcl-2, Bcl-xl and iNOS, and pro-apoptotic activity was 
measured by Caspase-3 (examples in Figure 1). The protein expression 
patterns were scored and statistically analyzed. Proliferation marker Ki67 
showed a significantly higher protein expression in the carcinomas as 
compared to normal prostate tissues (p=0.03). The pro-apoptotic activity, as 
measured by Caspase-3 did not show a significant difference between tumor 
and normal prostate tissue. For the anti-apoptotic markers low or absent 
protein expression levels were observed in (luminal) epithelium of both 
carcinomas and normal controls. However, positive immunostaining was 
seen for these markers in other (expected) cell types, such as basal epithelial 
cells, lymphocytes or fibromuscular stromal cells (Figure 1). Only iNOS 
showed a significant higher staining profile in the prostatic cancers (p=0.001).  
(table 2) . No significant associations were found between proliferative and 
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apoptotic activity of all our markers and tumor volume, Gleason score, and 
pathologic stage. 
 
Figure 1 a-c Immunostaining of cellular proliferation with Ki67 showing 
occasional positive cell nuclei in normal basal cells (a), whereas (luminal) 
cancer cells display low (b) and high (c) frequencies of labeling. d Pro-
apoptotic marker Caspase-3 revealing positive staining in normal luminal 
cells (gland at right), but not in adenocarcinoma cells. e-h Anti-apoptotic 
activity illustrated by iNOS, Bcl-xl, Bcl-2 and COX-2. Note cytoplasmic 
positivity for iNOS (e) in tumor cells; in contrast, the normal gland (at right) is 
negative. F shows weak cytoplasmic staining of cancer cells with Bcl-xl, 
whereas Bcl-2 (g) reveals negative tumor cells, but positive labeling of basal 
cells in normal glands (at right). COX-2 (h) is negative in (normal) prostatic 
epithelium, whereas myofibroblasts are clearly positive. 
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Table 2 differences between tumor and nomal prostate tissue 
 % postivity in 
normal 
% postivity in 
tumor 
P 
Ki-67 1.8 2.8 0.03 
COX—2 4,3 10,4 Ns 
Bcl-xl 2.3 7.5 ns 
Bcl-2 - 56,9 ns 
iNOS 0.1 4,1 <0.0001 
 
Discussion 
We investigated markers related to apoptotic activity in asymptomatic 
prostate cancers, detected by a population based screening. Of all the markers 
only iNOS was significantly different between the prostate cancer specimens 
and normal prostate tissues. This low spectrum of apoptosis might be 
explained by the great proportion of low-stage (83%) and well-differentiated 
tumors (62%) in our series. In the literature, a correlation between Ki67 
expression and increasing Gleason score has been reported 16. We found a 
significant difference in prostate cancer versus normal prostate tissue, but no 
association was present between the Ki-67 defined proliferation index and 
cancer grade or stage. This can be attributed to the fact that only one high-
grade prostate carcinoma (Gleason score >7) was present in our series of 
asymptomatic cancers. 
iNOS (inducible nitric oxide synthases) conducts the cytotoxicity of 
macrophages and tumor-induced immunosuppression 17. Positive iNOS 
immunostaining was described in BPH, PIN and prostatic carcinoma 18. 
Furthermore, prostate cancer samples showed increased staining, when 
compared to BPH samples 18. However, a higher Gleason score was not 
correlated with increased iNOS expression. In another immunohistochemistry 
study benign hyperplasia stained negative, but prostate cancer cells were 
highly positive for iNOS 19. Also a marked variation of iNOS mRNA levels in 
prostate cancer was reported 20. All these findings are in line with the results 
of our study. Finally, strong iNOS protein expression was found to be a 
predictor of poor survival in univariate analysis, but appeared inferior to 
established prognostic factors in multivariate analysis 21. 
Recent studies suggest that induction of apoptosis may be a potential 
mechanism for prostate cancer prevention, especially by using COX-2 
inhibitors 9.  Grupta et al. described over expression of COX-2 in prostate 
cancer 22. They showed that prostate carcinoma cells stained intense as 
compared to mild staining in benign prostatic epithelium. Other investigators 
described similar results. However, when COX-2 expression according to 
pathological stage was compared, no significant difference was found 
between pT1/pT2 tumors and BPH samples 23. Immunohistochemical analysis 
of prostate cancer also showed that there was no consistent over expression of 
COX-2 in cancer or high-grade PIN versus adjacent normal prostate tissue 24. 
Positive staining was seen only in scattered cells (<1%) in both tumor and 
normal tissue. Thus, no consistent line of literature seems present concerning 
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COX-2 expression in the successive stages of prostate cancer. This is 
supported by a recent study describing a lack of involvement of COX-2 in 
prostate cancer development 25. 
The Bcl-2 protein is predominantly expressed in prostate basal cells in benign 
prostate epithelium, is absent in most low to intermediate grade carcinomas 
and is highly expressed in androgen independent prostate cancers 26. Another 
study reported that almost all androgen independent prostate cancers stained 
positive for Bcl-2, whereas androgen dependent prostate cancers stained 
negative and weak in 2/3 and 1/3 of cases 27. It is suggested that Bcl-2 over 
expression might be a useful prognosticator in more advanced tumors, 
because the expression increased with stage and grade 28. In a recent tissue 
micro-array study immunostaining of the TMA was positive for Bcl-2 in only 
24% of the cores, whereas the corresponding radical prostatectomy specimen 
stained positive in 66% 29. The investigators concluded that the heterogeneity 
of immunohistochemical protein expression of this marker requires a 
sufficient number of tissue for adequate TMA evaluation. In our study a large 
number of cancer cores was present in the TMA. We therefore attribute the 
overall negative expression profile of Bcl-2 to the predominance of low-grade 
and low–stage cancers in our asymptomatic screen detected series of prostate 
cancers. A likewise scenario seems to be present for Bcl-xl, a gene closely 
related to Bcl-2 30. 
 Caspase-3 protein expression by immunohistochemistry as a measure 
for apoptotic activity has been demonstrated before 31. Winter et al. showed a 
significantly reduced staining pattern in prostate cancer cells, as compared 
with normal tissues 32. Further, a relation between increasing Gleason score 
and apoptotic index was seen. This was, however, not confirmed in another 
investigation 33.  
 
Conclusions  
In literature there is no consistent line of evidence to firmly support the use of 
apoptosis modulators, such as COX-2 inhibitors, for prevention or treatment 
of prostate cancer. In this study we used a tissue micro-array that comprised 
of 100 asymptomatic prostatic cancers, detected by a PSA-based screening 
study, to assess the spectrum of apoptosis. In general, a low anti-apoptotic 
activity was detected. This could in part be explained by the large proportion 
of low-stage and well-differentiated tumors. However, based on our results 
we can not recommend COX-2 inhibitors as medication for the treatment of 
asymptomatic prostate cancer. 
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General discussion 
Introduction of the large scale PSA testing for prostate cancer without prior 
evidence for its efficacy has now created a social economic health problem in 
the Western world. Its’ unintended use, on large numbers of aging men, led to 
a considerable claim on health budgets at the expense of other health related 
issues. It was calculated that the costs of a nation wide screening program 
(screening interval of 3 years) in Sweden with almost 9 million people would 
cost 244 million Swedish crones (27 million euros) per year 1. The costs would 
be much higher in countries with a larger population.  The clinical complexity 
of prostate cancer still remains a challenge. While much is known about the 
risk factors and biology of other common cancers such as breast and lung 
cancer, prostate cancer is surrounded by uncertainties.  
What has become clear in the last decade is that PSA screening and to a 
lesser extent, aging of the population has brought about enormous changes in 
the epidemiology of prostate cancer. Since the recommendation to test men 50 
years or older for PSA in 1993 in the USA, and after introduction of two 
randomized clinical trials (ERSPC and PLCO) more than 10 years ago, it is as 
yet unknown whether PSA screening reduces prostate cancer mortality, let 
alone overall mortality.  
One of the goals of PSA screening is to detect prostate cancer at an 
early stage, reducing the number of patients with advanced disease, which 
are likely to be beyond of cure.  Indeed the efforts to detect prostate cancer at 
an early stage seemed to be successful since the enormous gap between 
clinical incidence (8–15% lifetime risk) 2 and autopsy-based prevalence (80% 
by age 80 years was reduced 3. As a consequence of the tremendous increase 
in prostate cancer incidence (e.g. in the USA the prostate cancer detection rate 
increased twofold since the introduction of  PSA 2, a great proportion of the 
prostate cancers detected by PSA screening might now be considered as over 
diagnosis. In the ERSPC, the over diagnosis was calculated to be as high as 
48% on the basis of computer modeling 4. Others even find that this 
percentage would be 84% with respect to prostate cancer mortality 5. One of 
the important challenges of PSA screening is not to detect as many prostate 
cancers as possible, but to determine which men after a diagnosis of prostate 
cancer are at greatest risk of developing advanced disease. To these men, an 
appropriate curative treatment might be offered in order to reduce the risk of 
disease recurrence and progress to metastasis. In men with favorable tumor 
characteristics, initially watchful waiting might be considered in order to 
reduce over treatment.  
At present, the age-adjusted prostate cancer mortality per 100,000 men 
is declining in the USA 6. This is probably attributed at least partly to PSA 
screening. These results might be influenced by lead time bias (clinical tumors 
are detected later without screening and therefore the life span is longer in a 
screen detected cancer) and length time bias (detection of tumors that would 
not have been detected without screening and would not otherwise pose a 
threat on the life expectancy of the host.   
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Unfortunately, the final outcome of the ERSPC is not to be expected 
until the end of 2008 or later 7. The studies outlined in this thesis describe the 
intermediate endpoints, concerning stage and grade of prostate cancer in 
subsequent screening rounds and the forthcoming therapy choices, the 
efficiency of the screening protocol employed at the Rotterdam section of the 
ERSPC and the natural biology of prostate cancer and its’ possible 
premalignant lesions. 
 
Importance of lesions with potentially increased risk for subsequent 
detection of prostate cancer 
The conclusions of chapter 2 are that the prostate cancer incidence after repeat 
biopsy in men with a benign biopsy in the 1st round was 12.1%, a percentage 
not significantly different from the prostate cancer incidence after repeat 
biopsy for PIN (13.3%) neither in the 1st nor in the 2nd screening round. Before 
completion of the 1st screening round of the ERSPC, Vis et al. 8 already 
reported that the risk for subsequent detection of prostate cancer was not 
significantly increased. The data of chapter 2 include the longer follow-up 
after completion of the 1st and 2nd screening round. A yearly linkage with the 
cancer registry allowed us to detect prostate cancers which were diagnosed 
outside the ERSPC trial. Even after a long follow-up, including the 
recognition of cancers diagnosed outside the trial, the prostate cancer 
incidence in men previously diagnosed with isolated PIN proved to be 
limited. This finding was discrepant with several previous data from other 
studies. Reports from opportunistic screening studies demonstrated that 
prostate cancer was diagnosed in 22-100% of men that underwent repeat 
biopsy after an intial diagnosis of PIN 9-15,16-18. Our finding that PIN is not 
associated with increased risk of detecting prostate cancer was confirmed be a 
few other studies, confirming that the risk for detecion of prostate cancer at 
repeat biopsy after a PIN diagnosis is not increased 19,20. 
The incidence of PIN in a screening based population might be 
considered as a reflection of that in the general male population. Although the 
PIN incidence increases in the 2nd screening round towards 2.5%, it continues 
to be low compared to literature, where a PIN incidence of 3.7-29% was 
reported on needle biopsies 21. The incidence of PIN in autopsy specimens in 
benign prostates was reported to be as high as 43% 22. At radical 
cystoprostatectomy specimens with concurrent cancer, the PIN incidence was 
even higher, 85-100% 21. It must be concluded that the limited amount of 
tissue sampled by prostate needle biopsies (sampling bias) explains the 
comparatively low incidence of PIN detected in our screened population. 
Other explanations for the discrepancies in incidence and subsequent prostate 
cancer detection at repeat biopsy are for the main part due to differences in 
study populations, but also indications for biopsy, inter-observer variation of   
pathologists and differences in the biopsy protocol might influence the 
observed incidence of PIN 23. Both the high incidence of PIN in autopsy series 
in men dying of other causes than prostate cancer 22 and the low risk of 
subsequent prostate cancer detection would-to our opinion- imply a diagnosis 
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of isolated PIN by itself does not require repeat biopsies. A repeat biopsy also  
is not favored, because, despite physical side effecs, it might induce 
psychological stress and therefore reduce the quality of life. In addition repeat 
biopsies have an impact on the costs associated with prostate cancer 
screening, which is another argument, to restrict repeat biopsies in men with 
isolated PIN.   
In contrast to our finding regarding PIN lesions, the incidence of LSPC 
lesions (not premalignant lesions) and the subsequent detection of prostate 
cancer in repeat biopsy in the ERSPC screening study were comparable to 
literature 24-26. Based on these findings, we do advise continuation of 
performing repeat biopsies in men with a LSPC, even though the risk of a 
subseqeunt cancer is much lower in the 2nd screening round. 
New immunohistochemical markers as basal cell marker p63 and α-
methylacyl CoA racemase (AMACR) have been introduced to more easily 
distinguish between prostate cancers and their benign mimics, which may 
raise suspicion for a cancer. The marker p63 is generally used for 
distinguishing benign small acinar proliferations from Gleason pattern 2 and 
3 prostate cancers; it is a basal cell marker that is absent in prostate cancer. 
The AMACR marker gives a particular, intense staining in prostate cancer 
and PIN lesions and is of diagnostic use in resolving ASAP or LSPC foci in 
prostate biopsies. Because the markers distinguish between prostate cancer 
and foci suspicious for malignancy, more suspicious cases will be definatively 
diagnosed and a decrease would be expected in the incidence of LSPC lesions. 
However, as a consequence of this, there is a risk that suspicious foci might be 
more often diagnosed as PIN lesions because morphologically unremarkable 
prostate glands are occasionally positive for AMACR and basal cell markers 
(p63, 34ße12) (ref).  
 
In chapter 3, the incidence of different variants of atrophy and the subsequent 
prostate cancer incidence is reported. Some authors suggested that atrophy 
might be a precursor lesion for prostate cancer. If so, a more close surveilance 
of men with atrophy in their biiopsy might be warranted. The incidence of 
atrophy was not reported before on prostate needle biopsies.  If atrophy 
would carry an increased risk for prostate cancer, it would be important to 
have an estimate of the incidence of atrophy in a general screening population 
28. After reviewing 202 benign prostate needle biopsies with a follow-up of 8 
years, 94% of the biopsies contained some form of atrophy. After expanding 
follow-up until 2005 4.4% of men with atrophy in their biopsy had a prostate 
cancer in the follow-up, which is sligthly lower than the prostate cancer 
detection rate in the general screening population (5.1%). More importantly, 
the extent of atrophy in the biopsies was also not relevant to subsequent 
cancer risk. Although a small proportion of these patients underwent repeat 
biopy in the 4-year screening interval, the limited number of interval cancers, 
detected through linkage with the cancer registry, supports the view that in 
the general population atrophy diagnosed on prostate biopsy, does not 
increase the risk of having a prostate cancer diagnosed within at least 8 years. 
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Therefore, due to the extremely high incidence of atrophy in sextant biopsies 
and the low cancer detection rate, we do not consider this lesion as a 
premalignant lesion and will not encourage to do repeat biopsies on these 
men. We can not exclude however, that atrophy, as a consequence of chronic 
inflammation, with an onset at a young age and persisting for e.g. 10 years or 
more will not eventually progress to prostate cancer.  
 
Intermediate endpoints to determine the efficacy of the screening protocol 
We tried to shed a light on the efficacy of the screening protocol used in the 
Rotterdam section of the ERSPC. Optimalization of the screening protocol 
may involve parameters such as DRE, TRUS, different PSA cut-offs for 
indication of biopsy, employment of sub forms of PSA (e.g. pro-PSA, free 
PSA), number of prostate biopsy cores, site of punction and age category.  
The ERSPC was heavily criticized for the adoption of the long interval of 4 
years between two screening rounds employed by most of the centers 29. It 
was hypothesized that 77% of the prostate cancer diagnoses would be 
delayed if a 4-year screening interval was used 29. However, it was not 
investigated whether this delay might lead to increased morbidity or 
mortality. In addition, in the ERSPC Rotterdam, lateral sextant biopsies are 
used, which are now considered as old fashioned because the chance to miss 
prostate cancer is as high as 20-30% 30,31.  
The efficacy of the screening protocol in the Rotterdam section of the 
ERSPC was investigated by determination of the incidence of potentially 
advanced and focal cancers in 1st and 2nd screening round. In addition, 
pathological stage and therapy choices were examined during the two 
screening rounds and in the control arm. Since biopsy Gleason score is one of 
the best predictive factors for prostate cancer recurrence and is correlated 
with pathological tumor stage, 32 we used this parameter for the assessment of 
the aggressiveness of prostate cancer. The incidence of potentially advanced 
cancer, defined as Gleason score 7 (4+3, or 3+4 with a >30% cancer 
involvement) or Gleason score 8-10 carcinoma in sextant biopsies decreased 
from 20% in the 1st to 6.0% in the 2nd round, respectively. This implies that the 
screened population was effectively depleted of aggressive cancers during the 
1st round, an effect lasting for at least 4 years. The incidence of focal cancer, 
defined as ≤3.0 mm involvement by cancer in one biopsy core lacking Gleason 
pattern 4 or 5 on sextant biopsy, increased significantly from 16% in the 1st to 
29% in the 2nd screening round. This observation is consistent with a 
screening protocol, detecting cancers at an early stage. The dramatic increase 
of focal cancers in the 2nd round would suggest that the 4-year interval does 
not allow most tumors to grow to a large size. The latter could be confirmed 
by findings reported in chapter 6.  
 
In chapter 6, features of prostate cancer detected during two subsequent 
screening rounds in relation to changes in therapy choice were reported. 
Gleason score, involvement of biopsy by tumor, clinical stage and PSA level 
were more favorable in patients of the 2nd round compared to those of the 1st 
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round. It was already reported that there was a stage and grade shift when a 
limited proportion of men were screened in the 2nd screening round 33. The 
number of men chosing for watchful waiting increased from 10% in the first 
to 22% in the second round. In patients undergoing radical prostatectomy, 
median tumor-volume in the first, respectively second screening round was 
0.65 resp. 0.45 ml. Minimal cancer (cancer <0.5 ml, organ confined, no Gleason 
pattern 4 or 5) was found in 31.6% in the first and 42.6% in the second 
screening round, a significant increase. Independent Prognostic factors for 
PSA failure were positive resection margins, age, biopsy Gleason score, and 
pT-stage. Thus the biopsy findings in chapter 5 could be confirmed by the 
observation made on radical prostatectomy. However, it should be realized 
that only a proportion of men underwent surgery for their cancer. This may 
have biased the less dramatic findings in radical prostatectomy specimens.  
The prostate cancer incidence rate decreased from 5.1% in the 1st 
towards 4.4% in the 2nd round. This observation should be considered with 
caution, because of protocol changes and side studies in the 2nd screening 
round with lower cut-off levels for biopsy indication. It must be realized that 
the prostate cancer incidence in Rotterdam was the highest among the other 
European centers (other centers reported incidences varied between 1.7 and 
2.7%). Thus the observations made of the Rotterdam section of the ERSPC 
may not necessarily be extrapolated to the other screening centers 34.  
The incidence of high-grade cancer (Gleason score 8-10) not only 
decreased in the Rotterdam section, but also in Finland. Sweden had already a 
very low incidence of high grade prostate cancers in the 1st round, making it 
drop below that initial incidence of high grade prostate cancer very unlikely. 
To some extent, the overall cancer detection rate as well as the high-grade 
cancer detection rate was related to the biopsy compliance 34. The fact that 
prostate cancer incidence is dependent on biopsy compliance was also 
supported by a recent publication of the PLCO study. They reported in the 
same age categories a biopsy compliance of 31.5%, which resulted in an 
overall prostate cancer detection rate of 1.4% as compared to the cancer 
detection rate of 5.1% in the ERSPC Rotterdam 35. 
The median tumor volume in our series of radical prostatectomy 
specimens was small. As a manifestation of the efficacy of screening, one 
would also expect that tumors detected in the screening arm of the ERSPC are 
smaller compared to tumors detected by clinical symptoms. The median 
tumor volume reported in another screening study by Humphrey et al was 
1.0 ml 36. Ohori et al reported a median tumor volume of 2.23 ml, which was 
considerably larger compared to our data37. A few explanations for the 
discrepant findings in volume between studies may concern technical aspects 
of tumor volume measurements. In the ERSPC Rotterdam tumor volume is 
calculated after the radical prostatectomy was submitted in toto and cut 
serially in slices of 4 mm. The tumor volume area was measured by 
morphometry and multiplied by 4. Prior experiments had shown that no 
correction factor was required for the alleged shrinking effects of fixation and 
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paraffin embedding. Some other authors, however used a correction factor of 
1.4 or 1.3 for alleged shrinkage 38.  
Tumor volume was an independent predictive factor in the 1st 
screening round for biochemical recurrence 39. After completion of the 2nd 
round, tumor volume lost its’ predictive value additional to Gleason score 
pathological stage and resection margin status. This might probably 
explained by the limited variation in size of the tumors. Because of the small 
tumor size, other factors such as Gleason score and pathological stage have 
become more important, compared to tumor volume.  
On the basis of the above mentioned results, and the observation that 
the number of interval carcinomas was limited, while displaying favorable 
tumor characteristics 40, we must conclude that the ERSPC protocol conducted 
in Rotterdam, i.e. PSA cut-off ≥3 ng/ml, employment of sextant needle biopsy 
and a screening interval of 4 years is highly effective at an early stage, and in 
preventing the development of advanced cancers.  
As yet, no proper definition of insignificant cancer, also designated as: 
minimal cancer or cancer that does no harm, or cancer that should be 
considered as over diagnosis, can be given. The parameters to define a 
minimal cancer in a radical prostatectomy specimen are somewhat arbitrary 
and it remains unproven that minimal cancers are indeed harmless cancers on 
the long term. On the basis of our results, we would argue that a focal cancer 
on sextant biopsy, or a minimal cancer in a radical prostatectomy specimen 
might be considered as an insignificant cancer. Their detection could be 
considered as over diagnosis, and indeed these cancers were shown to have a 
good prognosis in the ERSPC Rotterdam.  
Our analysis of needle biopsy and prostatectomy specimens of men 
diagnosed with prostate cancer in the screening arm, was an attempt to 
confirm whether the over diagnosis of 48% based on computer modeling 
would be an appropriate calculation. The incidence of focal cancers on sextant 
biopsies increased to almost 30% in the 2nd screening round brings us close to 
the 48% calculation. We could confirm this by investigating radical 
prostatectomy specimens in the 2nd screening round as we detected a 43% 
incidence of minimal cancers. It should be mentioned that some focal cancers 
in sextant needle biopsies are just the tip of the iceberg. Five percent of the 
focal cancers were upstaged to a pT3 or higher after radical prostatectomy. 
Therefore it is hard to predict, at the individual level, which patient would 
really harbor an indolent cancer. 
A marker that detects specifically the aggressive or indolent cancers is 
urgently needed to solve the problem of over diagnosis. However, for over 15 
years researchers have been investigating this issue, with as yet no result that 
may lead to a change in prostate cancer detection. Even in this era of cDNA 
arrays and proteomics no really exciting markers have been discovered at 
present, so more practical solutions need to be put in the practice at this time. 
A less intensive screening protocol might also decrease over diagnosis but at 
the cost of missing cancers that are beyond of cure. Another practical way to 
avoid over diagnosis or rather over treatment is to defer treatment, i.e. 
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managing men with favorable pre-operative features (i.e. Gleason score ≤6, 
limited tumor involvement, low PSA or PSA density) with watchful waiting. 
The proportion of men on watchful waiting in the Dutch part of the ERSPC 
has now doubled in the 2nd screening round, which we consider as a good 
development, bearing in mind the detection of a comparatively large 
proportion of focal cancers in the 2nd screening round. To date there has been 
one randomized clinical trial comparing radical prostatectomy and watchful 
waiting. In this trial men treated with radical prostatectomy showed 
significantly increased prostate cancer specific survival as well as overall 
survival compared to men managed by watchful waiting 41. However, 
patients with presence of Gleason pattern 4 (<25%) and 5 (<5%) cancers 
identified ar=t radical prostatectomy were also included in this trial. As 
mentioned before, patients with a high grade Gleason pattern in their biopsy 
do worse, compared to patients without a high grade component 42. In 
contrast, the natural history studies of Johansson en Albertson 43,44 show a 
prostate cancer specific survival rate of 72% and 73% without curative 
treatment after a follow-up of 20-years in men with a well-differentiated 
prostate cancer. The latter studies support the initiation of watchful waiting in 
men with favorable tumor characteristics. We do hearten the initial 
management of these men with watchful waiting. A delayed treatment can 
always be given in these men, with a very small risk of metastasis or death 
from prostate cancer. Furthermore, it was shown that their delayed treatment 
is almost always curative (manuscript in preparation). 
 
Significantly more prostate cancers were detected in the screening arm vs. the 
control arm (15.9 vs. 4.2 per 1000 man years, p<0.0001)(chapter 7). Clinical 
(c)T stage, biopsy and radical prostatectomy Gleason score distribution were 
significantly less favorable in the control arm. The 5-year biochemical free 
survival after radical prostatectomy in both rounds of 87% was high and there 
was no significant difference between the two rounds. In two other large 
series, a somewhat lower 5-year biochemical progression free survival rate of 
78 and 80% was reported 45,46. This difference is explained by the fact that the 
men in the latter studies were not part of a screening study, which is in line 
with the presumed potential of screening to detect most cancers at a stage that 
they are curable. However, with a 50% of T1c tumors in the study by Roehl et 
al., one might speculate that a great proportion of their cancers detected on 
biopsy are due to increased PSA (opportunistic screening). We expect that in 
the future biochemical recurrence free survival will increase if the radical 
treatment of low-grade low stage cancers continues. The 5-year PSA 
progression free survival after radical prostatectomy was 68% in the control 
arm and 89% in the screening arm (p<0.0001). Advanced disease (T4/N1/M1) 
was significantly more common in the control arm (11.0%) as compared to the 
screening arm (3.8%) (p< 0.0001). All these features increase the likelihood of 
a reduction of prostate cancer mortality in the end. A recent publication on 
the pilot studies prior to the start of the ERSPC showed data on prostate 
cancer mortality with 12 and 3 prostate cancer deaths in the control and 
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screening arm, respectively 47. As these numbers of patients in this study are 
very small, no statistical calculations could be performed and the follow-up 
time (median 5 years) is still too short to encourage the view that screening 
for prostate cancer might reduce prostate specific mortality in the end.   
The power of the ERSPC might be undermined if a large number of 
prostate cancers in the control arm would be detected incidentally or by 
opportunistic screening.  Only a limited proportion of cancers in the control 
arm was detected incidentally. Incidentally detected cancers are most 
frequently low stage, low-grade tumors and they are found because of 
treatment for another disease than prostate cancer, e.g. bladder cancer or 
BPH. Since the incidence of these tumors was 9.3% of all tumors detected in 
the control arm, we don’t think their prevalence might have a strong impact 
of the power of study. Another effect that probably will have an impact of the 
power of the study is the opportunistic screening in the control arm. The 
opportunistic screening in the control arm was found to be 3,0% per year 48. 
However, the proportion of T1c cancers in the control arm has risen to 25% 
nowadays, which for a great part might be due to opportunistic PSA 
screening. To avoid that the opportunistic screening of the control arm affects 
the power of the study a Cuzick analysis is planned 49. This method was 
originally developed to adjust for non-compliers in the screening arm while 
respect to randomization and the prevention of bias were conserved. In this 
analysis adjustments for contamination (use of the treatment and screening by 
individuals in the control arm) were also developed, which might be useful in 
the ERSPC, since due to awareness of screening for prostate cancer in the 
population an increasing proportion of men (in the control arm) undergo PSA 
testing.  
 
Natural behavior of screen detected prostate cancers  
Prostate cancer is a heterogeneous and often multi-focal cancer, and 
frequently different Gleason patterns may be noted within one tumor. Two 
opposing hypotheses may explain the presence of both high-grade and low-
grade components in a prostatic cancer: 1) During their development a 
prostatic cancer starts to grow and to dedifferentiate from a well 
differentiated (low Gleason score) to a poorly differentiated (high Gleason 
score) tumor, or 2) the combination of low and high Gleason grade cancer 
evolves from multiple pluri-potent stem cells that form a heterogeneous 
single cancer focus after the collision of the low-and high-grade cancer. Both 
mechanisms might also occur at the same time. If prostate cancer would be 
high grade at the onset of disease, the effect of screening might be limited as 
at an early stage the prostate cancer cells may have already acquired the 
capacity to metastasize. 
In chapter 8 it is shown that a high Gleason score is significantly associated 
with age in the first screening round. The percentage of cancers with Gleason 
scores less than 7 decreased from 76% in men aged 55-59 to 57% in men aged 
70-74; Those with Gleason scores more than 7 increased from 9% to 32% in the 
same age categories. Notably, in the 2nd screening round and in the control 
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arm no significant association between Gleason scores and age was found. To 
examine whether these findings could provide a clue to the underlying 
mechanism of prostate cancer heterogeneity, MISCAN modeling was used. 
Two models were developed and tested for best fit with the actual findings in 
the screening study: 1) A model wherein the Gleason score is allowed to 
progress towards a higher score in time and 2) a model wherein the Gleason 
score would be fixed at the time of detection by screening. The 1st model fitted 
best to the first and second screening round findings in the ERSPC-
Rotterdam. These results support the view that dedifferentiation is the most 
important mechanism to explain the heterogeneity of prostate cancers. 
Moreover, they indicate that detection of prostate cancer by screening is early 
enough to intercept this dedifferentiation process. This is the first time that 
epidemiological evidence is found for the view that dedifferentiation 
represents a common pathway and occurs early in the prostate 
carcinogenesis.  
Another striking result as identified in chapter 6 was that age, 
independent of Gleason score, was a significant predictor of biochemical 
recurrence of prostate cancer after radical prostatectomy. This finding was 
reported only by one article before 50. For this finding we have no proper 
explanation. It might be that the generally small size, low grade cancers 
diagnosed in the screening arm of the ERSPC brings about a reduction in the 
predictive power for the other well known prognostic factors, allowing the 
aging effect to be a more significant parameter.  We hypothesized that it could 
be that in older men micro metastasis occurs more frequently because of a 
diminished functionality of the immune system or because of yet unknown 
genetic alterations or increase genetic instability of tumor cells that would 
occur more frequently in older men. Such factors might lead to an enhanced 
metastatic potential of prostate cancer cells in older as compared to younger 
men. 
 In chapter 9 we tried to obt additional evidence for the 
dedifferentiation hypothesis at the genomic level. Array comparative genomic 
hybridization was performed on tumor areas with Gleason pattern 3 and 4 
within the same geographically defined tumor. However, there were no 
significant genetic differences neither between Gleason pattern 3 and 4 in the 
same tumor, nor between Gleason patterns 3 of Gleason score 6 and 7 tumors. 
Thus, we could not obtain genetic evidence for the view that dedifferentiation 
actually would occur in these tumors. A previous paper from our group was 
also not able to find genetic differences between Gleason pattern 3 and 4 51. 
However, in the latter study, the tumor areas with different Gleason patterns 
were not taken from the same geographically defined tumor 51. The study 
reported in this thesis has a few limitations: 1) The number of samples was 
limited and as a consequence it was hard to detect BAC clones with 
significant differences between two Gleason groups, 2) The tissue samples 
that were suitable for analysis had a considerable “noise” reducing the 
sensitivity to identify significantly different BAC clones, because an increased 
or decreased log2 ratio (gain or loss), compared to baseline level, pointing at a 
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real gain or loss that might be masked by the noise and 3) the DNA was 
extracted from tissue obtained by punching of the paraffin blocks. Although 
an H&E slide was performed to control whether the correct part of the tumor 
was punched out, mixing of different tumor parts and normal tissue might 
have occurred, as we could not check the deepest part of the tissue core that 
was punched from the paraffin block. Therefore it is possible that admixed 
normal cells may have diluted the Log2 ratios. Nevertheless, we were able to 
demonstrate that tumors in the 1.0-1.5 ml range with a Gleason score 6 or 7 do 
have genetic abnormalities that are typically found in advanced prostate 
cancers. This observation would suggest that this subset of tumors might be 
considered clinically significant tumors on genetic grounds. This was 
confirmed by the occurrence of biochemical failure in almost half of these 
tumors during follow-up compared to 13% of biochemical failure when 
considering all men who underwent radical prostatectomy. 
 
In chapter 10, an attempt was made to investigate the apoptotic activity and 
the presence of some apoptosis-related molecules in screen-detected cancers 
with different Gleason patterns and volumes. Prospective cohort studies 
showed a significant reduction in prostate cancer detection rate in men 
regularly using aspirin (NSAID). Potential mechanisms include inhibition of 
cyclooxygenase 2 (COX-2) by aspirin which induces apoptosis 52. Apoptosis 
may play an important role in the natural behavior of prostate cancer 53. Some 
reports claim that prostate cancer show an increased expression of COX-2 54. 
It was therefore hypothesized that prostate cancer might be prevented or 
progression of the tumor might be delayed, when COX-2 inhibitors were 
taken. In our study, we did not see a significant difference in apoptosis level 
in COX-2 between prostate cancer and control samples, let alone there was a 
significant difference between the different Gleason patterns and tumor 
volumes. This was in line with another report in literature, that failed to 
observe a significant difference in COX-2 expression between benign prostatic 
hyperplasia and low stage prostate cancers 55. Despite a significantly lower 
incidence of prostate cancer in aspirin users, we cannot attribute this effect to 
COX-2 inhibition and we consider it more likely that some other mechanism 
explains the lower prostate cancer incidence in aspirin users. 
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Summary 
The studies in this thesis were aimed at the histopathologic characteristics and 
therapy choices of prostate cancer detected in the Rotterdam section of the 
ERSPC in the screening and control arm. The studies were performed to get 
insight in 1) intermediate endpoints, concerning stage and grade of prostate 
cancer in subsequent screening rounds and the forthcoming therapy choices, 
2) the efficiency of the screening protocol employed at the Rotterdam section 
of the ERSPC and 3) the natural biology of prostate cancer and its’ possible 
pre-malignant lesions.  
 Since the outcome of the final analysis of the ERSPC is not expected 
until the end of 2008, intermediate endpoints were studied. In the screening 
arm of the ERSPC, the proportion of men diagnosed with low stage and low-
grade disease was significantly higher compared to the control arm. In 
addition, the number of men diagnosed with low stage and low-grade disease 
increased further from the 1st to the 2nd screening round of the ERSPC. These 
proportional differences were also reflected in therapy choices. The number of 
men managed by watchful waiting more than doubled from the 1st to the 2nd 
screening round. Accompanying the increase in low stage and low-grade 
cancers (focal cancer on sextant biopsy and minimal cancer in the radical 
prostatectomy) the incidence of advanced cancers decreased. We stated 
arbitrarily that minimal cancers were probably indolent cancers, because of 
their good follow-up results. We therefore considered minimal cancers as 
over diagnosis. The proportion of over diagnosis in the ERSPC Rotterdam 
was estimated to be 48% of all detected cancers on the basis of 
epidemiological data. The actual incidence of minimal cancers found in 
prostatectomy specimens proved to be 43% in the 2nd screening round, which 
is in line with the estimated incidence. It is difficult to predict on the basis of 
prostate needle biopsy findings which cancer should be considered as 
clinically indolent. However, if a patient was diagnosed with a focal cancer on 
sextant biopsy combined with a PSA density of ≤ 0.1 ng/ml/cm3 there was a 
94% chance that the cancer was minimal in radical prostatectomy specimen. 
This was an attempt to predict the risk of over diagnosis pre-operatively.  
In combination with the limited amount of interval carcinomas 
detected within the 4-year screening interval, the small proportion of 
advanced cancers and the increasing incidence of low stage and low grade 
cancers in the 2nd screening round, the conclusion may be drawn that a 4 year 
screening interval is short enough to restrain the development of advanced 
tumors.  
 In the screening arm of the ERSPC Rotterdam, the incidence of isolated 
PIN diagnosed on sextant needle biopsies was low. Importantly, the follow-
up of PIN did not reveal a significantly increased risk of a subsequent 
prostate cancer after this diagnosis. Thus, this small subset of men would not 
require extensive repeat biopsies in order to demonstrate a cancer. Since 
atrophy is considered by some as a potential preneoplastic lesion or condition 
we determined the incidence of different variants in prostate biopsies and we 
analyzed the follow-up. The incidence of atrophy was very high, and men 
180
 180
with atrophy in their biopsies were not at an increased risk for a prostate 
cancer diagnosis at repeat biopsy or at follow-up. We conclude that men with 
(extensive) atrophy in their prostate biopsies do not require increased 
surveillance.  In contrast, lesions suspicious for cancer in a biopsy were often 
followed by a prostate cancer diagnosis in subsequent biopsies, particularly 
during the first screening round. Although in the 2nd screening round these 
suspicious lesions predicted much less the presence of a carcinoma during 
follow-up we still consider it wise to continue to perform a repeat biopsy after 
this diagnosis.  
 Older men were diagnosed with higher Gleason scores in the 1st round 
of the ERSPC, which supports the hypothesis that prostate cancer might 
dedifferentiate in time from a well-differentiated tumor to a less differentiated 
tumor. With MISCAN modeling we were able to support this hypothesis of 
dedifferentiation. Furthermore, we showed that the Rotterdam screening 
protocol allowed the interception of carcinomas at an early enough stage to 
prevent dedifferentiation. Although, as a consequence of “dedifferentiation” 
prostate cancers are morphologically heterogeneous, this morphological 
heterogeneity was not reflected by genetic heterogeneity.  On the other hand, 
screen detected prostate cancers of intermediate size (volume 1.0- 1.5 ml) 
displayed genetic changes that are associated with more aggressive disease.  
This underlines that these moderate cancers are a good target for curative 
therapy.  If it would be possible with simple means to inhibit the growth of 
minimal prostate cancers by enhancing apoptosis, this would be a potential 
chemo preventive measure. Unfortunately, our study on apoptosis related 
molecules showed that this therapeutic approach is unlikely to be of benefit.  
The studies performed in this thesis point without exceptions show favorable 
characteristics of screen detected cancers. However, they do not provide 
evidence that men with screen-detected cancers show decreased prostate 
cancer mortality.  
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Samenvatting 
Prostaatkanker is de meest voorkomende kanker bij mannen na huidkanker 
en is, na longkanker, de meest frequente doodsoorzaak aan kanker in de 
Westerse wereld. 
In Nederland zijn momenteel twee bevolkingsonderzoeken: landelijk 
onderzoek naar baarmoederhalskanker en naar borstkanker. Een 
screeningsprogramma Er komt een bevolkingsonderzoek als is vastgesteld 
dat een bepaalde soort kanker een aanzienlijk risico op ziekte of sterfte geeft; 
deze soort kanker met een test in een vroeg stadium kan worden opgespoord; 
de test de ziektespecifieke mortaliteit verlaagt en, de test betrouwbaar, 
'betaalbaar', eenvoudig en weinig belastend is. Voordat besloten wordt of een 
bevolkingsonderzoek naar prostaatkanker zinvol is, moet bekend zijn of 
prostaatkanker met een screeningstest daadwerkelijk in een vroeg stadium 
kan worden ontdekt of door vroegere ontdekking van prostaatkanker minder 
mannen aan deze ziekte overlijden en welke test men zou moeten toepassen. 
Er zijn voor prostaatkanker diverse screeningstest beschikbaar. De meest 
gebruikte test is het prostaat specifieke antigen (PSA). PSA is een eiwit dat 
door de prostaat gemaakt wordt en dat in het bloed gemeten kan worden 
gemeten. Het PSA is verhoogd in mannen die prostaatkanker hebben. Echter, 
ook mannen met prostaatziekten zoals benigne prostaat vergroting en 
prostaatontsteking hebben ook een verhoogd PSA.  Daarom is bij mannen met 
een verhoogd PSA nader onderzoek nodig om prostaatkanker aan te tonen. 
Het rectaal toucher (DRE) is een andere screeningstest net als een rectale 
echografie (TRUS). Om prostaatkanker vast te stellen moet men een 
prostaatbiopsie ondergaan. In het prostaatweefsel kan dan prostaatkanker 
worden aangetoond, danwel uitgesloten.  
In 1994 is vanuit Nederland begonnen met een Europees onderzoek naar 
prostaatkanker screening (ERSPC). Het onderzoek wordt uitgevoerd in 7 
Europese landen. Het doel van de ERSPC is de prostaatkanker specifieke 
mortaliteit te verlagen met 20%. Het betreft een gerandomiseerde studie 
waarbij in de regio Rotterdam ongeveer tweeënveertig duizend mannen 
tussen de 55 en 74 jaar zijn gerandomiseerd. Zij zijn gerandomiseerd in een 
screening en controle groep. De mannen in de screeningsgroep worden iedere 
vier jaar onderzocht d.m.v. een PSA test. Indien deze test 3,0 ng/ml of hoger 
is dan wordt een prostaatbiopsie verricht. De PSA test in positief in ongeveer 
20% van de onderzochte mannen. Uiteindelijk wordt bij 5% van de mannen 
prostaatkanker vastgesteld. De mannen in de controlegroep ondergaan geen 
tests. Een jaarlijkse koppeling met de kankerregistratie identificeert mannen 
met kanker. De uitkomst tussen van deze studie wordt op zijn vroegst pas 
verwacht aan het eind van 2008. Omdat de uitkomst van de ERPSC nog niet 
bekend is, zijn in dit proefschrift tussentijdse uitkomsten onderzocht. In de 
screenigsgroep van de ERSPC is het deel mannen met een laaggradig en 
kanker in een vroeg stadium significant hoger dan in de controle groep. 
Tevens neemt het percentage mannen met laaggradige kankers in een vroeg 
stadium significant toe, in een tweede screeningsronde. Dit was onder meer 
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ook te zien in therapie keuzes. Het aantal mannen wat nu werd behandeld 
met watchful waiting (afwachtend beleid) verdubbelde in de tweede ronde. 
Samengaande met de toename van laaggradige kankers in een vroeg stadium, 
nam het aantal vergevorderde agressieve kankers af. We hebben arbitrair 
gesteld dat minimale tumoren (<0.5 ml, laaggradig, vroeg stadium) 
waarschijnlijk tumoren zijn waar een man niet aan zal overlijden, omdat deze 
tumoren goede follow-up resultaten geven. Daarom hebben we deze tumoren 
beschouwd als overdiagnose. Het berekende percentage overdiagnose in de 
Rotterdamse ERSPC was 48%, gebaseerd op epidemiologische data. De 
incidentie van minimale tumoren in radicale prostatectomie preparaten in de 
tweede screenings ronde was 43%, welke in de buurt komt van de berekende 
48%. Het is moeilijk om vooraf te  voorspellen op basis van 
prostaatnaaldbiopten aan welke tumoren een man niet zou overlijden. Maar 
als een man gediagnosticeerd is met een focaal carcinoom (≤3 mm in 1 biopt) 
in combinatie met een PSA dichtheid van ≤0.1 ng/ml/cm3, was de kans op 
een minimale tumor 94% in het radicale prostatectomie preparaat. Dit was 
een poging om preoperatief het risico op overdiagnose vast te stellen. 
In combinatie met een beperkt aantal interval kankers die in het 4-jaar interval 
ontdekt zijn in de mannen van de screening groep, een klein deel 
vergevorderde agressieve kankers en een steeds groter wordende groep 
langdradige kankers in een vroeg stadium in de tweede screenings ronde, 
kunnen we concluderen dat een screeningsinterval van vier jaar is kort 
genoeg om de ontwikkeling van agressieve kankers tegen te gaan. De 
incidentie van PIN in the screenings groep van de  Rotterdamse ERSPC was 
laag. Belangrijker is dat in de follow-up van deze mannen PIN geen 
significant verhoogd risico geeft op het ontdekken van prostaatkanker. Een 
herhalingsbiopsie (om de kanker beter te kunnen vinden) in deze kleine groep 
mannen is dus niet geïndiceerd. Prostaat atrofie wordt sinds kort ook 
beschouwd als een voorloper laesie van prostaatkanker. Daarom hebben we 
de incidentie van (verschillende soorten) atrofie onderzocht in 
prostaatnaaldbiopten, omdat dit nog niet bekend was, en het risico tot het 
ontwikkelen van prostaatkanker in de follow-up. Het bleek dat atrofie 
ontzettend veel voorkwam in prostaatnaaldbiopten van mannen zonder 
kanker. Mannen met atrofie in hun prostaatnaaldbiopsie hadden geen 
verhoogd risico tot het ontwikkelen van kanker in een follow-up periode van 
8 jaar. Hieruit kunnen we concluderen dat ook mannen met atrofie geen 
herhalingsbiopsie hoeven ondergaan. Mannen met Laesies die verdacht zijn 
voor prostaatkanker, maar waarop niet met zekerheid de diagnose 
prostaatkanker op kan worden vastgesteld, hadden in tegenstelling tot 
mannen met PIN en atrofie wel een verhoogde risico op een prostaatkanker 
diagnose in een herhalingsbiopsie, met name in de eerste ronde. In de tweede 
ronde was het risico op prostaatkanker niet significant hoger vergeleken bij 
een herhalingsbiopsie in een prostaatnaaldbiopt zonder afwijkingen maar de 
kans was nog steeds verhoogd, daarom adviseren we nog steeds een 
herhalingsbiopt in mannen met een laesie die verdacht is voor 
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prostaatkanker. Oudere mannen hadden een significant hogere Gleason score 
in de eerste screenings ronde. Deze bevinding ondersteund de hypothese dat 
prostaatkanker kan dedifferentieren van een goed gedifferentieerde tumor tot 
een slecht gedifferentieerde tumor in de loop van de tijd. Een computer model 
(MISCAN) ondersteunde deze hypothese. Verder konden we laten zien dat 
het screenings programma van Rotterdam tumoren kan ontdekken in een 
stadium voordat dedifferentiatie optreedt. Hoewel prostaatkanker (o.a. door 
dedifferentiatie) morfologisch een heterogene tumor is, kon dit niet worden 
aangetoond in het genetische profiel van tumoren. Aan de andere kant, de 
tumoren van gemiddelede grootte (1.0-1.5 ml) lieten wel genetische 
afwijkingen zien, die ook in agressieve vergevorderde tumoren voorkomen. 
Dit onderstreept het feit dat een tumor van gemiddelde grootte een goede 
kandidaat is voor curatieve therapie. Als het mogelijk zou zijn om minimale 
tumoren in hun groei te kunnen remmen door middel van het bevorderen 
van apoptose, dan zou dit een goede chemopreventieve therapie zijn. Alleen, 
hoofdstuk 10  van dit proefschrift laat zien dat deze therapie waarschijnlijk 
geen nut heeft. De studies de in dit proefschrift beschreven staan laten zonder 
uitzondering allemaal gunstige tumorkarakteristieken zien van mannen die in 
de screenings groep gedetecteerd zijn. Ondanks deze gunstige tumoren, 
kunnen we nog geen uitspraken doen over een eventuele mortaliteitsreductie 
in de screenings groep. 
 
 
 
184
 184
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
185
 185
List of Co-Authors  
Herman van Dekken 
Department of Pathology 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Mark van Duin 
Department of Pathology 
Erasmus Medical Center, Rotterdam 
The Netherlands  
 
Robert F. Hoedemaeker 
Department Of  Pathology 
Sint Franciscus Gasthuis, Rotterdam 
The Netherlands 
 
Wim J. Hop 
Department of Epidemiology and 
Biostatistics 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Harry J. de Koning 
Department of Public Health 
Erasmus Medical Center, Rotterdam, 
the Netherlands 
 
Theo H. van der Kwast 
Pathology & Laboratory Medicine 
Mount Sinai Hospital, Toronto  
Canada 
 
Geert J.L.H. van Leenders 
Department of Pathology 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Ronald van Marion 
Department of Pathology 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Monique J. Roobol 
Department Of Urology, ERSPC 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Fritz H. Schröder  
Department Of Urology,  
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
K. Szuhai 
Department of Molecular Cell Biology 
Leiden University Medical Center 
The Netherlands 
 
H.J. Tanke 
Department of Molecular Cell Biology 
Leiden University Medical Center 
The Netherlands 
 
Andre N. Vis 
Department Of Urology 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Kees J. Vissers 
Department of Pathology 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Stijn H. de Vries 
Department Of Urology 
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Mark F. Wildhagen 
Department Of Urology,  
Erasmus Medical Center, Rotterdam 
The Netherlands 
 
Josiane Wink 
Department of Pathology 
Erasmus Medical Center, Rotterdam 
The Netherlands
 
 
 
 
 
 
 
186
 186
List of publications 
1. Postma R, Roobol M, Schröder FH, van der Kwast TH 
Potentially advanced malignancies detected by screening for prostate 
carcinoma after an interval of 4 years 
Cancer. 2004 Mar 1;100(5):968-75. 
 
2. Postma R, Haagsma EB, Peeters PM, Van Den Berg AP, Slooff MJ. 
Retransplantation of the liver in adults: outcome and predictive factors 
for survival. Transpl Int. 2004 May;17(5):234-40. 
 
3. Postma R, Roobol M, Schröder FH, van der Kwast TH  
Lesions predictive for prostate cancer in a screened population: first 
and second screening round findings 
Prostate. 2004 Nov 1;61(3):260-6. 
 
4. R. Postma MD12, S.H. de Vries MD1, M.J. Roobol1, M.F. Wildhagen 
PhD1, F.H. Schröder MD PhD1, T.H. van der Kwast MD PhD1 
Incidence and follow-up of focal prostate cancer in two screening 
rounds after an interval of 4 years 
Cancer. 2005 Feb 15;103(4):708-16. 
 
5. Postma R, Schröder F.H, Kwast van der T.H. 
Atrophy in needle biopsies and their predictive value for cancer in a 
population-based screening program 
Urology. 2005 Apr;65(4):745-9.  
 
6. Postma R, Schröder F.H 
Screening for prostate cancer 
Eur J Cancer. 2005 Apr;41(6):825-33. 
 
7. Schröder F.H, Raaijmakers R, Postma R, van der Kwast T.H, Roobol 
M.J  
4-year prostate specific antigen progression and diagnosis of prostate 
cancer in the European randomized study of screening for prostate 
cancer, section Rotterdam. 
J Urol. 2005 Aug;174(2):489-94; discussion 493-4.  
 
8. Van der Kwast T.H, Postma R, Hoedemaeker R.F. van Leenders G.J, 
Schröder F.H 
Features of prostate cancers detected during a prevalence screening 
round. The Rotterdam experience 
Can J Urol. 2005 Jun;12(3 Suppl):16-20. 
187
 187
Curriculum Vitae 
Ik ben geboren op 10 februari 1978 te Bolsward. In 1995 heb ik het HAVO 
diploma gehaald aan het Titus Brandsma college te Bolsward. Hierna heb ik 
de propadeuse voor biotechnologie gedaan op de Noordelijke Hoge school 
Leeuwarden. Met dit diploma kon ik meeloten voor geneeskunde. Omdat 
geneeskunde toch altijd in mijn achterhoofd bleef zitten. Ik werd gelukkig 
ingeloot en ben ik in Groningen geneeskunde gaan studeren. Tijdens mijn 
studie heb ik een keuze co-schap chirurgie gedaan. Verder heb ik onderzoek 
verrricht naar levertransplantatie en per/post-operatieve complicaties op een 
chirurgie addeling. Na het behalen van mijn doctoraal en arts-examen ben ik 
in 2003 begonnen bij de afdeling urologie en pathologie met het onderzoek 
dat de basis vormt voot dit proefschrift. Mijn onderzoek werd geleid door 
prof. Dr. Theo van der Kwast en prof. Dr. F.H. Schröder. Sinds april 2005 ben 
ik in opleiding tot patholoog. Mijn opleider is dr. Michael den Bakker samen 
met prof. Dr. J.W. Oosterhuis. 
188
 188
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
189
 189
Dankwoord 
 
Allereerst zou ik willen bedanken alle mannen die deelnamen/nemen aan de 
ERSPC studie. Zonder deze mannen zou dit proefschrift en die van mijn 
voorgangers er niet zijn geweest.  
 
Ik wil de mensen op het screenings bureau (Monique, Wilma, Ellen en 
Lakshmi) erg bedanken. Jullie waren de eersten die me wegwijs maakten op 
de poli urologie en het draaien van een prostaat biopsie spreekuur. Ik wist in 
het begin niet waar ik moest beginnen.  
 
In het begin van mijn promotietraject heb ik me gestort op muizenbloed, om 
“de” perfecte marker voor prostaatkanker op te sporen. Guido Jenster, heeft 
me hierin vreselijk goed geholpen en me enthousiast gemaakt voor “echt” 
onderzoek doen. Helaas leverde het onderzoek niet de gewenste resultaten 
op, maar ik heb wel veel geleerd. 
 
Nadat ik de poli urologie een beetje onder de knie had, kwam ik op een 
kamer in het JNI terecht, bij Cees. Beste Cees, bedankt voor het wegwijs 
maken op de afdeling en me mee te nemen met de vaste lunchclub. Een 
gewoonte die ik zeer kon waarderen.  
 
Dan wil ik nu mijn beide promotoren bedanken; 
Beste Prof.dr. Schröder, ik sta versteld van de kennis die u paraat hebt, niet 
alleen over prostaatkanker. U bent zeer gedreven en weet dat ook op een 
prettige manier over te brengen op anderen. Daarnaast bent u een zeer 
aimabel persoon. Ik heb veel aan u te danken.  
Mijn andere promotor, Prof.dr.  van der Kwast, beste Theo, u was mijn meest 
directe begeleider. U gaf me een zeer uitgebreid inzicht in de pathologie en 
niet alleen van prostaatkanker. Dank zij u kwam ik erachter dat pathologie 
helemaal niet suf is. Na een jaar onderzoek was ik er zelfs van overtuigd dat 
het zelfs leuker is dan urologie. Naast dat was u een zeer prettige man, 
waarbij binnenlopen voor een gesprek of een paar prostaten kijken geen 
probleem was. Ook die maand in Toronto was erg plezierig en zorgde ervoor 
dat de laatste loodjes van het proefschrift iets minder zwaar waren.  
 
Herman, beste copromotor, en hoofd ISH lab, jij hebt me ook op een prettige 
manier wijs gemaakt hoe het er op een lab aan toe gaat. Daarnaast weet ik nu 
hoe een array werkt. De maandagochtend besprekingen waren altijd weer een 
stimulans, als het weer iets moeilijker was, om toch weer verder te gaan.  
 
En natuurlijk wil ik naast Herman, de anderen van het ISH lab bedanken voor 
de gezelligheid en leerzame momenten. In het bijzonder Ronald, naast analist, 
de computerexpert. Jij had voor elk probleem een oplossing, en hebt me vaak 
geholpen. Cees, Josiane, Mark, en Matihlde jullie ook bedankt! 
 
190
 190
Bedankt medewerkers (Gerrit, Ida, Harry, Suzy) van MGZ 
 
Ik heb natuurlijk ook veel steun gehad aan mijn medepromovendi en 
voorgangers. Dankzij de promovendi avondjes heb ik jullie ook beter leren 
kennen. André, Robert bedankt. Ook aan jullie proefschriften heb ik veel 
gehad. Bas, Monique, Ida, jullie is het al gelukt afgelopen jaar, alsnog 
gefeliciteerd. Ingrid, René, Stijn (kleine en lange) Madelon en Claartje jullie 
ook veel succes toegewenst. Het gaat jullie vast lukken. 
 
Nu ik in opleiding ben, wil ik ook mijn collega arts-assistenten (AIOS 
tegenwoordig) bedanken. En mijn collega’s in Dordrecht waar ik nu tijdelijk 
verblijf, voor de collegialiteit en het geduld om alles uit te leggen. 
 
Leave heit, mem, en Djo, tige tank foar untelbarre kwestjes 
 
Lieve Mark, dank je voor je alles. 
 
 
 
